U.S. patent application number 15/601291 was filed with the patent office on 2017-09-14 for amine polymers for use as bile acid sequestrants.
The applicant listed for this patent is Relypsa, Inc.. Invention is credited to David E. Bergbreiter, Kalpesh Biyani, Eric Connor, Michael James Cope, Elizabeth Goka, Scott Hecker, Grace Huynh, Angela Lee, Inez Lees, Deidre Madsen, Paul Mansky, YongQi Mu, Faleh Salaymeh, Jun Shao, Hongmin Zhang, Xinnan Zhang.
Application Number | 20170258825 15/601291 |
Document ID | / |
Family ID | 43901141 |
Filed Date | 2017-09-14 |
United States Patent
Application |
20170258825 |
Kind Code |
A1 |
Connor; Eric ; et
al. |
September 14, 2017 |
AMINE POLYMERS FOR USE AS BILE ACID SEQUESTRANTS
Abstract
The present invention provides crosslinked amine polymers
effective for binding and removing bile salts from the
gastrointestinal tract. These bile acid binding polymers or
pharmaceutical compositions thereof can be administered to subjects
to treat various conditions, including hypercholesteremia,
diabetes, pruritus, irritable bowel syndrome-diarrhea (IBS-D), bile
acid malabsorption, and the like.
Inventors: |
Connor; Eric; (Los Gatos,
CA) ; Biyani; Kalpesh; (Newark, CA) ; Hecker;
Scott; (Del Mar, CA) ; Lees; Inez; (Menlo
Park, CA) ; Mansky; Paul; (San Francisco, CA)
; Mu; YongQi; (Los Altos, CA) ; Salaymeh;
Faleh; (Sunnyvale, CA) ; Zhang; Hongmin;
(Fremont, CA) ; Bergbreiter; David E.; (College
Station, TX) ; Huynh; Grace; (San Francisco, CA)
; Cope; Michael James; (Berkeley, CA) ; Goka;
Elizabeth; (San Jose, CA) ; Lee; Angela; (San
Jose, CA) ; Madsen; Deidre; (Los Altos, CA) ;
Shao; Jun; (Fremont, CA) ; Zhang; Xinnan;
(Campbell, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Relypsa, Inc. |
Redwood City |
CA |
US |
|
|
Family ID: |
43901141 |
Appl. No.: |
15/601291 |
Filed: |
May 22, 2017 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13581148 |
Aug 20, 2014 |
9655920 |
|
|
PCT/US2011/026106 |
Feb 24, 2011 |
|
|
|
15601291 |
|
|
|
|
61307822 |
Feb 24, 2010 |
|
|
|
61307820 |
Feb 24, 2010 |
|
|
|
61373682 |
Aug 13, 2010 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 17/04 20180101;
A61P 25/28 20180101; A61P 13/00 20180101; A61P 3/06 20180101; A61P
1/00 20180101; A61P 43/00 20180101; C08G 73/0206 20130101; A61K
31/785 20130101; A61P 1/16 20180101; A61P 3/00 20180101; C08G 73/02
20130101; A61K 45/06 20130101; A61P 3/10 20180101; A61K 31/785
20130101; A61K 2300/00 20130101 |
International
Class: |
A61K 31/785 20060101
A61K031/785; C08G 73/02 20060101 C08G073/02; A61K 45/06 20060101
A61K045/06 |
Claims
1. An amine polymer comprising repeat units derived from
polymerization of an amine monomer having six, seven or eight
possible reaction sites and a crosslinking monomer having two or
three possible reaction sites, wherein the molar ratio of the amine
monomer to the crosslinking monomer is in the range of from 1:3 to
about 1:1.1, and the amine polymer has a binding affinity for bile
acids of at least 0.46 mmol/g when measured using an in vitro A
assay.
2. An amine polymer comprising the reaction product of an amine
monomer having six, seven or eight possible reaction sites and a
crosslinking monomer, wherein units of the polymer have the
structure of formula 1 ##STR00068## wherein R.sub.10 is derived
from the crosslinking monomer and is C.sub.2 to C.sub.16 alkylene,
--NH--C(NH)--NH--, --NH--C(NH.sub.2.sup.+)--NH--, or C.sub.2 to
C.sub.50 alkylene wherein one or more of the --CH.sub.2-- groups of
the alkylene group is replaced with an amide, a carbonyl, an ether,
an ester, a cycloalkyl, or a heterocyclo functional group, or one
or more of the --CH.sub.2-- groups of the alkylene group is
substituted with hydroxy; R.sub.30 is derived from the amine
monomer and is C.sub.2 to C.sub.12 alkylene, arylene,
diformylheterocyclo, or C.sub.2 to C.sub.12 alkylene wherein one or
more of the --CH.sub.2-- groups of the alkylene group is replaced
with an amide, a carbonyl, a cycloalkyl, an aryl, or a heterocyclo
functional group; each R.sub.20 is independently C.sub.2 to C.sub.6
alkylene or C.sub.2 to C.sub.6 alkylene wherein one or more of the
--CH.sub.2-- groups of the alkylene group is replaced with an amide
functional group; and at least one of R.sub.10 or R.sub.30 is a
hydrophobic group having a calculated log P (c Log P) of greater
than 4.
3. An amine polymer comprising the reaction product of an amine
monomer having six, seven or eight possible reaction sites and a
crosslinking monomer wherein units of the polymer have the
structure of formula 1 ##STR00069## wherein R.sub.10 is derived
from the crosslinking monomer and is C.sub.2 to C.sub.16 alkylene,
--NH--C(NH)--NH--, --NH--C(NH.sub.2.sup.+)--NH--, or C.sub.2 to
C.sub.50 alkylene wherein one or more of the --CH.sub.2-- groups of
the alkylene group is replaced with an amide, a carbonyl, an ether,
an ester, a cycloalkyl, or a heterocyclo functional group, or one
or more of the --CH.sub.2-- groups of the alkylene group is
substituted with hydroxy; R.sub.30 is derived from the amine
monomer and is C.sub.2 to C.sub.6 alkylene; each R.sub.20 is
independently C.sub.2 to C.sub.6 alkylene or C.sub.2 to C.sub.6
alkylene wherein one or more of the --CH.sub.2-- groups of the
alkylene group is replaced with an amide functional group; and
R.sub.10 is a hydrophobic group having a calculated log P (c Log P)
of greater than 4.
4. An amine polymer comprising the reaction product of an amine
monomer having six, seven or eight possible reaction sites and a
crosslinking monomer wherein units of the polymer have the
structure of formula 1 ##STR00070## wherein R.sub.10 is derived
from the crosslinking monomer and is C.sub.8 to C.sub.16 alkylene,
or C.sub.8 to C.sub.50 alkylene wherein one or more of the
--CH.sub.2-- groups of the alkylene group is replaced with an
amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a
heterocyclo functional group; R.sub.30 is derived from the amine
monomer and is C.sub.2 to C.sub.12 alkylene, arylene,
diformylheterocyclo, or C.sub.2 to C.sub.12 alkylene wherein one or
more of the --CH.sub.2-- groups of the alkylene group is replaced
with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an
aryl, or a heterocyclo functional group; and each R.sub.20 is
independently C.sub.2 to C.sub.6 alkylene or C.sub.2 to C.sub.6
alkylene wherein one or more of the --CH.sub.2-- groups of the
alkylene group is replaced with an amide functional group.
5. An amine polymer comprising the reaction product of an amine
monomer having six, seven or eight possible reaction sites and a
crosslinking monomer wherein units of the polymer have the
structure of formula 1 ##STR00071## wherein R.sub.10 is derived
from the crosslinking monomer and is C.sub.2 to C.sub.6 alkylene,
or C.sub.2 to C.sub.6 alkylene wherein one or more of the
--CH.sub.2-- groups of the alkylene group is replaced with an
amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a
heterocyclo functional group, or one or more of the --CH.sub.2--
groups of the alkylene group is substituted with hydroxy; R.sub.30
is derived from the amine monomer and is C.sub.8 to C.sub.16
alkylene, arylene, diformylheterocyclo, or C.sub.8 to C.sub.16
alkylene wherein one or more of the --CH.sub.2-- groups of the
alkylene group is replaced with an amide, a carbonyl, an ether, an
ester, a cycloalkyl, an aryl, or a heterocyclo functional group;
and each R.sub.20 is independently C.sub.2 to C.sub.6 alkylene or
C.sub.2 to C.sub.6 alkylene wherein one or more of the --CH.sub.2--
groups of the alkylene group is replaced with an amide functional
group.
6. The amine polymer of any one of claims 2 to 5 wherein the
polymer comprises primary and secondary amine atoms in a calculated
ratio in the range of from 1:1 to about 1:5.
7. The amine polymer of any one of claims 2 to 6 wherein the molar
ratio of the amine monomer to the crosslinking monomer is in the
range of from 1:3 to about 1:1.1.
8. The amine polymer of any one of claims 2 to 7 having a binding
affinity for bile acids of at least 0.46 mmol/g when measured using
an in vitro A assay.
9. An amine polymer comprising the reaction product of an amine
monomer having six, seven or eight possible reaction sites and a
crosslinking monomer having two or three possible reaction sites,
said polymer being insoluble in water, at least some of said amine
secondary nitrogen atoms being part of a crosslinked polymer
network, the crosslinking monomer is a compound having the formula
X-R.sub.1-X, wherein each X is independently a leaving group, and
R.sub.1 is C.sub.8 to C.sub.16 alkylene, or C.sub.8 to C.sub.50
alkylene wherein one or more of the --CH.sub.2-- groups of the
alkylene group is replaced with an amide, a carbonyl, an ether, an
ester, a cycloalkyl, an aryl, or a heterocyclo functional group,
and the calculated log P (c Log P) of the crosslinking monomer is
greater than 4.
10. An amine polymer comprising the reaction product of an amine
monomer having six, seven or eight possible reaction sites and a
crosslinking monomer having two or three possible reaction sites,
said polymer being insoluble in water, at least some of said amine
secondary nitrogen atoms being part of a crosslinked polymer
network, the amine monomer having at least one segment that is a
C.sub.8 to C.sub.16 alkylene, arylene, or C.sub.8 to C.sub.50
alkylene wherein one or more of the --CH.sub.2-- groups of the
alkylene group is replaced with an amide, a carbonyl, an ether, an
ester, a cycloalkyl, an aryl, or a heterocyclo functional group,
and a calculated log P (c Log P) of the at least one segment of the
amine monomer is greater than 4, and the crosslinking monomer is a
compound having the formula X-R.sub.1-X, wherein each X is
independently a leaving group, and R.sub.1 is C.sub.2 to C.sub.6
alkylene, or C.sub.2 to C.sub.6 alkylene wherein one or more of the
--CH.sub.2-- groups of the alkylene group is replaced with an
amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a
heterocyclo functional group, or one or more of the --CH.sub.2--
groups of the alkylene group is substituted with hydroxy.
11. The polymer of claim 9 wherein the crosslinking monomer is
X-R.sub.1-X wherein each X is independently a leaving group, and
R.sub.1 is C.sub.8 to C.sub.16 alkylene, or C.sub.8 to C.sub.50
alkylene wherein one or more of the --CH.sub.2-- groups of the
alkylene group is replaced with a heterocyclo functional group.
12. The polymer of claim 10 wherein the crosslinking monomer is
X-R.sub.1-X wherein each X is independently a leaving group, and
R.sub.1 is C.sub.2 to C.sub.6 alkylene wherein one or more of the
--CH.sub.2-- groups of the alkylene group is replaced with a
heterocyclo functional group, or one or more of the --CH.sub.2--
groups of the alkylene group is substituted with hydroxy.
13. An amine polymer comprising repeat units derived from
polymerization of an amine monomer having six, seven or eight
possible reaction sites and a crosslinking monomer having two or
three possible reaction sites, wherein the molar ratio of the amine
monomer to the crosslinking monomer is in the range of from 1:3 to
about 1:1.1, and wherein: said polymer binds phosphate in vitro in
an amount of less than 0.3 mmol/gram of polymer when measured using
a B assay; and said polymer binds bile acids with an in vitro
capacity of greater than about 3 mmol/gram of polymer when measured
using a B assay.
14. An amine polymer comprising units of the polymer having nodes
of positive charge separated by aliphatic segments, wherein the
nodes of positive charge have a charge density of at least 19.0
mEq/g and a molecular weight of at least 200.0 g/mol and at least
one aliphatic segment is bonded to each node of positive charge,
the at least one aliphatic segment having a calculated log P (c Log
P) greater than 4 and wherein each of the nodes of positive charge
does not contain an aliphatic segment having a calculated log P (c
Log P) greater than 4.
15. An amine polymer comprising units of the polymer having nodes
of positive charge separated by aliphatic segments, wherein the
nodes of positive charge have a charge density greater than 17.3
mEq/g and the structure of formula A ##STR00072## wherein each
R.sub.20 is independently C.sub.3 to C.sub.8 alkylene or C.sub.3 to
C.sub.8 alkylene wherein one or more of the --CH.sub.2-- groups of
the alkylene group is replaced with an amide functional group; and
wherein at least one aliphatic segment is bonded to each node of
positive charge, each aliphatic segment having a calculated log P
(c Log P) greater than 4.
16. The amine polymer of claim 14 or 15, wherein the at least one
aliphatic segment is a C.sub.8 to C.sub.16 alkylene, or C.sub.8 to
C.sub.50 alkylene wherein one or more of the --CH.sub.2-- groups of
the alkylene group is replaced with an amide, a carbonyl, an ether,
an ester, a cycloalkyl, an aryl, or a heterocyclo functional
group.
17. The amine polymer of any one of claims 14 to 16, wherein said
polymer binds phosphate in vitro in an amount of less than 0.3
mmol/gram of polymer when measured using a B assay; and said
polymer binds bile acids with an in vitro capacity of greater than
about 3 mmol/gram of polymer when measured using the B assay.
18. The amine polymer of claim 17, wherein said polymer binds
phosphate in vitro in an amount of less than 0.2 mmol/gram of
polymer when measured using the B assay.
19. The amine polymer of any one of claims 15 to 18 wherein each of
the nodes of positive charge does not contain an aliphatic segment
having a calculated log P (c Log P) greater than 4.
20. An amine polymer comprising units of the polymer having the
structure of formula 1 ##STR00073## wherein R.sub.10 is C.sub.2 to
C.sub.16 alkylene, arylene, --NH--C(NH)--NH--,
--NH--C(NH.sub.2.sup.+)--NH--, dimethylbiphenyl, or C.sub.2 to
C.sub.50 alkylene wherein one or more of the --CH.sub.2-- groups of
the alkylene group is replaced with an amide, a carbonyl, a
cycloalkyl, an ether, an ester, a cycloalkyl, an aryl, or a
heterocyclo functional group, or one or more of the --CH.sub.2--
groups of the alkylene group is substituted with hydroxy; R.sub.30
is C.sub.2 to C.sub.12 alkylene, arylene, diformylheterocyclo, or
C.sub.2 to C.sub.12 alkylene wherein one or more of the
--CH.sub.2-- groups of the alkylene group is replaced with an
amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a
heterocyclo functional group; and each R.sub.20 is independently
C.sub.2 to C.sub.8 alkylene or C.sub.2 to C.sub.8 alkylene wherein
one or more of the --CH.sub.2-- groups of the alkylene group is
replaced with an amide functional group; said polymer binds
phosphate in vitro in an amount of less than 0.3 mmol/gram of
polymer when measured using a B assay; and said polymer binds bile
acids with an in vitro capacity of greater than about 3 mmol/gram
of polymer when measured using a B assay.
21. The amine polymer of claim 20 wherein the amine polymer
comprises the reaction product of an amine monomer having six,
seven or eight possible reaction sites and a crosslinking monomer
and R.sub.10 is derived from the crosslinking monomer and R.sub.30
is derived from the amine monomer.
22. The amine polymer of claim 20 wherein the amine polymer binds
phosphate in vitro in an amount of less than 0.2 mmol/gram of
polymer when measured using a B assay.
23. The amine polymer of any of claims 1 to 22 wherein the
calculated Log P is greater than 4.5.
24. The amine polymer of any of claims 1 to 22 wherein the
calculated Log P is greater than 5.
25. The amine polymer of any of claims 1 to 22 wherein the
calculated Log P is greater than 5.5.
26. The amine polymer of any of claims 1 to 22 wherein the
calculated Log P is greater than 6.
27. An amine polymer comprising repeat units derived from
polymerization of an amine monomer and a crosslinking monomer,
wherein the amine monomer is an amine of formula 2 having the
structure: ##STR00074## wherein each R.sub.2 is independently
C.sub.2 to C.sub.8 alkylene or C.sub.2 to C.sub.8 alkylene wherein
one or more of the --CH.sub.2-- groups of the alkylene group is
replaced with at least one amide functional group, and R.sub.3 is
C.sub.2 to C.sub.12 alkylene, arylene, diformylheterocyclo, or
C.sub.2 to C.sub.8 alkylene wherein one or more of the --CH.sub.2--
groups of the alkylene group is replaced with an amide, a carbonyl,
an ether, an ester, a cycloalkyl, an aryl, or a heterocyclo
functional group; and the crosslinking monomer is guanidine, a
guanidinium salt, a compound having the formula X-R.sub.1-X, or a
combination thereof, wherein each X is independently a leaving
group, R.sub.1 is C.sub.8 to C.sub.16 alkylene, or C.sub.5 to
C.sub.50 alkylene wherein one or more of the --CH.sub.2-- groups of
the alkylene group is replaced with an amide, a carbonyl, an ether,
an ester, a cycloalkyl, an aryl, or a heterocyclo functional group,
or one or more of the --CH.sub.2-- groups of the alkylene group is
substituted with hydroxy.
28. The amine polymer of any one of claims 1 to 26 wherein the
amine monomer is an amine of formula 2 having the structure:
##STR00075## wherein each R.sub.2 is independently C.sub.2 to
C.sub.8 alkylene or C.sub.2 to C.sub.8 alkylene wherein one or more
of the --CH.sub.2-- groups of the alkylene group is replaced with
an amide functional group, and R.sub.3 is C.sub.2 to C.sub.12
alkylene, arylene, diformylheterocyclo, or C.sub.2 to C.sub.8
alkylene wherein one or more of the --CH.sub.2-- groups of the
alkylene group is replaced with an amide, a carbonyl, an ether, an
ester, a cycloalkyl, an aryl, or a heterocyclo functional
group.
29. The amine polymer of any one of claims 1 to 26 wherein the
amine monomer is an amine of formula 2 having the structure:
##STR00076## wherein each R.sub.2 is independently C.sub.2 to
C.sub.8 alkylene or C.sub.2 to C.sub.8 alkylene wherein one or more
of the --CH.sub.2-- groups of the alkylene group is replaced with
an amide functional group, and R.sub.3 is C.sub.8 to C.sub.16
alkylene, arylene, diformylheterocyclo, or C.sub.8 to C.sub.16
alkylene wherein one or more of the --CH.sub.2-- groups of the
alkylene group is replaced with an amide, a carbonyl, an ether, an
ester, a cycloalkyl, an aryl, or a heterocyclo functional group;
and the crosslinking monomer is a compound having the formula
X-R.sub.1-X, wherein each X is independently a leaving group,
R.sub.1 is C.sub.2 to C.sub.6 alkylene or C.sub.2 to C.sub.6
alkylene wherein one or more of the --CH.sub.2-- groups of the
alkylene group is replaced with an amide, a carbonyl, an ether, an
ester, a cycloalkyl, an aryl, or a heterocyclo functional group, or
one or more of the --CH.sub.2-- groups of the alkylene group is
substituted with hydroxy.
30. The amine polymer of claim 28 wherein the crosslinking monomer
is guanidine, a guanidinium salt, a compound having the formula
X-R.sub.1-X, or a combination thereof, wherein each X is
independently a leaving group, R.sub.1 is C.sub.8 to C.sub.16
alkylene, dimethylbiphenyl, or C.sub.2 to C.sub.50 alkylene wherein
one or more of the --CH.sub.2-- groups of the alkylene group is
replaced with one or two phenyl, piperidinium or imidazolium
functional groups.
31. The amine polymer of claim 30 wherein the C.sub.2 to C.sub.50
alkylene wherein one or more of the --CH.sub.2-- groups of the
alkylene group is replaced with one or two phenyl, piperidinium or
imidazolium functional groups is p-xylene,
1,3-bis(m-haloC.sub.malkyl)-1H-imidazol-3-ium,
4,4'-(C.sub.xalkane-Lx-diyl)bis(1-(m-haloC.sub.malkyl)-1-methylpiperidini-
um), or
1-(q-haloC.sub.qalkyl)-3-(m-(3-(p-haloC.sub.palkyl)-1H-imidazol-3--
ium-1-yl)C.sub.malkyl)-1H-imidazol-3-ium, wherein m is an integer
from 2 to 14, p is an integer from 2 to 14, q is an integer from 2
to 14, and x is an integer from 2 to 8.
32. The amine polymer of claim 28 wherein the crosslinking monomer
is guanidine, a compound having the formula X-R.sub.1-X wherein
R.sub.1 is C.sub.8 to C.sub.16 alkylene, or a combination thereof,
and the amine polymer comprises a comonomer, the comonomer being
C.sub.malkane-1,m-diyldiamine, alkylenedicycloalkanamine,
(m-aminoC.sub.malkyl)heterocycle,
3-(m-aminoC.sub.malkyl)-1H-imidazol-3-ium, or a combination
thereof, wherein m is an integer from 2 to 16, and each X is
independently a leaving group.
33. The amine polymer of claim 29 wherein the crosslinking monomer
is a compound having the formula X-R.sub.1-X wherein R.sub.1 is
C.sub.2 to C.sub.6 alkylene, and the amine polymer comprises a
comonomer, the comonomer being C.sub.malkane-1,m-diyldiamine,
alkylenedicycloalkanamine, (m-aminoC.sub.malkyl)heterocycle,
3-(m-aminoC.sub.malkyl)-1H-imidazol-3-ium, or a combination
thereof, wherein m is an integer from 2 to 16, and each X is
independently a leaving group.
34. The amine polymer of claim 29 wherein R.sub.3 is octylene,
decylene, undecylene, or dodecylene.
35. The amine polymer of claim 29 wherein the polymer comprises a
comonomer, the comonomer being hexane-1,6-diyldiamine,
heptane-1,7-diylamine, octane-1,8-diyldiamine,
nonane-1,9-diylamine, decane-1,10-diyldiamine,
undecane-1,11-diylamine, dodecane-1,12-diyldiamine,
4,4'-methylenedicyclohexanamine,
3-(3-aminopropyl)-1H-imidazol-3-ium, or a combination thereof.
36. The amine polymer of claim 28 wherein R.sub.3 is ethylene,
propylene, butylene, pentylene, hexylene, heptylene, octylene,
decylene, undecylene, dodecylene, 1,4-phenylenedimethyl,
1,6-dioxohexane-1,6-diyl, 1,4-dioxobutane-1,4-diyl or
2,6-diformylpyridine.
37. The amine polymer of claim 1 wherein the amine monomer is an
amine of formula 3 having the structure: ##STR00077## wherein each
R.sub.21 is independently C.sub.2 to C.sub.8 alkylene wherein one
or more of the --CH.sub.2-- groups of the alkylene group is
replaced with at least one sulfur atom, and R.sub.31 is C.sub.2 to
C.sub.12 alkylene, arylene, diformylheterocyclo, or C.sub.2 to
C.sub.12 alkylene wherein one or more of the --CH.sub.2-- groups of
the alkylene group is replaced with an amide, a carbonyl, an ether,
an ester, a cycloalkyl, an aryl, or a heterocyclo functional group;
and the crosslinking monomer is guanidine, a guanidinium salt, a
compound having the formula X-R.sub.1-X, or a combination thereof,
wherein each X is independently a leaving group, and R.sub.1 is
C.sub.2 to C.sub.16 alkylene, arylene, dimethylbiphenyl, or C.sub.2
to C.sub.50 alkylene wherein one or more of the --CH.sub.2-- groups
of the alkylene group is replaced with an amide, a carbonyl, an
ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional
group, or one or more of the --CH.sub.2-- groups of the alkylene
group is substituted with hydroxy.
38. The amine polymer of claim 37 wherein each R.sub.21 is
m-sulfidoC.sub.malkyl, m is an integer from 1 to 6 and R.sub.31 is
C.sub.3 to C.sub.8 alkylene.
39. An amine polymer comprising repeat units derived from
polymerization of an amine monomer of formula 2 and a crosslinking
monomer, wherein the amine monomer of formula 2 has the structure:
##STR00078## wherein each R.sub.2 is independently C.sub.2 to
C.sub.8 alkylene or C.sub.2 to C.sub.8 alkylene wherein one or more
of the --CH.sub.2-- groups of the alkylene group is replaced with
an amide functional group; and R.sub.3 is C.sub.2 to C.sub.12
alkylene, arylene, diformylheterocyclo, or C.sub.2 to C.sub.12
alkylene wherein one or more of the --CH.sub.2-- groups of the
alkylene group is replaced with an amide, a carbonyl, an ether, an
ester, a cycloalkyl, an aryl, or a heterocyclo functional group;
and a portion of the nitrogen atoms of the amine polymer are
substituted with a ligand selected from aminoalkyl, aryl,
arylalkyl, oxoalkyl, cycloalkyl, (cycloalkyl)alkyl, guanidino,
heterocyclo, heterocycloalkyl, (trialkylammonio)alkyl, 2-(protected
amino)-m-(heterocyclo)-1-oxoC.sub.malkyl, 2-(protected
amino)-1-oxoC.sub.malkyl, 2-(protected
amino)-3-methyl-1-oxoC.sub.malkyl, 2-(protected
amino)-4-methyl-1-oxoC.sub.malkyl, 2-(protected
amino)-1-oxo-m-arylC.sub.malkyl, 2-(protected
amino)-m-(alkylthio)-1-oxoC.sub.malkyl, 2-(protected
amino)-m-(aryl)-1-oxoC.sub.malkyl, 2-(protected
amino)-m-carboxy-1-oxoC.sub.malkyl, 2-(protected
amino)-m-guanidino-1-oxoC.sub.malkyl, 2-(protected
amino)-(m-1)-hydroxy-1-oxoC.sub.malkyl, 2-(protected
amino)-m-hydroxy-1-oxoC.sub.malkyl, 2-(protected
amino)-m-mercapto-1-oxoC.sub.malkyl,
m-(alkylamino)-m-oxoC.sub.malkyl, m-(alkylheterocyclo)C.sub.malkyl,
m-amino-2-(protected amino)-1-oxoC.sub.malkyl, m-amino-2-(protected
amino)-1,m-dioxoC.sub.malkyl,
m-(x-aminoC.sub.xalkyl)heterocycloC.sub.malkyl,
(m-1)-amino-m-(heterocyclo)-1-oxoC.sub.malkyl,
m-(arylalkylamino)-m-oxoC.sub.malkyl,
m-(x-(alkylthio)C.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-aminoC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-amino-x-oxoC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-carboxyC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(heterocycloalkylamino)-m-oxoC.sub.malkyl,
m-(x-hydroxyC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-((x-1)-hydroxyC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-mercaptoC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-trialkylammonioC.sub.xalkyl)heterocycloC.sub.malkyl,
m-(x-(2-(alkoxy)benzamido)C.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-(3-(alkoxy)benzamido)C.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-(4-(alkoxy)benzamido)C.sub.xalkylamino)-m-oxoC.sub.malkyl, a
ligand of formula 4 *-R.sub.46-R.sub.47-R.sub.48 (4) or a
combination thereof, wherein R.sub.46 is C.sub.6 to C.sub.16
alkylene, R.sub.47 is
1,y-bis(1-methylpiperidin-4-yl)C.sub.yalkylene, R.sub.48 is C.sub.6
to C.sub.16 alkyl, m is an integer from 3 to 12, x is an integer
from 1 to 12, y is an integer from 1 to 14, and z is an integer
from 1 to 16.
40. The amine polymer of any one of claims 1 to 38 wherein a
portion of the nitrogen atoms of the amine polymer are substituted
with a ligand selected from alkyl, aminoalkyl, aryl, arylalkyl,
oxoalkyl, cycloalkyl, (cycloalkyl)alkyl, guanidino, heterocyclo,
heterocycloalkyl, (trialkylammonio)alkyl, 2-(protected
amino)-m-(heterocyclo)-1-oxoC.sub.malkyl, 2-(protected
amino)-1-oxoC.sub.malkyl, 2-(protected
amino)-3-methyl-1-oxoC.sub.malkyl, 2-(protected
amino)-4-methyl-1-oxoC.sub.malkyl, 2-(protected
amino)-1-oxo-m-arylC.sub.malkyl, 2-(protected
amino)-m-(alkylthio)-1-oxoC.sub.malkyl, 2-(protected
amino)-m-(aryl)-1-oxoC.sub.malkyl, 2-(protected
amino)-m-carboxy-1-oxoC.sub.malkyl, 2-(protected
amino)-m-guanidino-1-oxoC.sub.malkyl, 2-(protected
amino)-(m-1)-hydroxy-1-oxoC.sub.malkyl, 2-(protected
amino)-m-hydroxy-1-oxoC.sub.malkyl, 2-(protected
amino)-m-mercapto-1-oxoC.sub.malkyl,
m-(alkylamino)-m-oxoC.sub.malkyl, m-(alkylheterocyclo)C.sub.malkyl,
m-amino-2-(protected amino)-1-oxoC.sub.malkyl, m-amino-2-(protected
amino)-1,m-dioxoC.sub.malkyl,
m-(x-aminoC.sub.xalkyl)heterocycloC.sub.malkyl,
(m-1)-amino-m-(heterocyclo)-1-oxoC.sub.malkyl,
m-(arylalkylamino)-m-oxoC.sub.malkyl,
m-(x-(alkylthio)C.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-aminoC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-amino-x-oxoC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-carboxyC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(heterocycloalkylamino)-m-oxoC.sub.malkyl,
m-(x-hydroxyC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-((x-1)-hydroxyC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-mercaptoC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-trialkylammonioC.sub.xalkyl)heterocycloC.sub.malkyl,
m-(x-(2-(alkoxy)benzamido)C.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-(3-(alkoxy)benzamido)C.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-(4-(alkoxy)benzamido)C.sub.xalkylamino)-m-oxoC.sub.malkyl, a
ligand of formula 4 *-R.sub.46-R.sub.47-R.sub.48 (4) or a
combination thereof, wherein R.sub.46 is C.sub.6 to C.sub.16
alkylene, R.sub.47 is
1,y-bis(1-methylpiperidin-4-yl)C.sub.yalkylene, R.sub.48 is C.sub.6
to C.sub.16 alkyl, m is an integer from 3 to 12, x is an integer
from 1 to 12, y is an integer from 1 to 14, and z is an integer
from 1 to 16.
41. The amine polymer of claim 39 or 40 wherein the ligand is
arylalkyl selected from naphthalen-2-ylalkyl or
naphthalen-1-ylalkyl; heterocycloalkyl selected from
m-(1-methylpyrrolidinium-1-yl)C.sub.malkyl,
m-(2-(1H-indol-3-yl)ethylamino)-m-oxoC.sub.malkyl,
m-(2-methylthiazol-3-ium-3-yl)C.sub.malkyl,
m-(benzo[d]thiazol-3-ium-3-yl)C.sub.malkyl,
m-(pyridinium-1-yl)C.sub.malkyl,
m-(tetrahydro-1H-thiophenium-1-yl)C.sub.malkyl,
z-(1,2-dialkyl-1H-imidazol-3-ium-3-yl)C.sub.zalkyl,
m-(2,3-dialkyl-1H-imidazol-3-ium-1-yl)C.sub.malkyl,
z-(1-alkyl-1H-imidazol-3-ium-3-yl)C.sub.zalkyl,
m-(3-alkyl-1H-imidazol-3-ium-1-yl)C.sub.malkyl, or
z-(thiazol-3-ium-3-yl)C.sub.zalkyl; 2-(protected
amino)-m-(heterocyclo)-1-oxoC.sub.malkyl selected from 2-(protected
amino)-m-(1H-indol-3-yl)-1-oxoC.sub.m-alkyl or 2-(protected
amino)-m-(1H-imidazol-4-yl)-1-oxoC.sub.malkyl; 2-(protected
amino)-1-oxo-m-phenylC.sub.malkyl; 2-(protected
amino)-m-(hydroxyphenyl)-1-oxoC.sub.malkyl;
m-(alkylheterocyclo)C.sub.malkyl selected from
m-(3-alkyl-1H-imidazol-3-ium-1-yl)C.sub.malkyl,
m-(1-alkyl-1H-imidazol-3-ium-3-yl)C.sub.malkyl,
m-(1-alkyl-2-methyl-1H-imidazol-3-ium-3-yl)C.sub.malkyl, or
m-(3-alkyl-2-methyl-1H-imidazol-3-ium-1-yl)C.sub.malkyl;
m-(x-aminoC.sub.xalkyl)heterocycloC.sub.malkyl selected from
m-(3-(x-aminoC.sub.xalkyl)-1H-imidazol-3-ium-1-yl)C.sub.malkyl or
m-(1-(x-aminoC.sub.xalkyl)-1H-imidazol-3-ium-3-yl) C.sub.malkyl;
(m-1)-amino-m-(1H-indol-2-yl)-1-oxoC.sub.malkyl;
m-(arylalkylamino)-m-oxoC.sub.malkyl selected from
m-(hydroxyphenalkylamino)-m-oxoC.sub.malkyl or
m-(phenalkylamino)-m-oxo-C.sub.malkyl;
m-(x-(heterocyclo)C.sub.xalkyl)heterocycloC.sub.malkyl selected
from
m-(1-(x-(1-methyl-1H-imidazol-3-ium-3-yl)C.sub.xalkyl)-1H-imidazol-3-ium--
3-yl) C.sub.malkyl,
m-(1-(x-(3-methyl-1H-imidazol-3-ium-1-yl)C.sub.xalkyl)-1H-imidazol-3-ium--
3-yl) C.sub.malkyl,
m-(3-(x-(1-methyl-1H-imidazol-3-ium-3-yl)C.sub.xalkyl)-1H-imidazol-3-ium--
1-yl) C.sub.malkyl, or
m-(3-(x-(3-methyl-1H-imidazol-3-ium-1-yl)C.sub.xalkyl)-1H-imidazol-3-ium--
1-yl) C.sub.malkyl;
m-(x-(1H-imidazol-4-yl)C.sub.xalkylamino)-m-oxoC.sub.malkyl; or
m-(x-trialkylammonioC.sub.xalkyl)heterocycloC.sub.malkyl selected
from
m-(3-(x-trialkylammonio)C.sub.xalkyl)-1H-imidazol-3-ium-1-yl)C.sub.malkyl
or
m-(1-(x-trialkylammonio)C.sub.xalkyl)-1H-imidazol-3-ium-3-yl)C.sub.mal-
kyl wherein m is an integer from 3 to 12, x is an integer from 1 to
12, and z is an integer from 1 to 16.
42. The amine polymer of claim 39 or 40 wherein the ligand is
2-(protected amino)-m-(heterocyclo)-1-oxoC.sub.malkyl,
m-amino-2-(protected amino)-1,m-dioxoC.sub.malkyl,
m-amino-2-(protected amino)-1-oxoC.sub.malkyl, 2-(protected
amino)-1-oxoC.sub.malkyl, 2-(protected
amino)-m-(alkylthio)-1-oxoC.sub.malkyl, 2-(protected
amino)-m-(hydroxyphenyl)-1-oxoC.sub.malkyl, 2-(protected
amino)-1-oxo-m-phenylC.sub.malkyl, 2-(protected
amino)-m-(1H-imidazol-4-yl)-1-oxoC.sub.malkyl, 2-(protected
amino)-m-carboxy-1-oxoC.sub.malkyl, 2-(protected
amino)-3-methyl-1-oxoC.sub.malkyl, 2-(protected
amino)-4-methyl-1-oxoC.sub.malkyl, 2-(protected
amino)-m-mercapto-1-oxoC.sub.malkyl, 2-(protected
amino)-(m-1)-hydroxy-1-oxoC.sub.malkyl, 2-(protected
amino)-m-hydroxy-1-oxoC.sub.malkyl, 2-(protected
amino)-m-guanidino-1-oxoC.sub.malkyl,
m-(x-(alkylthio)C.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(hydroxyphenalkylamino)-m-oxoC.sub.malkyl,
m-oxo-m-(phenalkylamino)C.sub.malkyl,
m-(x-(1H-imidazol-4-yl)C.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-carboxyC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(alkylamino)-m-oxoC.sub.malkyl,
m-(x-mercaptoC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-((x-1)-hydroxyC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-hydroxyC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-aminoC.sub.xalkylamino)-m-oxoC.sub.malkyl, or
m-(x-amino-x-oxoC.sub.xalkylamino)-m-oxoC.sub.malkyl, wherein m is
an integer from 3 to 12, and x is an integer from 1 to 12.
43. The amine polymer of claim 39 or 40 wherein the ligand is
2-(tert-butoxycarbonylamino)-3-(1H-indol-3-yl)-1-oxopropyl,
5-(2-(4-(nonyloxy)benzamido)ethylamino)-5-oxopentyl,
(4,5-dihydro-1H-imidazolyl, 10-(pyridinium-1-yl)decyl,
2-(1H-indol-3-yl)ethyl,
5-(2-(1H-indol-3-yl)ethylamino)-5-oxopentyl,
2-amino-3-(1H-indol-2-yl)-1-oxopropyl,
3-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)propyl,
10-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)decyl,
10-(1-methyl-1H-imidazol-3-ium-3-yl)decyl,
3-(thiazol-3-ium-3-yl)propyl, 3-aminopropyl, 3-cyclohexylpropyl,
3-phenylpropyl, 3-(trimethylammonio)propyl,
3-(1-methylpyrrolidinium-1-yl)propyl,
3-(2-methylthiazol-3-ium-3-yl)propyl,
3-(benzo[d]thiazol-3-ium-3-yl)propyl,
3-(tetrahydro-1H-thiophenium-1-yl)propyl,
3-(3-methyl-1H-imidazol-3-ium-1-yl)propyl,
3-(1-methyl-1H-imidazol-3-ium-3-yl)propyl,
3-(3-(3-aminopropyl)-1H-imidazol-3-ium-1-yl)propyl,
3-(1-(3-aminopropyl)-1H-imidazol-3-ium-3-yl)propyl,
3-(3-(5-trimethylammonio)pentyl)-1H-imidazol-3-ium-1-yl)propyl,
3-(1-(5-trimethylammonio)pentyl)-1H-imidazol-3-ium-3-yl)propyl,
3-(3-decyl-1H-imidazol-3-ium-1-yl)propyl,
3-(1-decyl-1H-imidazol-3-ium-3-yl)propyl,
3-(3-(9-(3-methyl-1H-imidazol-3-ium-1-yl)nonyl)-1H-imidazol-3-ium-1-yl)pr-
opyl,
3-(1-(9-(1-methyl-1H-imidazol-3-ium-3-yl)nonyl)-1H-imidazol-3-ium-3--
yl)propyl,
3-(1-(9-(3-methyl-1H-imidazol-3-ium-1-yl)nonyl)-1H-imidazol-3-i-
um-3-yl)propyl,
3-(3-(9-(1-methyl-1H-imidazol-3-ium-3-yl)nonyl)-1H-imidazol-3-ium-1-yl)pr-
opyl, 4-(3-decyl-1H-imidazol-3-ium-1-yl)butyl,
4-(1-decyl-1H-imidazol-3-ium-3-yl)butyl,
10-(1-decyl-2-methyl-1H-imidazol-3-ium-3-yl)decyl,
10-(3-decyl-2-methyl-1H-imidazol-3-ium-1-yl)decyl,
3-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)propyl,
3-(2,3-dimethyl-1H-imidazol-3-ium-1-yl)propyl,
10-(2,3-dimethyl-1H-imidazol-3-ium-1-yl)decyl,
10-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)decyl,
10-(1-methyl-1H-imidazol-3-ium-3-yl)decyl,
10-(3-methyl-1H-imidazol-3-ium-1-yl)decyl,
10-(1-butyl-1H-imidazol-3-ium-3-yl)decyl,
10-(3-butyl-1H-imidazol-3-ium-1-yl)decyl,
10-(pyridinium-1-yl)decyl, 10-(1-methylpyrrolidinium-1-yl)decyl,
naphthalen-2-ylmethyl, naphthalen-1-ylmethyl,
4-amino-2-(tert-butoxycarbonylamino)-1,4-dioxobutyl,
2-(tert-butoxycarbonylamino)-1-oxoethyl,
2-(tert-butoxycarbonylamino)-4-(methylthio)-1-oxobutyl,
5-(3-(methylthio)propylamino)-5-oxopentyl,
2-(tert-butoxycarbonylamino)-3-(4-hydroxyphenyl)-1-oxopropyl,
5-(4-hydroxyphenethylamino)-5-oxopentyl,
2-(tert-butoxycarbonylamino)-1-oxo-3-phenylpropyl,
5-oxo-5-(phenethylamino)pentyl,
2-(tert-butoxycarbonylamino)-3-(1H-imidazol-4-yl)-1-oxopropyl,
5-(2-(1H-imidazol-4-yl)ethylamino)-5-oxopentyl,
2-(tert-butoxycarbonylamino)-3-carboxy-1-oxopropyl,
5-(2-carboxyethylamino)-5-oxopentyl,
2-(tert-butoxycarbonylamino)-3-methyl-1-oxobutyl,
5-(isobutylamino)-5-oxopentyl,(3R)-2-(tert-butoxycarbonylamino)-3-methyl--
1-oxopentyl,(R)-5-(2-methylbutylamino)-5-oxopentyl,
2-(tert-butoxycarbonylamino)-3-mercapto-1-oxopropyl,
5-(2-mercaptoethylamino)-5-oxopentyl,(3R)-2-(tert-butoxycarbonylamino)-3--
hydroxy-1-oxobutyl,(R)-5-(2-hydroxypropylamino)-5-oxopentyl,
6-amino-2-(tert-butoxycarbonylamino)-1-oxohexyl,
5-(5-aminopentylamino)-5-oxopentyl,
5-amino-2-(tert-butoxycarbonylamino)-1,5-dioxopentyl,
5-(4-amino-4-oxobutylamino)-5-oxopentyl,
2-(tert-butoxycarbonylamino)-5-guanidino-1-oxopentyl,
5-(4-guanidinobutylamino)-5-oxopentyl,
2-(tert-butoxycarbonylamino)-3-hydroxy-1-oxopropyl,
5-(2-hydroxyethylamino)-5-oxopentyl,
2-(tert-butoxycarbonylamino)-4-methyl-1-oxopentyl,
5-(isopentylamino)-5-oxopentyl,
2-(tert-butoxycarbonylamino)-4-carboxy-1-oxobutyl,
5-(3-carboxypropylamino)-5-oxopentyl,
2-(tert-butoxycarbonylamino)-1-oxopropyl,
5-(ethylamino)-5-oxopentyl, a ligand of formula 4
*-R.sub.46-R.sub.47-R.sub.48 (4) or a combination thereof, wherein
R.sub.46 is decylene, R.sub.47 is
1,3-bis(1-methylpiperidin-4-yl)propane, and R.sub.48 is decyl.
44. The amine polymer of claim 39 or 40 wherein the ligand is
2-(tert-butoxycarbonylamino)-3-(1H-indol-3-yl)-1-oxopropyl,
5-(2-(4-(nonyloxy)benzamido)ethylamino)-5-oxopentyl,
(4,5-dihydro-1H-imidazolyl, 10-(pyridinium-1-yl)decyl,
2-(1H-indol-3-yl)ethyl,
5-(2-(1H-indol-3-yl)ethylamino)-5-oxopentyl,
2-amino-3-(1H-indol-2-yl)-1-oxopropyl,
3-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)propyl,
10-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)decyl,
10-(1-methyl-1H-imidazol-3-ium-3-yl)decyl,
3-(thiazol-3-ium-3-yl)propyl, 3-aminopropyl, 3-cyclohexylpropyl,
3-phenylpropyl, 3-(trimethylammonio)propyl,
3-(1-methylpyrrolidinium-1-yl)propyl,
3-(2-methylthiazol-3-ium-3-yl)propyl,
3-(benzo[d]thiazol-3-ium-3-yl)propyl,
3-(tetrahydro-1H-thiophenium-1-yl)propyl,
3-(3-methyl-1H-imidazol-3-ium-1-yl)propyl,
3-(1-methyl-1H-imidazol-3-ium-3-yl)propyl,
3-(3-(3-aminopropyl)-1H-imidazol-3-ium-1-yl)propyl,
3-(1-(3-aminopropyl)-1H-imidazol-3-ium-3-yl)propyl,
3-(3-(5-trimethylammonio)pentyl)-1H-imidazol-3-ium-1-yl)propyl,
3-(1-(5-trimethylammonio)pentyl)-1H-imidazol-3-ium-3-yl)propyl,
3-(3-decyl-1H-imidazol-3-ium-1-yl)propyl,
3-(1-decyl-1H-imidazol-3-ium-3-yl)propyl,
3-(3-(9-(3-methyl-1H-imidazol-3-ium-1-yl)nonyl)-1H-imidazol-3-ium-1-yl)pr-
opyl,
3-(1-(9-(1-methyl-1H-imidazol-3-ium-3-yl)nonyl)-1H-imidazol-3-ium-3--
yl)propyl,
3-(1-(9-(3-methyl-1H-imidazol-3-ium-1-yl)nonyl)-1H-imidazol-3-i-
um-3-yl)propyl,
3-(3-(9-(1-methyl-1H-imidazol-3-ium-3-yl)nonyl)-1H-imidazol-3-ium-1-yl)pr-
opyl, 4-(3-decyl-1H-imidazol-3-ium-1-yl)butyl,
4-(1-decyl-1H-imidazol-3-ium-3-yl)butyl,
10-(1-decyl-2-methyl-1H-imidazol-3-ium-3-yl)decyl,
10-(3-decyl-2-methyl-1H-imidazol-3-ium-1-yl)decyl,
3-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)propyl,
3-(2,3-dimethyl-1H-imidazol-3-ium-1-yl)propyl,
10-(2,3-dimethyl-1H-imidazol-3-ium-1-yl)decyl,
10-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)decyl,
10-(1-methyl-1H-imidazol-3-ium-3-yl)decyl,
10-(3-methyl-1H-imidazol-3-ium-1-yl)decyl,
10-(1-butyl-1H-imidazol-3-ium-3-yl)decyl,
10-(3-butyl-1H-imidazol-3-ium-1-yl)decyl,
10-(pyridinium-1-yl)decyl, 10-(1-methylpyrrolidinium-1-yl)decyl,
naphthalen-2-ylmethyl, naphthalen-1-ylmethyl, a ligand of formula 4
*-R.sub.46-R.sub.47-R.sub.48 (4) or a combination thereof, wherein
R.sub.46 is decylene, R.sub.47 is
1,3-bis(1-methylpiperidin-4-yl)propane, and R.sub.48 is decyl.
45. The amine polymer of any one of claims 39 to 42 wherein the
protecting group is independently --C(O)OR.sub.49, --C(O)R.sub.50,
wherein R.sub.49 is alkyl or aryl, and R.sub.50 is amino, hydrogen,
alkyl, or haloalkyl.
46. The amine polymer of claim 39 wherein the crosslinking monomer
is guanidine, a guanidinium salt, a compound having the formula
X-R.sub.1-X, or a combination thereof, wherein each X is
independently a leaving group, and R.sub.1 is C.sub.2 to C.sub.16
alkylene, arylene, dimethylbiphenyl, or C.sub.2 to C.sub.50
alkylene wherein one or more of the --CH.sub.2-- groups of the
alkylene group is replaced with an amide, a carbonyl, an ether, an
ester, a cycloalkyl, an aryl, or a heterocyclo functional group, or
one or more of the --CH.sub.2-- groups of the alkylene group is
substituted with hydroxy.
47. The amine polymer of any one of claims 39 to 46 comprising
about 5 mole % to about 60 mole % ligand based on the moles of
amine monomer.
48. The amine polymer of any one of claims 39 to 46 comprising
about 5 mole % to about 50 mole % ligand based on the moles of
amine monomer.
49. The amine polymer of any one of claims 39 to 46 comprising
about 10 mole % to about 30 mole % ligand based on the moles of
amine monomer.
50. The amine polymer of any one of claims 9 to 12, 27, and 29 to
49 wherein X is halo, epoxy, diaziridino or a combination
thereof.
51. The amine polymer of any one of claims 29 to 50 wherein R.sub.1
is C.sub.8 to C.sub.14 alkylene.
52. The amine polymer of claim 51 wherein R.sub.1 is decylene or
dodecylene.
53. The amine polymer of any one of claims 2, 5 to 8, 10, 20-26,
29, 37, 38, 40 to 45, and 47 to 50 wherein R.sub.1 or R.sub.10 is
C.sub.2 to C.sub.6 alkylene wherein one or more of the --CH.sub.2--
groups of the alkylene group is substituted with hydroxy.
54. The amine polymer of claim 53 wherein R.sub.1 or R.sub.10 is
--CH.sub.2--CH(OH)--CH.sub.2--.
55. The amine polymer of any one of claims 29 to 54 wherein R.sub.3
or R.sub.30 is C.sub.3 to C.sub.12 alkylene.
56. The amine polymer of claim 55 wherein R.sub.3 or R.sub.30 is
butylene.
57. The amine polymer of claim 55 wherein R.sub.3 or R.sub.30 is
decylene.
58. The amine polymer of any one of claims 2, 4 to 8, 20 to 36 and
39 to 54 wherein R.sub.3 or R.sub.30 is dodecylene.
59. The amine polymer of any one of claims 2 to 8, 20 to 36 and 39
to 58 wherein each R.sub.2 or R.sub.20 is independently C.sub.2 to
C.sub.6 alkylene.
60. The amine polymer of claim 59 wherein each R.sub.2 or R.sub.20
is independently C.sub.2 to C.sub.4 alkylene.
61. The amine polymer of claim 60 wherein each R.sub.2 or R.sub.20
is propylene.
62. The amine polymer of any one of claims 1 to 61 having an in
vivo binding capacity at least 25% greater than colesevelam
hydrochloride when measured at a dosage of 0.5% in male Golden
Syrian hamsters fed a Western diet.
63. The amine polymer of claim 62 wherein the in vivo binding
capacity is at least 50% greater than colesevelam
hydrochloride.
64. The amine polymer of claim 62 wherein the in vivo binding
capacity is at least 75% greater than colesevelam
hydrochloride.
65. The amine polymer of claim 62 wherein the in vivo binding
capacity is at least 100% greater than colesevelam
hydrochloride.
66. The amine polymer of any one of claims 1 to 65 wherein the
binding affinity for bile acids is at least about 0.46 mmol/g when
measured using an in vitro A assay.
67. The amine polymer of any one of claims 1 to 65 wherein the
binding affinity for bile acids is at least about 0.55 mmol/g when
measured using an in vitro A assay.
68. The amine polymer of any one of claims 1 to 65 wherein the
binding affinity for bile acids is at least about 0.60 mmol/g when
measured using an in vitro A assay.
69. The amine polymer of any one of claims 1 to 65 wherein the
binding affinity for bile acids is at least about 0.65 mmol/g when
measured using an in vitro A assay.
70. The amine polymer of any one of claims 1 to 69 having a binding
capacity at least 25% greater than colesevelam hydrochloride when
measured using an in vitro B assay.
71. The amine polymer of claim 70 wherein the in vitro binding
capacity is at least 50% greater than colesevelam hydrochloride
when measured using an in vitro B assay.
72. The amine polymer of claim 70 wherein the in vivo binding
capacity is at least 75% greater than colesevelam hydrochloride
when measured using an in vitro B assay.
73. The amine polymer of claim 70 wherein the in vivo binding
capacity is at least 100% greater than colesevelam hydrochloride
when measured using an in vitro B assay.
74. The amine polymer of any one of claims 1 to 73, wherein, in an
in vivo measurement, on average there are at least 11% primary bile
acids in the feces.
75. The amine polymer of any one of claims 1 to 73, wherein, in an
in vivo measurement, on average there are at least 15% primary bile
acids in the feces.
76. The amine polymer of any one of claims 1 to 75 wherein the
binding capacity for bile acids is at least about 2.22 mmol/g when
measured using the B assay.
77. The amine polymer of any one of claims 1 to 76 wherein the
concentration of bound taurocholic acid is greater than 1.5 mmol/g
polymer and the concentration of unbound taurocholic acid is less
than 1.0 mmol/g polymer when the polymer is placed in a buffer
solution having a 2.5 mM taurocholic acid concentration at
37.degree. C. and the concentration of bound taurocholic acid is
greater than 5.0 mmol/g polymer and the concentration of unbound
taurocholic acid is greater than 4.0 mmol/g polymer when the
polymer is placed in a buffer solution having a taurocholic acid
concentration of at least 10 mM at 37.degree. C.
78. The amine polymer of any one of claims 1 to 76 wherein the
concentration of bound glycodeoxycholate is greater than 1.0 mmol/g
polymer and the concentration of unbound glycodeoxycholate is less
than 0.1 mmol/g polymer when the polymer is placed in a buffer
solution having a 1.25 mM glycodeoxycholate concentration at
37.degree. C. and the concentration of bound glycodeoxycholate is
greater than 6.0 mmol/g polymer and the concentration of unbound
glycodeoxycholate is greater than 2.0 mmol/g polymer when the
polymer is placed in a buffer solution having a glycodeoxycholate
concentration of at least 10 mM at 37.degree. C.
79. An amine polymer useful as a bile acid sequestrant, wherein, in
a buffer solution at 37.degree. C. containing less than 2.6 mM
taurocholic acid, the amine polymer binds more of the acid than
sevelamer and in a buffer solution at 37.degree. C. containing more
than 5.0 mM taurocholic acid the amine polymer binds more of the
acid than colesevelam.
80. The amine polymer of claim 79 having the structure of any one
of claims 1 to 75.
81. The amine polymer of claim 80 wherein the amine polymer is
derived from the polymerization of an amine monomer and a
crosslinking monomer wherein the amine monomer comprises
N,N,N',N'-tetrakis(3-aminopropyl)-1,12-diaminododecane and the
crosslinking monomer comprises 1,3-dichloropropanol.
82. The amine polymer of any one of claims 1 to 81 having a
swelling ratio of from about 1 to about 10.
83. The amine polymer of claim 82 wherein the swelling ratio of
from about 2 to about 6.
84. The amine polymer of claim 83 wherein the swelling ratio of
from about 2 to about 4.
85. The amine polymer of any one of claims 1 to 84 wherein the
polymer is a particle having a mean diameter from about 50 microns
to about 100 microns.
86. The amine polymer of claim 85 wherein the particle is a
bead.
87. The amine polymer of claim 86 wherein the bead is a
substantially spherical bead.
88. A pharmaceutical composition comprising the amine polymer of
any one of claims 1 to 87 and a pharmaceutically acceptable
excipient.
89. A method of reducing serum LDL-cholesterol in an animal subject
comprising administering an effective amount of an amine polymer of
any one of claims 1 to 87 or a pharmaceutical composition of claim
88 to an animal subject in need thereof.
90. A method of treating diabetes in an animal subject comprising
administering an effective amount of an amine polymer of any one of
claims 1 to 87 or a pharmaceutical composition of claim 88 to an
animal subject in need thereof.
91. A method of treating Alzheimer's disease, non-alcoholic
steatohepatitis, pruritus, IBS-D, or idiopathic bile acid
malabsorption in an animal subject comprising administering an
effective amount of an amine polymer of any one of claims 1 to 87
or a pharmaceutical composition of claim 88 to an animal subject in
need thereof.
92. A method of removing bile salts from an animal subject
comprising administering an effective amount of an amine polymer of
any one of claims 1 to 87 or a pharmaceutical composition of claim
88 to an animal subject in need thereof.
93. The method of any one of claims 89 to 92 further comprising
administering an agent that treats dyslipidemia to an animal
subject.
94. The method of claim 93 wherein the agent that treats
dyslipidemia is a hydroxymethyl-glutaryl-coenzyme A (HMG CoA)
reductase inhibitor, a fibrate, a cholesterol absorption inhibitor,
niacin (i.e. nicotinic acid or derivatives thereof), a phytosterol,
an intestinal lipase inhibitor, an intestinal or secreted
phospholipase A2 inhibitor, inhibitors of the synthesis or normal
activity of Apo-B100, agonists of the synthesis or normal activity
of ApoA, or any agent that modulates cholesterol absorption or
metabolism, or a combination thereof to the animal subject.
95. The method of claim 93 or 94 wherein the amine polymer and the
agent that treats dyslipidemia, or the combination thereof are
administered to the animal subject at the same time.
96. The method of claim 93 or 94 wherein the amine polymer and the
agent that treats dyslipidemia, or the combination thereof are
sequentially administered to the animal subject.
97. The method of any one of claims 94 to 96 wherein the agent that
treats dyslipidemia is a HMG CoA reductase inhibitor, the HMG CoA
reductase inhibitor comprising a statin selected from the group
consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin,
mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin,
and a combination thereof.
98. The method of any one of claims 94 to 96 wherein the agent that
treats dyslipidemia is a fibrate, the fibrate comprising
benzafibrate, ciprofibrate, clofibrate, gemfibrozil, fenofibrate,
or a combination thereof.
99. The method of any one of claims 94 to 96 wherein agent that
treats dyslipidemia is a cholesterol absorption inhibitor, the
cholesterol absorption inhibitor comprising ezetimibe.
100. The method of any one of claims 89 to 99 wherein mean serum
LDL is decreased by at least 15% after 2, 4, 12, 26, 52 or more
weeks of treatment with the amine polymer at a daily dose at which
the subject experiences no severe gastrointestinal adverse
events.
101. The method of claim 100 wherein mean serum LDL is decreased by
at least 20% after 2, 4, 12, 26, 52 or more weeks of treatment with
the amine polymer at a daily dose at which the subject experiences
no severe gastrointestinal adverse events.
102. The method of claim 100 wherein mean serum LDL is decreased by
at least 25% after 2, 4, 12, 26, 52 or more weeks of treatment with
the amine polymer at a daily dose at which the subject experiences
no severe gastrointestinal adverse events.
103. The method of claim 100 wherein mean serum LDL is decreased by
at least 30% after 2, 4, 12, 26, 52 or more weeks of treatment with
the amine polymer at a daily dose at which the subject experiences
no severe gastrointestinal adverse events.
104. The method of any one of claims 89 to 99 wherein mean serum
LDL is decreased by at least 15% after 2, 4, 12, 26, 52 or more
weeks of treatment with the amine polymer at a daily dose of 6.0
g/day.
105. The method of claim 104 wherein mean serum LDL is decreased by
at least 20% after 2, 4, 12, 26, 52 or more weeks of treatment with
the amine polymer at a dose of 6.0 g/day or less.
106. The method of claim 104 wherein mean serum LDL is decreased by
at least 25% after 2, 4, 12, 26, 52 or more weeks of treatment with
the amine polymer at a dose of 6.0 g/day or less.
107. The method of claim 104 wherein mean serum LDL is decreased by
at least 30% after 2, 4, 12, 26, 52 or more weeks of treatment with
the amine polymer at a dose of 6.0 g/day or less.
108. The method of any one of claims 89 to 107 wherein the animal
subject has primary hyperlipidemia or coronary heart disease.
109. A method of improving glycemic control in an animal subject
with Type II diabetes mellitus comprising administering an
effective amount of an amine polymer of any one of claims 1 to 87
or a pharmaceutical composition of claim 88 to the animal
subject.
110. The method of any one of claims 89 to 109 further comprising
administration of an agent that treats diabetes to the animal
subject.
111. The method of claim 110 wherein the amine polymer, the agent
that treats diabetes, or the combination thereof are administered
to the animal subject at the same time.
112. The method of claim 107 wherein the amine polymer, the agent
that treats diabetes, or the combination thereof are sequentially
administered to the animal subject.
113. The method of any one of claims 110 to 112 wherein the agent
that treats diabetes is a sulfonylurea, a biguanide, a glitazone, a
thiazolidinedione, an activator of peroxisome
proliferator-activated receptors (PPARs), an alpha-glucosidase
inhibitor, a potassium channel antagonist, an aldose reductase
inhibitor, a glucagon antagonist, a retinoid X receptor (RXR)
antagonist, a farnesoid X receptor (FXR) agonist, a FXR antagonist,
glucagon-like peptide-1 (GLP-1), a GLP-1 analog, a dipeptidyl
peptidase IV (DPP-IV) inhibitor, amylin, an amylin analog, an SGLT2
inhibitor, insulin, an insulin secretagogue, a thyroid hormone, a
thyroid hormone analog or a combination thereof.
114. The method of claim 113 wherein the agent that treats diabetes
is a biguanide, wherein the biguanidine is metformin, buformin,
phenformin, or a combination thereof.
115. The method of claim 113 wherein the agent that treats diabetes
is a thiazolidinedione, wherein the thiazolidinedione is
pioglitazone, rivoglitazone, rosiglitazone, troglitazone, or a
combination thereof.
116. The method of claim 114 wherein the agent that treats diabetes
is a sulfonylurea, wherein the sulfonylurea is acetohexamide,
chlorpropamide, tolbutamide, tolazamide, glipizide, gliclazide,
glibenclamide, gliquidone, glyclopyramide, glimepiride, or a
combination thereof.
117. The method of claim 113 wherein the agent that treats diabetes
is a DPP-IV inhibitor, wherein the DPP-IV inhibitor is alogliptin,
linagliptin, saxagliptin, sitagliptin, vildagliptin, or a
combination thereof.
118. The method of claim 113 wherein the agent that treats diabetes
is a GLP-1 analog, wherein the GLP-1 analog is exenatide,
liraglutide, albiglutide, or a combination thereof.
119. The method of any one of claims 109 to 118 wherein glycated
hemoglobin (Hb.sub.A1c) is decreased by at least 0.5% after 18
weeks of treatment with the amine polymer at a daily dose at which
the subject experiences no severe gastrointestinal adverse
events.
120. The method of any one of claims 109 to 118 wherein fasting
plasma glucose is decreased by at least 14 mg/dL (0.8 mmol/L) after
18 weeks of treatment with the amine polymer at a daily dose at
which the subject experiences no severe gastrointestinal adverse
events.
121. The method of any one of claims 109 to 118 wherein glycated
hemoglobin (Hb.sub.A1c) is decreased by at least 0.5% after 18
weeks of treatment with the amine polymer at a dose of 6.0 g/day or
less.
122. The method of any one of claims 109 to 118 wherein fasting
plasma glucose is decreased by at least 14 mg/dL (0.8 mmol/L) after
18 weeks of treatment with the amine polymer at a dose of 6.0 g/day
or less.
123. The method of any one of claims 89 to 122 wherein the animal
subject is a human.
124. The method of any one of claims 89 to 123 wherein less than
four unit doses of the amine polymer are administered per day.
125. The method of any one of claims 89 to 123 wherein less than
three unit doses of the amine polymer are administered per day.
126. The method of any one of claims 89 to 123 wherein the amine
polymer is administered once per day.
127. The method of any one of claims 89 to 126 wherein the amine
polymer is administered in the form of a chewable or
mouth-disintegrating tablet, a liquid, a powder, a powder contained
within a sachet, a soft gelatin capsule, or a hard gelatin
capsule.
128. The method of any one of claims 89 to 127 wherein a daily
amount of the polymer administered once per day or twice per day
has a bile acid binding capacity of at least 75% of the same daily
amount of the same polymer administered three times per day.
129. The method of claim 128 wherein a daily amount of the polymer
administered once per day or twice per day has a bile acid binding
capacity of at least 85% of the same daily amount of the same
polymer or the same composition administered three times per
day.
130. The method of claim 128 wherein a daily amount of the polymer
administered once per day or twice per day has a bile acid binding
capacity of at least 95% of the same daily amount of the same
polymer or the same composition administered three times per
day.
131. The method of any one of claims 89 to 130 wherein less than
25% of subjects taking the polymer once per day or twice per day
experience mild or moderate gastrointestinal adverse events.
132. The method of any one of claims 89 to 131 wherein the polymer
or composition administered once a day or twice a day have about
substantially the same tolerability as the same polymer or the same
composition of the same daily amount administered three times a
day.
133. The method of any one of claims 128 to 132 wherein the daily
amount is at least 2 grams of polymer.
134. The method of claim 133 wherein the daily amount is at least 4
grams of polymer.
135. The method of claim 133 wherein the daily amount is at least 6
grams of polymer.
136. The method of any one of claims 128 to 135 wherein the
sediment yield stress of the polymer is less than 4000 Pa.
137. The method of claim 136 wherein the sediment yield stress of
the polymer is less than 3000 Pa.
138. The method of claim 136 wherein the sediment yield stress of
the polymer is less than 2500 Pa.
139. The method of any one of claims 128 to 138 wherein a mass of
the polymer particles formed by hydration and sedimentation of the
polymer has a viscosity of less than about 2,500,000 Pas, the
viscosity being measured at a shear rate of 0.01 sec.sup.-1.
140. The method of claim 139 wherein the sedimented mass of
particles has a viscosity of less than 2,000,000 Pas.
141. The method of claim 139 wherein the sedimented mass of
particles has a viscosity of less than 1,500,000 Pas.
142. The method of claim 139 wherein the sedimented mass of
particles has a viscosity of less than 1,000,000 Pas.
143. The method of claim 139 wherein the sedimented mass of
particles has a viscosity of less than 500,000 Pas.
144. The method of any one of claims 136 to 143 wherein the polymer
particles in dry form have a compressibility index of less than
about 30, wherein the compressibility index is defined as
100*(TD-BD)/TD, and BD and TD are the bulk density and tap density,
respectively.
145. The method of claim 144 wherein the compressibility index is
less than about 25.
146. The method of claim 144 wherein the compressibility index is
less than about 20.
147. The method of claim 144 wherein the compressibility index is
less than about 15.
148. The method of claim 144 wherein the compressibility index is
less than about 10.
149. A process for preparing the amine polymers of any one of
claims 1 to 87 comprising contacting the amine monomer with the
crosslinking monomer.
150. An amine of formula 6 having the structure: ##STR00079##
wherein each R.sub.25 is independently C.sub.2 to C.sub.8 alkylene
or C.sub.2 to C.sub.8 alkylene wherein one or more of the
--CH.sub.2-- groups of the alkylene group is replaced with at least
one amide functional group, and R.sub.35 is C.sub.8 to C.sub.16
alkylene, or C.sub.8 to C.sub.16 alkylene wherein one or more of
the --CH.sub.2-- groups of the alkylene group is replaced with an
amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a
heterocyclo functional group.
151. The amine of claim 150 wherein each R.sub.25 is independently
C.sub.3 to C.sub.6 alkylene.
152. The amine of claim 150 wherein each R.sub.25 is propylene.
153. The amine of any one of claims 150 to 152 wherein R.sub.35 is
C.sub.10 to C.sub.14 alkylene.
154. The amine of claim 153 wherein R.sub.35 is decylene.
155. The amine of claim 153 wherein R.sub.35 is dodecylene.
Description
FIELD OF THE INVENTION
[0001] The present invention generally relates to amine polymers
useful to bind bile acids in the gastrointestinal tract of a
patient in need of bile acid removal. These polymers and
pharmaceutical compositions thereof are useful to lower
cholesterol, particularly, non-high density lipoprotein (non-HDL),
or more particularly, low-density lipoprotein (LDL) cholesterol, in
patients in need thereof.
BACKGROUND OF THE INVENTION
[0002] Cholesterol is used by the body as a structural component of
cell membranes. In addition, it is a basic building block for the
production of many hormones, adrenal steroids, vitamin D and bile
acids. Elevated levels of cholesterol carried in particles of low
density lipoprotein cholesterol (LDL-C), or less specifically,
cholesterol not carried in particles of high-density cholesterol
(non HDL-C) are associated with an increased risk of coronary heart
disease. A direct link between high blood cholesterol and
cardiovascular disease (CVD) has been confirmed for both non-statin
and statin trials, consistent with a direct relationship between
LDL-C lowering and CVD reduction. These studies as well as many
others have led to recommendations by health authorities for
lowering elevated total cholesterol and LDL-C levels.
[0003] Bile acids are amphipathic detergents with micelle-forming
properties that are synthesized in the liver from cholesterol and
solubilize lipids to aid in their uptake from the gastrointestinal
lumen. Common bile acids found in man include unconjugated bile
acids (for example cholic acid, chenodeoxycholic acid, deoxycholic
acid, lithocholic acid) and conjugated bile acids (for example
taurocholic acid, glycocholic acid, glycochenodeoxycholic acid,
taurochenodeoxycholic acid, glycodeoxycholic acid, taurodeoxycholic
acid, glycolithocholic acid, and taurolithocholic acid). After a
meal, bile acids are released by the gall bladder. At ileal pH, the
bile acids are predominantly deprotonated and are in their salt
form. The majority of bile acids are reabsorbed, primarily by
active transport in the distal ileum, with elimination in the feces
being the primary route of cholesterol excretion.
[0004] A bile acid sequestrant can bind bile acids to prevent
reabsorption of the bile acids and cause more of the bile acids to
be excreted in the stool. The sequestrant reduces the amount of
bile acids reabsorbed by the intestine and subsequently transported
to the liver. To compensate for this disruption in enterohepatic
circulation and consequent reduction of the endogenous bile acid
pool, hepatic cholesterol 7-alpha-hydroxylase is upregulated. This
results in additional conversion of cholesterol into bile acids,
thereby restoring the bile acid pool. Upregulation of cholesterol
conversion to bile acids also involves a cascade of signaling that
results in up-regulation of liver LDL-receptors and consequent
lowering of serum LDL-C levels, amongst other effects.
[0005] Existing bile acid sequestrants do not reduce the serum
LDL-cholesterol concentration enough without requiring the patient
to take either large amounts of the sequestrant or another drug
that is combined with the sequestrant (e.g., statins). These reduce
patient compliance and tolerance. Thus, bile acid sequestrants
capable of more effectively removing bile salts from the
gastrointestinal tract with equal or lower doses are needed.
SUMMARY OF THE INVENTION
[0006] The present invention provides an amine polymer that is
effective for binding and removing bile salts from the
gastrointestinal tract.
[0007] One aspect of the invention is an amine polymer that
comprises repeat units derived from polymerization of an amine
monomer having six, seven or eight possible reaction sites and a
crosslinking monomer having two or three possible reaction sites,
wherein the molar ratio of the amine monomer to the crosslinking
monomer is in the range of from 1:3 to about 1:1.1, and the amine
polymer has a binding affinity for bile acids of at least 0.46
mmol/g when measured using an in vitro A assay.
[0008] Another aspect is an amine polymer comprising the reaction
product of an amine monomer having six, seven or eight possible
reaction sites and a crosslinking monomer, wherein units of the
polymer have the structure of formula 1
##STR00001##
wherein R.sub.10 is derived from the crosslinking monomer and is
C.sub.2 to C.sub.16 alkylene, --NH--C(NH)--NH--,
--NH--C(NH.sub.2.sup.+)--NH--, or C.sub.2 to C.sub.50 alkylene
wherein one or more of the --CH.sub.2-- groups of the alkylene
group is replaced with an amide, a carbonyl, an ether, an ester, a
cycloalkyl, or a heterocyclo functional group, or one or more of
the --CH.sub.2-- groups of the alkylene group is substituted with
hydroxy; R.sub.30 is derived from the amine monomer and is C.sub.2
to C.sub.12 alkylene, arylene, diformylheterocyclo, or C.sub.2 to
C.sub.12 alkylene wherein one or more of the --CH.sub.2-- groups of
the alkylene group is replaced with an amide, a carbonyl, a
cycloalkyl, an aryl, or a heterocyclo functional group; each
R.sub.20 is independently C.sub.2 to C.sub.6 alkylene or C.sub.2 to
C.sub.6 alkylene wherein one or more of the --CH.sub.2-- groups of
the alkylene group is replaced with an amide functional group; and
at least one of R.sub.10 or R.sub.30 is a hydrophobic group having
a calculated log P (c Log P) of greater than 4.
[0009] A further aspect is an amine polymer that comprises the
reaction product of an amine monomer having six, seven or eight
possible reaction sites and a crosslinking monomer wherein units of
the polymer have the general structure of formula 1 wherein
R.sub.10 is derived from the crosslinking monomer and is C.sub.2 to
C.sub.16 alkylene, --NH--C(NH)--NH--,
--NH--C(NH.sub.2.sup.+)--NH--, or C.sub.2 to C.sub.50 alkylene
wherein one or more of the --CH.sub.2-- groups of the alkylene
group is replaced with an amide, a carbonyl, an ether, an ester, a
cycloalkyl, or a heterocyclo functional group, or one or more of
the --CH.sub.2-- groups of the alkylene group is substituted with
hydroxy; R.sub.30 is derived from the amine monomer and is C.sub.2
to C.sub.6 alkylene; each R.sub.20 is independently C.sub.2 to
C.sub.6 alkylene or C.sub.2 to C.sub.6 alkylene wherein one or more
of the --CH.sub.2-- groups of the alkylene group is replaced with
an amide functional group; and R.sub.10 is a hydrophobic group
having a calculated log P (c Log P) of greater than 4.
[0010] Yet another aspect is an amine polymer that comprises the
reaction product of an amine monomer having six, seven or eight
possible reaction sites and a crosslinking monomer wherein units of
the polymer have the general structure of formula 1 wherein
R.sub.10 is derived from the crosslinking monomer and is C.sub.8 to
C.sub.16 alkylene, or C.sub.8 to C.sub.50 alkylene wherein one or
more of the --CH.sub.2-- groups of the alkylene group is replaced
with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an
aryl, or a heterocyclo functional group; R.sub.30 is derived from
the amine monomer and is C.sub.2 to C.sub.12 alkylene, arylene,
diformylheterocyclo, or C.sub.2 to C.sub.12 alkylene wherein one or
more of the --CH.sub.2-- groups of the alkylene group is replaced
with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an
aryl, or a heterocyclo functional group; and each R.sub.20 is
independently C.sub.2 to C.sub.6 alkylene or C.sub.2 to C.sub.6
alkylene wherein one or more of the --CH.sub.2-- groups of the
alkylene group is replaced with an amide functional group.
[0011] Yet another aspect of the another aspect is an amine polymer
that comprises the reaction product of an amine monomer having six,
seven or eight possible reaction sites and a crosslinking monomer
wherein units of the polymer have the general structure of formula
1 wherein R.sub.10 is derived from the crosslinking monomer and is
C.sub.2 to C.sub.6 alkylene, or C.sub.2 to C.sub.6 alkylene wherein
one or more of the --CH.sub.2-- groups of the alkylene group is
replaced with an amide, a carbonyl, an ether, an ester, a
cycloalkyl, an aryl, or a heterocyclo functional group, or one or
more of the --CH.sub.2-- groups of the alkylene group is
substituted with hydroxy; R.sub.30 is derived from the amine
monomer and is C.sub.8 to C.sub.16 alkylene, arylene,
diformylheterocyclo, or C.sub.8 to C.sub.16 alkylene wherein one or
more of the --CH.sub.2-- groups of the alkylene group is replaced
with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an
aryl, or a heterocyclo functional group, or one or more of the
--CH.sub.2-- groups of the alkylene group is substituted with
hydroxy; and each R.sub.20 is independently C.sub.2 to C.sub.6
alkylene or C.sub.2 to C.sub.6 alkylene wherein one or more of the
--CH.sub.2-- groups of the alkylene group is replaced with an amide
functional group.
[0012] A further aspect of the invention is an amine polymer that
comprises the reaction product of an amine monomer having six,
seven or eight possible reaction sites and a crosslinking monomer
having two or three possible reaction sites, wherein the polymer is
insoluble in water, at least some of said amine secondary nitrogen
atoms are part of a crosslinked polymer network, and the
crosslinking monomer is a hydrophobic group having a calculated log
P (c Log P) of greater than 4; and the crosslinking monomer is a
compound having the formula X-R.sub.1-X, wherein each X is
independently a leaving group, and R.sub.1 is C.sub.8 to C.sub.50
alkylene or C.sub.8 to C.sub.50 alkylene wherein one or more of the
--CH.sub.2-- groups of the alkylene group is replaced with an
amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a
heterocyclo functional group.
[0013] Yet a further aspect of the invention is an amine polymer
that comprises the reaction product of an amine monomer having six,
seven or eight possible reaction sites and a crosslinking monomer
having two or three possible reaction sites, wherein the polymer is
insoluble in water, at least some of said amine secondary nitrogen
atoms are part of a crosslinked polymer network, and the amine
monomer has at least one segment that is a C.sub.8 to C.sub.16
alkylene, arylene, or C.sub.8 to C.sub.50 alkylene wherein one or
more of the --CH.sub.2-- groups of the alkylene group is replaced
with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an
aryl, or a heterocyclo functional group, and the segment has a
calculated log P (c Log P) of greater than 4; and the crosslinking
monomer is a compound having the formula X-R.sub.1-X, wherein each
X is independently a leaving group, and R.sub.1 is C.sub.2 to
C.sub.6 alkylene, or C.sub.2 to C.sub.6 alkylene wherein one or
more of the --CH.sub.2-- groups of the alkylene group is replaced
with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an
aryl, or a heterocyclo functional group, or one or more of the
--CH.sub.2-- groups of the alkylene group is substituted with
hydroxy.
[0014] Another aspect is an amine polymer that comprises repeat
units derived from polymerization of an amine monomer having six,
seven or eight possible reaction sites and a crosslinking monomer
having two or three possible reaction sites, wherein the molar
ratio of the amine monomer to the crosslinking monomer is in the
range of from 1:3 to about 1:1, and wherein: the polymer binds
phosphate in vitro in an amount of less than 0.3 mmol/gram of
polymer when measured using a B assay; and the polymer binds bile
acids with an in vitro capacity of greater than about 3 mmol/gram
of polymer when measured using a B assay.
[0015] Yet another aspect is an amine polymer comprising units of
the polymer having nodes of positive charge separated by aliphatic
segments, wherein the nodes of positive charge have a charge
density of at least 19.0 mEq/g and a molecular weight of at least
200.0 g/mol and at least one aliphatic segment is bonded to each
node of positive charge, the at least one aliphatic segment having
a calculated log P (c Log P) greater than 4 and wherein each of the
nodes of positive charge does not contain an aliphatic segment
having a calculated log P (c Log P) greater than 4.
[0016] A further aspect is an amine polymer comprising units of the
polymer having nodes of positive charge separated by aliphatic
segments, wherein the nodes of positive charge have a charge
density greater than 17.3 mEq/g and the structure of formula A
##STR00002##
each R.sub.20 being independently C.sub.3 to C.sub.8 alkylene or
C.sub.3 to C.sub.8 alkylene wherein one or more of the --CH.sub.2--
groups of the alkylene group is replaced with an amide functional
group; and wherein at least one aliphatic segment is bonded to each
node of positive charge, each aliphatic segment having a calculated
log P (c Log P) greater than 4.
[0017] Yet another aspect is an amine polymer comprising units of
the polymer having the structure of formula 1 wherein R.sub.10 is
C.sub.2 to C.sub.16 alkylene, arylene, --NH--C(NH)--NH--,
--NH--C(NH.sub.2.sup.+)--NH--, dimethylbiphenyl, or C.sub.2 to
C.sub.50 alkylene wherein one or more of the --CH.sub.2-- groups of
the alkylene group is replaced with an amide, a carbonyl, an ether,
an ester, a cycloalkyl, an aryl, or a heterocyclo functional group,
or one or more of the --CH.sub.2-- groups of the alkylene group is
substituted with hydroxy; R.sub.30 is C.sub.2 to C.sub.12 alkylene,
arylene, diformylheterocyclo, or C.sub.2 to C.sub.12 alkylene
wherein one or more of the --CH.sub.2-- groups of the alkylene
group is replaced with an amide, a carbonyl, an ether, an ester, a
cycloalkyl, an aryl, or a heterocyclo functional group; and each
R.sub.20 is independently C.sub.2 to C.sub.8 alkylene or C.sub.2 to
C.sub.8 alkylene wherein one or more of the --CH.sub.2-- groups of
the alkylene group is replaced with an amide functional group; the
polymer binds phosphate in vitro in an amount of less than 0.3
mmol/gram of polymer when measured using a B assay; and the polymer
binds bile acids with an in vitro capacity of greater than about 3
mmol/gram of polymer when measured using a B assay.
[0018] Another aspect is an amine polymer that comprises repeat
units derived from polymerization of an amine monomer and a
crosslinking monomer, wherein the amine monomer is an amine of
formula 2 having the structure:
##STR00003##
wherein each R.sub.2 is independently C.sub.2 to C.sub.8 alkylene
or C.sub.2 to C.sub.8 alkylene wherein one or more of the
--CH.sub.2-- groups of the alkylene group is replaced with at least
one amide functional group, and R.sub.3 is C.sub.2 to C.sub.12
alkylene, arylene, diformylheterocyclo, or C.sub.2 to C.sub.8
alkylene wherein one or more of the --CH.sub.2-- groups of the
alkylene group is replaced with an amide, a carbonyl, an ether, an
ester, a cycloalkyl, an aryl, or a heterocyclo functional group;
and the crosslinking monomer is guanidine, a guanidinium salt, a
compound having the formula X-R.sub.1-X, or a combination thereof,
wherein each X is independently a leaving group, R.sub.1 is C.sub.8
to C.sub.16 alkylene, or C.sub.5 to C.sub.o5 alkylene wherein one
or more of the --CH.sub.2-- groups of the alkylene group is
replaced with an amide, a carbonyl, an ether, an ester, a
cycloalkyl, an aryl, or a heterocyclo functional group.
[0019] Yet another aspect is an amine polymer derived from
polymerization of an amine monomer and a crosslinking monomer
wherein the amine monomer is an amine of formula 3 having the
structure:
##STR00004##
wherein each R.sub.21 is independently C.sub.2 to C.sub.8 wherein
one or more of the --CH.sub.2-- groups of the alkylene group is
replaced with at least one sulfur atom, and R.sub.31 is C.sub.2 to
C.sub.12 alkylene, arylene, diformylheterocyclo, or C.sub.2 to
C.sub.12 alkylene wherein one or more of the --CH.sub.2-- groups of
the alkylene group is replaced with an amide, a carbonyl, an ether,
an ester, a cycloalkyl, an aryl, or a heterocyclo functional group;
and the crosslinking monomer is guanidine, a guanidinium salt, a
compound having the formula X-R.sub.1-X, or a combination thereof,
wherein each X is independently a leaving group, and R.sub.1 is
C.sub.2 to C.sub.16 alkylene, arylene, dimethylbiphenyl, or C.sub.2
to C.sub.50 alkylene wherein one or more of the --CH.sub.2-- groups
of the alkylene group is replaced with an amide, a carbonyl, an
ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional
group, or one or more of the --CH.sub.2-- groups of the alkylene
group is substituted with hydroxy.
[0020] A further aspect is an amine polymer that comprises repeat
units derived from polymerization of an amine monomer of formula 2
and a crosslinking monomer, wherein each R.sub.2 is independently
C.sub.2 to C.sub.8 alkylene or C.sub.2 to C.sub.8 alkylene wherein
one or more of the --CH.sub.2-- groups of the alkylene group is
replaced with an amide functional group; and R.sub.3 is C.sub.2 to
C.sub.12 alkylene, arylene, diformylheterocyclo, or C.sub.2 to
C.sub.12 alkylene wherein one or more of the --CH.sub.2-- groups of
the alkylene group is replaced with an amide, a carbonyl, an ether,
an ester, a cycloalkyl, an aryl, or a heterocyclo functional group;
and a portion of the nitrogen atoms of the amine polymer are
substituted with a ligand selected from aminoalkyl, aryl,
arylalkyl, oxoalkyl, cycloalkyl, (cycloalkyl)alkyl, guanidino,
heterocyclo, heterocyloalkyl, (trialkylammonio)alkyl, 2-(protected
amino)-m-(heterocyclo)-1-oxoC.sub.malkyl, 2-(protected
amino)-1-oxoC.sub.malkyl, 2-(protected
amino)-3-methyl-1-oxoC.sub.malkyl, 2-(protected
amino)-4-methyl-1-oxoC.sub.malkyl, 2-(protected
amino)-1-oxo-m-arylC.sub.malkyl, 2-(protected
amino)-m-(alkylthio)-1-oxoC.sub.malkyl, 2-(protected
amino)-m-(aryl)-1-oxoC.sub.malkyl, 2-(protected
amino)-m-carboxy-1-oxoC.sub.malkyl, 2-(protected
amino)-m-guanidino-1-oxoC.sub.malkyl, 2-(protected
amino)-(m-1)-hydroxy-1-oxoC.sub.malkyl, 2-(protected
amino)-m-hydroxy-1-oxoC.sub.malkyl, 2-(protected
amino)-m-mercapto-1-oxoC.sub.malkyl,
m-(alkylamino)-m-oxoC.sub.malkyl, m-(alkylheterocyclo)C.sub.malkyl,
m-amino-2-(protected amino)-1-oxoC.sub.malkyl, m-amino-2-(protected
amino)-1,m-dioxoC.sub.malkyl,
m-(x-aminoC.sub.xalkyl)heterocycloC.sub.malkyl,
(m-1)-amino-m-(heterocyclo)-1-oxoC.sub.malkyl,
m-(arylalkylamino)-m-oxoC.sub.malkyl,
m-(x-(alkylthio)C.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-aminoC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-amino-x-oxoC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-carboxyC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(heterocycloalkylamino)-m-oxoC.sub.malkyl,
m-(x-hydroxyC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-((x-1)-hydroxyC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-mercaptoC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-trialkylammonioC.sub.xalkyl)heterocycloC.sub.malkyl,
m-(x-(2-(alkoxy)benzamido)C.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-(3-(alkoxy)benzamido)C.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-(4-(alkoxy)benzamido)C.sub.xalkylamino)-m-oxoC.sub.malkyl, a
ligand of formula 4
*-R.sub.46-R.sub.47-R.sub.48 (4)
or a combination thereof, wherein R.sub.46 is C.sub.6 to C.sub.16
alkylene, R.sub.47 is
1,y-bis(1-methylpiperidin-4-yl)C.sub.yalkylene, R.sub.48 is C.sub.6
to C.sub.16 alkyl, m is an integer from 3 to 12, x is an integer
from 1 to 12, y is an integer from 1 to 14, and z is an integer
from 1 to 16.
[0021] Another aspect of the invention is an amine of formula 6
having the structure:
##STR00005##
wherein each R.sub.25 is independently C.sub.2 to C.sub.8 alkylene
or C.sub.2 to C.sub.8 alkylene wherein one or more of the
--CH.sub.2-- groups of the alkylene group is replaced with at least
one amide functional group, and R.sub.35 is C.sub.8 to C.sub.16
alkylene, or C.sub.8 to C.sub.16 alkylene wherein one or more of
the --CH.sub.2-- groups of the alkylene group is replaced with an
amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a
heterocyclo functional group.
[0022] Yet a further aspect is an amine polymer useful as a bile
acid sequestrant, wherein, in a buffer solution at 37.degree. C.
containing less than 2.6 mM taurocholic acid, the amine polymer
binds more of the acid than sevelamer and in a buffer solution at
37.degree. C. containing more than 5.0 mM taurocholic acid the
amine polymer binds more bile acid that colesevelam.
[0023] Other objects and features will be in part apparent and in
part pointed out hereinafter.
BRIEF DESCRIPTION OF THE DRAWINGS
[0024] FIG. 1A is a graph of the unbound taurocholic acid
concentration versus the bound taurocholic acid concentration for
various bile acid binders at taurocholic acid concentrations up to
20 mM.
[0025] FIG. 1B is the same graph as FIG. 1A at taurocholic acid
concentrations up to 5 mM.
[0026] FIG. 2A is a graph of the unbound glycodeoxycholic acid
concentration versus the bound taurocholic acid concentration for
various bile acid binders at glycodeoxycholic acid concentrations
up to 20 mM.
[0027] FIG. 2B is the same graph as FIG. 2A at glycodeoxycholic
acid concentrations up to 5 mM.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0028] The present invention is an amine polymer useful for binding
bile salts, pharmaceutical compositions comprising the amine
polymer, and methods of treating hypercholesterolemia, diabetes or
other conditions that might benefit from bile acid sequestration in
the gastrointestinal tract and/or increased fecal excretion of bile
acids and/or bile acid metabolites, by administering the amine
polymer to an animal subject in need thereof. The amine polymers
exhibit increased affinity and/or capacity for binding bile salts
and/or their retention as compared to commercial bile acid
sequestrants. The polymers have a combination of hydrogen bonding
and electrostatic properties, charged nitrogen atoms,
hydrophobicity and/or polymer architecture to provide such
increased affinity and/or capacity for bile salts. The terms "bile
acid" and "bile salt" are used interchangeably herein and those of
skill in the art will understand that a bile acid will be present
in salt form and, to a lesser degree, in the protonated form in the
gastrointestinal tract.
[0029] The amine polymer can comprise repeat units derived from
polymerization of an amine monomer having six, seven or eight
possible reaction sites and a crosslinking monomer having two or
three possible reaction sites, wherein the molar ratio of the amine
monomer to the crosslinking monomer is in the range of from 1:3 to
about 1:1.1, and the amine polymer has a binding affinity for bile
acids of at least 0.46 mmol/g when measured using an in vitro A
assay.
[0030] Also, the amine polymer can comprise the reaction product of
an amine monomer having six, seven or eight possible reaction sites
and a crosslinking monomer, wherein units of the polymer have the
structure of formula 1:
##STR00006##
wherein R.sub.10 is derived from the crosslinking monomer and is
C.sub.2 to C.sub.16 alkylene, --NH--C(NH)--NH--,
--NH--C(NH.sub.2.sup.+)--NH--, or C.sub.2 to C.sub.50 alkylene
wherein one or more of the --CH.sub.2-- groups of the alkylene
group is replaced with an amide, a carbonyl, an ether, an ester, a
cycloalkyl, or a heterocyclo functional group, or one or more of
the --CH.sub.2-- groups of the alkylene group is substituted with
hydroxy; R.sub.30 is derived from the amine monomer and is C.sub.2
to C.sub.12 alkylene, arylene, diformylheterocyclo, or C.sub.2 to
C.sub.12 alkylene wherein one or more of the --CH.sub.2-- groups of
the alkylene group is replaced with an amide, a carbonyl, a
cycloalkyl, an aryl, or a heterocyclo functional group; each
R.sub.20 is independently C.sub.2 to C.sub.6 alkylene or C.sub.2 to
C.sub.6 alkylene wherein one or more of the --CH.sub.2-- groups of
the alkylene group is replaced with an amide functional group; and
at least one of R.sub.10 or R.sub.30 is a hydrophobic group having
a calculated log P (c Log P) of greater than 4.
[0031] The amine polymer can also comprise the reaction product of
an amine monomer having six, seven or eight possible reaction sites
and a crosslinking monomer wherein units of the polymer have the
general structure of formula 1 wherein R.sub.10 is derived from the
crosslinking monomer and is C.sub.2 to C.sub.16 alkylene,
--NH--C(NH)--NH--, --NH--C(NH.sub.2.sup.+)--NH--, or C.sub.2 to
C.sub.50 alkylene wherein one or more of the --CH.sub.2-- groups of
the alkylene group is replaced with an amide, a carbonyl, an ether,
an ester, a cycloalkyl, or a heterocyclo functional group, or one
or more of the --CH.sub.2-- groups of the alkylene group is
substituted with hydroxy; R.sub.30 is derived from the amine
monomer and is C.sub.2 to C.sub.6 alkylene; each R.sub.20 is
independently C.sub.2 to C.sub.6 alkylene or C.sub.2 to C.sub.6
alkylene wherein one or more of the --CH.sub.2-- groups of the
alkylene group is replaced with an amide functional group; and
R.sub.10 is a hydrophobic group having a calculated log P (c Log P)
of greater than 4.
[0032] Additionally, the amine polymer can comprise the reaction
product of an amine monomer having six, seven or eight possible
reaction sites and a crosslinking monomer wherein units of the
polymer have the general structure of formula 1 wherein R.sub.10 is
derived from the crosslinking monomer and is C.sub.8 to C.sub.16
alkylene, or C.sub.8 to C.sub.50 alkylene wherein one or more of
the --CH.sub.2-- groups of the alkylene group is replaced with an
amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a
heterocyclo functional group; R.sub.30 is derived from the amine
monomer and is C.sub.2 to C.sub.12 alkylene, arylene,
diformylheterocyclo, or C.sub.2 to C.sub.12 alkylene wherein one or
more of the --CH.sub.2-- groups of the alkylene group is replaced
with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an
aryl, or a heterocyclo functional group; and each R.sub.20 is
independently C.sub.2 to C.sub.6 alkylene or C.sub.2 to C.sub.6
alkylene wherein one or more of the --CH.sub.2-- groups of the
alkylene group is replaced with an amide functional group.
[0033] The amine polymer can also comprise the reaction product of
an amine monomer having six, seven or eight possible reaction sites
and a crosslinking monomer wherein units of the polymer have the
general structure of formula 1 wherein R.sub.10 is derived from the
crosslinking monomer and is C.sub.2 to C.sub.6 alkylene, or C.sub.2
to C.sub.6 alkylene wherein one or more of the --CH.sub.2-- groups
of the alkylene group is replaced with an amide, a carbonyl, an
ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional
group, or one or more of the --CH.sub.2-- groups of the alkylene
group is substituted with hydroxy; R.sub.30 is derived from the
amine monomer and is C.sub.8 to C.sub.16 alkylene, arylene,
diformylheterocyclo, or C.sub.8 to C.sub.16 alkylene wherein one or
more of the --CH.sub.2-- groups of the alkylene group is replaced
with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an
aryl, or a heterocyclo functional group; and each R.sub.20 is
independently C.sub.2 to C.sub.6 alkylene or C.sub.2 to C.sub.6
alkylene wherein one or more of the --CH.sub.2-- groups of the
alkylene group is replaced with an amide functional group.
[0034] The amine polymers described herein can have a binding
affinity for bile acids of at least 0.46 mmol/g when measured in
vitro using an in vitro A assay. The amine polymers described
herein can also have a molar ratio of the amine monomer to the
crosslinking monomer in the range of from 1:3 to about 1:1.1. For
the amine polymers having a structure of formula 1, the primary and
secondary amine atoms can have a calculated ratio from 1:1 to about
1:5.
[0035] The amine polymer can also comprise the reaction product of
an amine monomer having six, seven or eight possible reaction sites
and a crosslinking monomer having two or three possible reaction
sites, wherein the polymer is insoluble in water, at least some of
said amine secondary nitrogen atoms are part of a crosslinked
polymer network, and the crosslinking monomer is a compound having
the formula X-R.sub.1-X, wherein each X is independently a leaving
group, and R.sub.1 is C.sub.8 to C.sub.50 alkylene, or C.sub.8 to
C.sub.50 alkylene wherein one or more of the --CH.sub.2-- groups of
the alkylene group is replaced with an amide, a carbonyl, an ether,
an ester, a cycloalkyl, an aryl, or a heterocyclo functional group
and the calculated log P (c Log P) of the crosslinking monomer is
greater than 4.
[0036] The amine polymer can also comprise the reaction product of
an amine monomer having six, seven or eight possible reaction sites
and a crosslinking monomer having two or three possible reaction
sites, wherein the polymer is insoluble in water, at least some of
said amine secondary nitrogen atoms are part of a crosslinked
polymer network, and the amine monomer has at least one segment
that is a C.sub.8 to C.sub.16 alkylene, arylene, or C.sub.8 to
C.sub.50 alkylene wherein one or more of the --CH.sub.2-- groups of
the alkylene group is replaced with an amide, a carbonyl, an ether,
an ester, a cycloalkyl, an aryl, or a heterocyclo functional group,
and a calculated log P (c Log P) of the at least one segment of the
amine monomer is greater than 4; and the crosslinking monomer is a
compound having the formula X-R.sub.1-X, wherein each X is
independently a leaving group, and R.sub.1 is C.sub.2 to C.sub.6
alkylene, or C.sub.2 to C.sub.6 alkylene wherein one or more of the
--CH.sub.2-- groups of the alkylene group is replaced with an
amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a
heterocyclo functional group, or one or more of the --CH.sub.2--
groups of the alkylene group is substituted with hydroxy.
[0037] Further, the amine polymer can comprise repeat units derived
from polymerization of an amine monomer having six, seven or eight
possible reaction sites and a crosslinking monomer having two or
three possible reaction sites, wherein the molar ratio of the amine
monomer to the crosslinking monomer is in the range of from 1:3 to
about 1:1.1, and wherein: the polymer binds phosphate in vitro in
an amount of less than 0.3 mmol/gram of polymer when measured using
a B assay; and the polymer binds bile acids with an in vitro
capacity of greater than about 3 mmol/gram of polymer when measured
using a B assay.
[0038] The amine polymer can comprise units of the polymer having
the structure of formula 1 wherein R.sub.10 is C.sub.2 to C.sub.16
alkylene, arylene, --NH--C(NH)--NH--,
--NH--C(NH.sub.2.sup.+)--NH--, dimethylbiphenyl, or C.sub.2 to
C.sub.50 alkylene wherein one or more of the --CH.sub.2-- groups of
the alkylene group is replaced with an amide, a carbonyl, an ether,
an ester, a cycloalkyl, an aryl, or a heterocyclo functional group,
or one or more of the --CH.sub.2-- groups of the alkylene group is
substituted with hydroxy; R.sub.30 is C.sub.2 to C.sub.12 alkylene,
arylene, diformylheterocyclo, or C.sub.2 to C.sub.12 alkylene
wherein one or more of the --CH.sub.2-- groups of the alkylene
group is replaced with an amide, a carbonyl, an ether, an ester, a
cycloalkyl, an aryl, or a heterocyclo functional group; and each
R.sub.20 is independently C.sub.2 to C.sub.8 alkylene or C.sub.2 to
C.sub.8 alkylene wherein one or more of the --CH.sub.2-- groups of
the alkylene group is replaced with an amide functional group; the
polymer binds phosphate in vitro in an amount of less than 0.3
mmol/gram of polymer when measured using a B assay; and the polymer
binds bile acids with an in vitro capacity of greater than about 3
mmol/gram of polymer when measured using a B assay. In some
instances, the amine polymer comprises the reaction product of an
amine monomer having six, seven or eight possible reaction sites
and a crosslinking monomer and R.sub.10 is derived from the
crosslinking monomer and R.sub.30 is derived from the amine
monomer. In some cases, the amine polymer binds phosphate in vitro
in an amount of less than 0.2 mmol/gram of polymer when measured
using a B assay.
[0039] Some of the amine polymers having units of the polymer of
Formula 1 can have an R.sub.30 of ethylene, propylene, butylene,
pentylene, hexylene, heptylene, octylene, decylene, undecylene,
dodecylene, 1,4-phenylenedimethyl, 1,6-dioxohexane-1,6-diyl, or
2,6-diformylpyridine. Further, in some amine polymers having units
of the polymer of Formula 1, R.sub.30 is C.sub.3 to C.sub.12
alkylene; particularly, R.sub.30 is butylene; also R.sub.30 can be
decylene or dodecylene. Further for amine polymers having units of
the polymer of Formula 1, each R.sub.20 can independently be
C.sub.2 to C.sub.6 alkylene; each R.sub.20 can independently be
C.sub.2 to C.sub.4 alkylene; particularly, each R.sub.20 can be
propylene.
[0040] Also, the amine polymer comprises units of the polymer
having nodes of positive charge separated by aliphatic segments.
The nodes of positive charge have a charge density of at least 19.0
mEq/g and a molecular weight of at least 200.0 g/mol and at least
one aliphatic segment is bonded to each node of positive charge,
the at least one aliphatic segment having a calculated log P (c Log
P) greater than 4 and wherein each of the nodes of positive charge
does not contain an aliphatic segment having a calculated log P (c
Log P) greater than 4.
[0041] In some instances, the amine polymer comprises units of the
polymer having nodes of positive charge separated by aliphatic
segments, wherein the nodes of positive charge have a charge
density greater than 17.3 mEq/g and the structure of formula A
##STR00007##
wherein each R.sub.20 is independently C.sub.3 to C.sub.8 alkylene
or C.sub.3 to C.sub.8 alkylene wherein one or more of the
--CH.sub.2-- groups of the alkylene group is replaced with an amide
functional group; and wherein at least one aliphatic segment is
bonded to each node of positive charge, each aliphatic segment
having a calculated log P (c Log P) greater than 4. The aliphatic
segments separating the nodes of positive charge can be a C.sub.8
to C.sub.16 alkylene, or C.sub.8 to C.sub.50 alkylene wherein one
or more of the --CH.sub.2-- groups of the alkylene group is
replaced with an amide, a carbonyl, an ether, an ester, a
cycloalkyl, an aryl, or a heterocyclo functional group. For some of
the polymers, the polymer binds phosphate in vitro in an amount of
less than 0.3 mmol/gram of polymer when measured using a B assay;
and the polymer binds bile acids with an in vitro capacity of
greater than about 3 mmol/gram of polymer when measured using the B
assay. In some cases, the polymer binds phosphate in vitro in an
amount of less than 0.2 mmol/gram of polymer when measured using
the B assay. Also, in some of the polymers, each of the nodes of
positive charge does not contain an aliphatic segment having a
calculated log P (c Log P) greater than 4.
[0042] An amine polymer can also comprise repeat units derived from
polymerization of an amine monomer and a crosslinking monomer,
wherein the amine monomer is an amine of formula 2 having the
structure:
##STR00008##
wherein each R.sub.2 is independently C.sub.2 to C.sub.8 alkylene
or C.sub.2 to C.sub.8 alkylene wherein one or more of the
--CH.sub.2-- groups of the alkylene group is replaced with at least
one amide functional group, and R.sub.3 is C.sub.2 to C.sub.12
alkylene, arylene, diformylheterocyclo, or C.sub.2 to C.sub.8
alkylene wherein one or more of the --CH.sub.2-- groups of the
alkylene group is replaced with an amide, a carbonyl, an ether, an
ester, a cycloalkyl, an aryl, or a heterocyclo functional group;
and the crosslinking monomer is guanidine, a guanidinium salt, a
compound having the formula X-R.sub.1-X, or a combination thereof,
wherein each X is independently a leaving group, R.sub.1 is C.sub.8
to C.sub.16 alkylene, or C.sub.5 to C.sub.50 alkylene wherein one
or more of the --CH.sub.2-- groups of the alkylene group is
replaced with an amide, a carbonyl, an ether, an ester, a
cycloalkyl, an aryl, or a heterocyclo functional group, or one or
more of the --CH.sub.2-- groups of the alkylene group is
substituted with hydroxy. In some instances, R.sub.1 is C.sub.8 to
C.sub.16 alkylene, or C.sub.5 to C.sub.50 alkylene wherein one or
more of the --CH.sub.2-- groups of the alkylene group is replaced
with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an
aryl, or a heterocyclo functional group.
[0043] Some of the amine polymers described herein above are
derived from an amine monomer which is an amine of formula 2
wherein each R.sub.2 is independently C.sub.2 to C.sub.8 alkylene
or C.sub.2 to C.sub.8 alkylene wherein one or more of the
--CH.sub.2-- groups of the alkylene group is replaced with an amide
functional group, and R.sub.3 is C.sub.2 to C.sub.12 alkylene,
arylene, diformylheterocyclo, or C.sub.2 to C.sub.8 alkylene
wherein one or more of the --CH.sub.2-- groups of the alkylene
group is replaced with an amide, a carbonyl, an ether, an ester, a
cycloalkyl, an aryl, or a heterocyclo functional group. In some
instances, the crosslinking monomer used in deriving the polymers
is guanidine, a guanidinium salt, a compound having the formula
X-R.sub.1-X, or a combination thereof, wherein each X is
independently a leaving group, R.sub.1 is C.sub.8 to C.sub.16
alkylene, dimethylbiphenyl, or C.sub.2 to C.sub.50 alkylene wherein
one or more of the --CH.sub.2-- groups of the alkylene group is
replaced with a phenyl, piperidinium or imidazolium functional
group. In some cases, R.sub.1 is C.sub.8 to C.sub.16 alkylene,
dimethylbiphenyl, or C.sub.2 to C.sub.50 alkylene wherein one or
two of the --CH.sub.2-- groups of the alkylene group is replaced
with one or two phenyl, piperidinium or imidazolium functional
groups.
[0044] Others of the amine polymers described herein are derived
from the polymerization of an amine of formula 2 wherein each
R.sub.2 is independently C.sub.2 to C.sub.8 alkylene or C.sub.2 to
C.sub.8 alkylene wherein one or more of the --CH.sub.2-- groups of
the alkylene group is replaced with an amide functional group, and
R.sub.3 is C.sub.8 to C.sub.16 alkylene, arylene,
diformylheterocyclo, or C.sub.8 to C.sub.16 alkylene wherein one or
more of the --CH.sub.2-- groups of the alkylene group is replaced
with an amide, a carbonyl, an ether, an ester, a cycloalkyl, an
aryl, or a heterocyclo functional group; and a crosslinking monomer
which is a compound having the formula X-R.sub.1-X, wherein each X
is independently a leaving group, R.sub.1 is C.sub.2 to C.sub.6
alkylene or C.sub.2 to C.sub.6 alkylene wherein one or more of the
--CH.sub.2-- groups of the alkylene group is replaced with an
amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a
heterocyclo functional group, or one or more of the --CH.sub.2--
groups of the alkylene group is substituted with hydroxy.
[0045] The amine polymers derived from an amine monomer of Formula
2 can have an R.sub.3 of ethylene, propylene, butylene, pentylene,
hexylene, heptylene, octylene, decylene, undecylene, dodecylene,
1,4-phenylenedimethyl, 1,6-dioxohexane-1,6-diyl, or
2,6-diformylpyridine. Further, in some amine polymers derived from
an amine monomer of Formula 2, R.sub.3 is C.sub.3 to C.sub.12
alkylene; particularly, R.sub.3 is butylene; also R.sub.3 can be
decylene or dodecylene. Further for amine polymers derived from an
amine monomer of Formula 2, each R.sub.2 can independently be
C.sub.2 to C.sub.6 alkylene; each R.sub.2 can independently be
C.sub.2 to C.sub.4 alkylene; particularly, each R.sub.2 can be
propylene.
[0046] In some embodiments, the amine polymer can have the general
structure of formula 5
##STR00009##
wherein R.sub.10, R.sub.20, and R.sub.30 have the definitions above
in connection with formula 1. Formula 5 represents a crosslink
within the polymer network, which may form. In some instances, the
crosslink can be represented in Formula 5 as a tetrasubstituted
nitrogen (quaternized) to generate a formula containing
N(R.sub.20)(R.sub.10).sub.3 or the crosslink can be represented in
Formula 1 as N(R.sub.20)(R.sub.10)(R.sub.10).
[0047] Additionally, the amine polymer can be derived from
polymerization of an amine monomer and a crosslinking monomer
wherein the amine monomer is an amine of formula 3 having the
structure:
##STR00010##
wherein each R.sub.21 is independently C.sub.2 to C.sub.8 wherein
one or more of the --CH.sub.2-- groups of the alkylene group is
replaced with at least one sulfur atom, and R.sub.31 is C.sub.2 to
C.sub.12 alkylene, arylene, diformylheterocyclo, or C.sub.2 to
C.sub.12 alkylene wherein one or more of the --CH.sub.2-- groups of
the alkylene group is replaced with an amide, a carbonyl, an ether,
an ester, a cycloalkyl, an aryl, or a heterocyclo functional group;
and the crosslinking monomer is guanidine, a guanidinium salt, a
compound having the formula X-R.sub.1-X, or a combination thereof,
wherein each X is independently a leaving group, and R.sub.1 is
C.sub.2 to C.sub.16 alkylene, arylene, dimethylbiphenyl, or C.sub.2
to C.sub.50 alkylene wherein one or more of the --CH.sub.2-- groups
of the alkylene group is replaced with an amide, a carbonyl, an
ether, an ester, a cycloalkyl, an aryl, or a heterocyclo functional
group, or one or more of the --CH.sub.2-- groups of the alkylene
group is substituted with hydroxy. In some instances, each R.sub.21
is m-sulfidoC.sub.malkyl, m is an integer from 1 to 6 and R.sub.31
is C.sub.3 to C.sub.8 alkylene. In some amine polymers derived from
an amine monomer of Formula 3, R.sub.31 is C.sub.3 to C.sub.12
alkylene; particularly, R.sub.31 is butylene; also R.sub.31 can be
decylene or dodecylene.
[0048] Further, an amine of formula 6 has the structure:
##STR00011##
wherein each R.sub.25 is independently C.sub.2 to C.sub.8 alkylene
or C.sub.2 to C.sub.8 alkylene wherein one or more of the
--CH.sub.2-- groups of the alkylene group is replaced with at least
one amide functional group, and R.sub.35 is C.sub.8 to C.sub.16
alkylene, or C.sub.8 to C.sub.16 alkylene wherein one or more of
the --CH.sub.2-- groups of the alkylene group is replaced with an
amide, a carbonyl, an ether, an ester, a cycloalkyl, an aryl, or a
heterocyclo functional group. In some embodiments, each R.sub.25 is
independently C.sub.3 to C.sub.6 alkylene; particularly propylene.
In various instances, R.sub.35 is C.sub.10 to C.sub.14 alkylene;
particularly decylene or dodecylene. The amine of Formula 6 can be
used as an amine monomer in the polymerization reaction to form
some of the amine polymers described herein.
[0049] Many of the amine polymers described herein can undergo a
post polymerization reaction, which comprises reaction of the amine
polymer with at least one additional crosslinking monomer or a
ligand. When the amine polymers undergo such a post polymerization
reaction with two crosslinking monomers, the reaction can proceed
with both the crosslinking monomers present (e.g., by using cross
linking monomers with different reactivity rates) or the amine
monomer can react with one crosslinking monomer and then react with
the second crosslinking monomer (e.g., the cross linking monomers
are added sequentially to the reactor or the polymer is recovered
prior to reaction with the second cross linking monomer). These
reactions with two or more different crosslinking monomers can
provide improved yield or improved physical characteristics. When
these further reactions occur with an additional ligand, the
crosslinking monomer and the ligand can be added simultaneously or
sequentially as well.
[0050] Further, the amine monomer is other than a dendrimer wherein
a dendrimer has a hyperbranched fractal-like structure that
emanates from a central core and consists of a large number of
terminal groups with a definite geometrical growth (Peppas et al.,
"Dendrimers and star polymers for pharmaceutical and medical
applications," Proceed. Intern. Symp. Control. Rel. Bioact. Mater,
20:143-144 (1993)).
[0051] In the amine polymers described herein the crosslinking
monomer can be guanidine, a guanidinium salt, a compound having the
formula X-R.sub.1-X, or a combination thereof, wherein each X is
independently a leaving group, and R.sub.1 is C.sub.2 to C.sub.16
alkylene, arylene, dimethylbiphenyl, or C.sub.2 to C.sub.50
alkylene wherein one or more of the --CH.sub.2-- groups of the
alkylene group is replaced with an amide, a carbonyl, an ether, an
ester, a cycloalkyl, an aryl, or a heterocyclo functional group, or
one or more of the --CH.sub.2-- groups of the alkylene group is
substituted with hydroxy. In some instances, the crosslinking
monomer is X-R.sub.1-X wherein each X is independently a leaving
group, and R.sub.1 is C.sub.8 to C.sub.16 alkylene, or C.sub.8 to
C.sub.50 alkylene wherein one or more of the --CH.sub.2-- groups of
the alkylene group is replaced with a heterocyclo functional group.
In other instances, the crosslinking monomer is X-R.sub.1-X wherein
each X is independently a leaving group, and R.sub.1 is C.sub.2 to
C.sub.6 alkylene wherein one or more of the --CH.sub.2-- groups of
the alkylene group is replaced with a heterocyclo functional group,
or one or more of the --CH.sub.2-- groups of the alkylene group is
substituted with hydroxy. In other instances, the crosslinking
monomer is guanidine, a guanidinium salt, a compound having the
formula X-R.sub.1-X, or a combination thereof, wherein each X is
independently a leaving group, R.sub.1 is C.sub.8 to C.sub.16
alkylene, dimethylbiphenyl, or C.sub.2 to C.sub.50 alkylene wherein
one or more of the --CH.sub.2-- groups of the alkylene group is
replaced with one or two phenyl, piperidinium or imidazolium
functional groups.
[0052] For the amine polymers having a crosslinking monomer of
formula X-R.sub.1-X, where R.sub.1 is C.sub.2 to C.sub.50 alkylene
wherein one or more of the --CH.sub.2-- groups of the alkylene
group is replaced with one or two phenyl, piperidinium or
imidazolium functional groups, the functional groups can be
p-xylene, 1,3-bis(m-haloC.sub.malkyl)-1H-imidazol-3-ium,
4,4'-(C.sub.xalkane-1,x-diyl)bis(1-(m-haloC.sub.malkyl)-1-methylpiperidin-
ium), or
1-(q-haloC.sub.qalkyl)-3-(m-(3-(p-haloC.sub.palkyl)-1H-imidazol-3-
-ium-1-yl)C.sub.malkyl)-1H-imidazol-3-ium, wherein m is an integer
from 2 to 14, p is an integer from 2 to 14, q is an integer from 2
to 14, and x is an integer from 2 to 8. For some amine polymers
where the crosslinking monomer is X-R.sub.1-X, X is independently a
leaving group, and R.sub.1 is C.sub.8 to C.sub.50 alkylene or
C.sub.8 to C.sub.50 alkylene wherein one or more of the
--CH.sub.2-- groups of the alkylene group is replaced with a
heterocyclo functional group.
[0053] In various amine polymers, the crosslinking monomer is
guanidine, guanidinium hydrohalide,
1,3-bis(3-halopropyl)-1H-imidazol-3-ium,
4,4'-(propane-1,3-diyl)bis(1-(10-halodecyl)-1-methylpiperidinium),
1-(12-halododecyl)-3-(12-(3-(12-halododecyl)-1H-imidazol-3-ium-1-yl)dodec-
yl)-1H-imidazol-3-ium, or
1-(10-halodecyl-3-(10-(3-(10-halodecyl)-1H-imidazol-3-ium-1-yl)decyl)-1H--
imidazol-3-ium.
[0054] In some of the amine polymers, the crosslinking monomer is
guanidine, a compound having the formula X-R.sub.1-X wherein
R.sub.1 is C.sub.8 to C.sub.16 alkylene, or a combination thereof,
and the polymer comprises a comonomer, the comonomer being
C.sub.malkane-1,m-diyldiamine, alkylenedicycloalkanamine,
(m-aminoC.sub.malkyl)heterocycle,
3-(m-aminoC.sub.malkyl)-1H-imidazol-3-ium, or a combination
thereof, wherein m is an integer from 2 to 16, and each X is
independently a leaving group, such as hexane-1,6-diyldiamine,
heptane-1,7-diylamine, octane-1,8-diyldiamine,
nonane-1,9-diylamine, decane-1,10-diyldiamine,
undecane-1,11-diylamine, dodecane-1,12-diyldiamine,
4,4'-methylenedicyclohexanamine,
3-(3-aminopropyl)-1H-imidazol-3-ium, or a combination thereof. In
some of the amine polymers, R.sub.1 is C.sub.8 to C.sub.14
alkylene; particularly, R.sub.1 is decylene or dodecylene. In other
amine polymers, R.sub.1 is C.sub.2 to C.sub.6 alkylene or C.sub.2
to C.sub.6 alkylene wherein one or more of the --CH.sub.2-- groups
of the alkylene group is substituted with hydroxy; particularly,
R.sub.1 is --CH.sub.2--CH(OH)--CH.sub.2--, and the polymer
comprises the comonomer.
[0055] In the amine polymers where the crosslinking monomer is
X-R.sub.1-X, X is halo, epoxy, diaziridino, mesylate, sulfate,
phosphate, aldehyde, ketone, or a combination thereof. Leaving
groups are well known and can be selected from those known in the
art, such as those in Larock, Comprehensive Organic Transformations
(VCH 1989), e.g., p. 397 et seq.
[0056] The amine polymers can comprise a comonomer, the comonomer
being C.sub.malkane-1,m-diyldiamine, alkylenedicycloalkanamine,
(m-aminoC.sub.malkyl)heterocycle,
3-(m-aminoC.sub.malkyl)-1H-imidazol-3-ium, or a combination
thereof, wherein m is an integer from 2 to 16, and each X is
independently a leaving group.
[0057] In one preferred embodiment, R.sub.1 is C.sub.8 to C.sub.14
alkylene or C.sub.8 to C.sub.12 alkylene, such as decylene or
dodecylene. In another preferred embodiment, R.sub.1 is a C.sub.2
to C.sub.6 alkylene wherein one or more of the --CH.sub.2-- groups
of the alkylene group is substituted with hydroxy, and more
preferably a C.sub.2 to C.sub.4 alkylene wherein one or more of the
--CH.sub.2-- groups of the alkylene group is substituted with
hydroxy, such as --CH.sub.2--CH(OH)--CH.sub.2--. In the amine
polymers wherein units of the polymer have the structure of Formula
1, R.sub.10 can be C.sub.8 to C.sub.14 alkylene or C.sub.8 to
C.sub.12 alkylene, such as decylene or dodecylene. In another
preferred embodiment, R.sub.10 is a C.sub.2 to C.sub.6 alkylene
wherein one or more of the --CH.sub.2-- groups of the alkylene
group is substituted with hydroxy, and more preferably a C.sub.2 to
C.sub.4 alkylene wherein one or more of the --CH.sub.2-- groups of
the alkylene group is substituted with hydroxy, such as
--CH.sub.2--CH(OH)--CH.sub.2--.
[0058] The various embodiments reflect that the amine polymer has
nodes of positive charge separated by aliphatic segments. The
aliphatic segments are preferably hydrophobic. The hydrophobicity
is combined with sufficient positive charge for efficient and
effective affinity and retention of bile salts. The combination
provides an unexpected improvement in bile acid binding affinity,
binding capacity, retention and removal as compared to (i)
conventional bile acid binders having hydrophilic crosslinkers that
prevent the collapsing of the polymer network due to the absorption
of hydrophobic elements, such as bile acids and fatty acids present
in the GI and (ii) conventional bile acid binders with insufficient
charge density in proximity to the hydrophobic elements. In various
embodiments, a node of positive charge is generally a collection of
three or more nitrogen atoms is defined by an appropriate
combination of charge density, molecular weight and/or structure.
The charge density of a node is generally greater than 16.5 mEq/g,
greater than 17.3 mEq/g, greater than 19 mEq/g, and even more
specifically greater than 22 mEq/g. Charge density is calculated in
accordance with formulas known to those of skill in the art
assuming a 100% degree of ionization of the nitrogen atoms for
purposes of the calculation. The formula used herein is that the
charge density in mEq/g units is equal to the number of nitrogen
atoms in the node multiplied by one over the molecular weight of
the node multiplied by one thousand or (# N
atoms).times.(1/molecular weight).times.(1000). The formula weight
of the node of positive charge is calculated for the neutral amine
by adding hydrogen atoms to each nitrogen atom of the node until
each nitrogen atom has three bonds. The nodes of positive charge
can have a molecular weight of greater than 50 mol/g, greater than
100 mol/g, greater than 125 mol/g or greater than 200 mol/g. For
example, the charge density and molecular weight for various nodes
are detailed in Table 1.
TABLE-US-00001 TABLE 1 Charge density and molecular weight of
selected nodes Charge Density Node Molecular weight (mEq/g)
##STR00012## 43.07 23 ##STR00013## 131.22 22.9 ##STR00014## 116.20
17.2 ##STR00015## 316.53 19.0 ##STR00016## 372.64 16.1 ##STR00017##
428.74 14.0 ##STR00018## 544.73 18.4
[0059] A node of positive charge preferably has the structure of
formula A
##STR00019##
wherein each R.sub.20 is independently C.sub.3 to C.sub.8 alkylene
or C.sub.3 to C.sub.8 alkylene wherein one or more of the
--CH.sub.2-- groups of the alkylene group is replaced with an amide
functional group.
[0060] In some embodiments, the nodes of positive charge are
separated by hydrophobic aliphatic segments. The hydrophobicity of
an aliphatic segment is expressed by the calculated log P, as
discussed herein.
[0061] The amine polymer can also comprise repeat units derived
from polymerization of an amine monomer of formula 2 and a
crosslinking monomer, wherein the amine monomer of formula 2 has
the structure:
##STR00020##
wherein each R.sub.2 is independently C.sub.2 to C.sub.8 alkylene
or C.sub.2 to C.sub.8 alkylene wherein one or more of the
--CH.sub.2-- groups of the alkylene group is replaced with an amide
functional group; and R.sub.3 is C.sub.2 to C.sub.12 alkylene,
arylene, diformylheterocyclo, or C.sub.2 to C.sub.12 alkylene
wherein one or more of the --CH.sub.2-- groups of the alkylene
group is replaced with an amide, a carbonyl, an ether, an ester, a
cycloalkyl, an aryl, or a heterocyclo functional group; and a
portion of the nitrogen atoms of the amine polymer are substituted
with a ligand selected from aminoalkyl, aryl, arylalkyl, oxoalkyl,
cycloalkyl, (cycloalkyl)alkyl, guanidino, heterocyclo,
heterocyloalkyl, (trialkylammonio)alkyl, 2-(protected
amino)-m-(heterocyclo)-1-oxoC.sub.malkyl, 2-(protected
amino)-1-oxoC.sub.malkyl, 2-(protected
amino)-3-methyl-1-oxoC.sub.malkyl, 2-(protected
amino)-4-methyl-1-oxoC.sub.malkyl, 2-(protected
amino)-1-oxo-m-arylC.sub.malkyl, 2-(protected
amino)-m-(alkylthio)-1-oxoC.sub.malkyl, 2-(protected
amino)-m-(aryl)-1-oxoC.sub.malkyl, 2-(protected
amino)-m-carboxy-1-oxoC.sub.malkyl, 2-(protected
amino)-m-guanidino-1-oxoC.sub.malkyl, 2-(protected
amino)-(m-1)-hydroxy-1-oxoC.sub.malkyl, 2-(protected
amino)-m-hydroxy-1-oxoC.sub.malkyl, 2-(protected
amino)-m-mercapto-1-oxoC.sub.malkyl,
m-(alkylamino)-m-oxoC.sub.malkyl, m-(alkylheterocyclo)C.sub.malkyl,
m-amino-2-(protected amino)-1-oxoC.sub.malkyl, m-amino-2-(protected
amino)-1,m-dioxoC.sub.malkyl,
m-(x-aminoC.sub.xalkyl)heterocycloC.sub.malkyl,
(m-1)-amino-m-(heterocyclo)-1-oxoC.sub.malkyl,
m-(arylalkylamino)-m-oxoC.sub.malkyl,
m-(x-(alkylthio)C.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-aminoC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-amino-x-oxoC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-carboxyC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(heterocycloalkylamino)-m-oxoC.sub.malkyl,
m-(x-hydroxyC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-((x-1)-hydroxyC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-mercaptoC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-trialkylammonioC.sub.xalkyl)heterocycloC.sub.malkyl,
m-(x-(2-(alkoxy)benzamido)C.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-(3-(alkoxy)benzamido)C.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-(4-(alkoxy)benzamido)C.sub.xalkylamino)-m-oxoC.sub.malkyl, a
ligand of formula 4
*-R.sub.46-R.sub.47-R.sub.48 (4)
or a combination thereof, wherein R.sub.46 is C.sub.6 to C.sub.16
alkylene, R.sub.47 is
1,y-bis(1-methylpiperidin-4-yl)C.sub.yalkylene, R.sub.48 is C.sub.6
to C.sub.16 alkyl, m is an integer from 3 to 12, x is an integer
from 1 to 12, y is an integer from 1 to 14, and z is an integer
from 1 to 16.
[0062] The amine polymers described herein can also have a portion
of the nitrogen atoms of the amine polymer substituted with a
ligand post-polymerization of alkyl, aminoalkyl, aryl, arylalkyl,
oxoalkyl, cycloalkyl, (cycloalkyl)alkyl, guanidino, heterocyclo,
heterocycloalkyl, (trialkylammonio)alkyl, 2-(protected
amino)-m-(heterocyclo)-1-oxoC.sub.malkyl, 2-(protected
amino)-1-oxoC.sub.malkyl, 2-(protected
amino)-3-methyl-1-oxoC.sub.malkyl, 2-(protected
amino)-4-methyl-1-oxoC.sub.malkyl, 2-(protected
amino)-1-oxo-m-arylC.sub.malkyl, 2-(protected
amino)-m-(alkylthio)-1-oxoC.sub.malkyl, 2-(protected
amino)-m-(aryl)-1-oxoC.sub.malkyl, 2-(protected
amino)-m-carboxy-1-oxoC.sub.malkyl, 2-(protected
amino)-m-guanidino-1-oxoC.sub.malkyl, 2-(protected
amino)-(m-1)-hydroxy-1-oxoC.sub.malkyl, 2-(protected
amino)-m-hydroxy-1-oxoC.sub.malkyl, 2-(protected
amino)-m-mercapto-1-oxoC.sub.malkyl,
m-(alkylamino)-m-oxoC.sub.malkyl, m-(alkylheterocyclo)C.sub.malkyl,
m-amino-2-(protected amino)-1-oxoC.sub.malkyl, m-amino-2-(protected
amino)-1,m-dioxoC.sub.malkyl,
m-(x-aminoC.sub.xalkyl)heterocycloC.sub.malkyl,
(m-1)-amino-m-(heterocyclo)-1-oxoC.sub.malkyl,
m-(arylalkylamino)-m-oxoC.sub.malkyl,
m-(x-(alkylthio)C.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-aminoC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-amino-x-oxoC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-carboxyC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(heterocycloalkylamino)-m-oxoC.sub.malkyl,
m-(x-hydroxyC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-((x-1)-hydroxyC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-mercaptoC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-trialkylammonioC.sub.xalkyl)heterocycloC.sub.malkyl,
m-(x-(2-(alkoxy)benzamido)C.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-(3-(alkoxy)benzamido)C.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-(4-(alkoxy)benzamido)C.sub.xalkylamino)-m-oxoC.sub.malkyl, a
ligand of formula 4
*-R.sub.46-R.sub.47-R.sub.48 (4)
or a combination thereof, wherein R.sub.46 is C.sub.6 to C.sub.16
alkylene, R.sub.47 is
1,y-bis(1-methylpiperidin-4-yl)C.sub.yalkylene, R.sub.48 is C.sub.6
to C.sub.16 alkyl, m is an integer from 3 to 12, x is an integer
from 1 to 12, y is an integer from 1 to 14, and z is an integer
from 1 to 16.
[0063] In some embodiments, the ligand is arylalkyl selected from
naphthalen-2-ylalkyl or naphthalen-1-ylalkyl; heterocycloalkyl
selected from m-(1-methylpyrrolidinium-1-yl)C.sub.malkyl,
m-(2-(1H-indol-3-yl)ethylamino)-m-oxoC.sub.malkyl,
m-(2-methylthiazol-3-ium-3-yl)C.sub.malkyl,
m-(benzo[d]thiazol-3-ium-3-yl)C.sub.malkyl,
m-(pyridinium-1-yl)C.sub.malkyl,
m-(tetrahydro-1H-thiophenium-1-yl)C.sub.malkyl,
z-(1,2-dialkyl-1H-imidazol-3-ium-3-yl)C.sub.zalkyl,
m-(2,3-dialkyl-1H-imidazol-3-ium-1-yl)C.sub.malkyl,
z-(1-alkyl-1H-imidazol-3-ium-3-yl)C.sub.zalkyl,
m-(3-alkyl-1H-imidazol-3-ium-1-yl)C.sub.malkyl, or
z-(thiazol-3-ium-3-yl)C.sub.zalkyl; 2-(protected
amino)-m-(heterocyclo)-1-oxoC.sub.malkyl selected from 2-(protected
amino)-m-(1H-indol-3-yl)-1-oxoC.sub.m-alkyl or 2-(protected
amino)-m-(1H-imidazol-4-yl)-1-oxoC.sub.malkyl; 2-(protected
amino)-1-oxo-m-phenylC.sub.malkyl; 2-(protected
amino)-m-(hydroxyphenyl)-1-oxoC.sub.malkyl;
m-(alkylheterocyclo)C.sub.malkyl selected from
m-(3-alkyl-1H-imidazol-3-ium-1-yl)C.sub.malkyl,
m-(1-alkyl-1H-imidazol-3-ium-3-yl)C.sub.malkyl,
m-(1-alkyl-2-methyl-1H-imidazol-3-ium-3-yl)C.sub.malkyl, or
m-(3-alkyl-2-methyl-1H-imidazol-3-ium-1-yl)C.sub.malkyl;
m-(x-aminoC.sub.xalkyl)heterocycloC.sub.malkyl selected from
m-(3-(x-aminoC.sub.xalkyl)-1H-imidazol-3-ium-1-yl)C.sub.malkyl or
m-(1-(x-aminoC.sub.xalkyl)-1H-imidazol-3-ium-3-yl) C.sub.malkyl;
(m-1)-amino-m-(1H-indol-2-yl)-1-oxoC.sub.malkyl;
m-(arylalkylamino)-m-oxoC.sub.malkyl selected from
m-(hydroxyphenalkylamino)-m-oxoC.sub.malkyl or
m-(phenalkylamino)-m-oxo-C.sub.malkyl;
m-(x-(heterocyclo)C.sub.xalkyl)heterocycloC.sub.malkyl selected
from
m-(1-(x-(1-methyl-1H-imidazol-3-ium-3-yl)C.sub.xalkyl)-1H-imidazol-3-ium--
3-yl) C.sub.malkyl,
m-(1-(x-(3-methyl-1H-imidazol-3-ium-1-yl)C.sub.xalkyl)-1H-imidazol-3-ium--
3-yl) C.sub.malkyl,
m-(3-(x-(1-methyl-1H-imidazol-3-ium-3-yl)C.sub.xalkyl)-1H-imidazol-3-ium--
1-yl) C.sub.malkyl, or
m-(3-(x-(3-methyl-1H-imidazol-3-ium-1-yl)C.sub.xalkyl)-1H-imidazol-3-ium--
1-yl) C.sub.malkyl;
m-(x-(1H-imidazol-4-yl)C.sub.xalkylamino)-m-oxoC.sub.malkyl; or
m-(x-trialkylammonioC.sub.xalkyl)heterocycloC.sub.malkyl selected
from
m-(3-(x-trialkylammonio)C.sub.xalkyl)-1H-imidazol-3-ium-1-yl)C.sub.malkyl
or
m-(1-(x-trialkylammonio)C.sub.xalkyl)-1H-imidazol-3-ium-3-yl)C.sub.mal-
kyl wherein m is an integer from 3 to 12, x is an integer from 1 to
12, and z is an integer from 1 to 16.
[0064] In some instances, the ligand is derived from an amino acid.
Such ligands include, but are not limited to, 2-(protected
amino)-m-(heterocyclo)-1-oxoC.sub.malkyl, m-amino-2-(protected
amino)-1,m-dioxoC.sub.malkyl, m-amino-2-(protected
amino)-1-oxoC.sub.malkyl, 2-(protected amino)-1-oxoC.sub.malkyl,
2-(protected amino)-m-(alkylthio)-1-oxoC.sub.malkyl, 2-(protected
amino)-m-(hydroxyphenyl)-1-oxoC.sub.malkyl, 2-(protected
amino)-1-oxo-m-phenylC.sub.malkyl, 2-(protected
amino)-m-(1H-imidazol-4-yl)-1-oxoC.sub.malkyl, 2-(protected
amino)-m-carboxy-1-oxoC.sub.malkyl, 2-(protected
amino)-3-methyl-1-oxoC.sub.malkyl, 2-(protected
amino)-4-methyl-1-oxoC.sub.malkyl, 2-(protected
amino)-m-mercapto-1-oxoC.sub.malkyl, 2-(protected
amino)-(m-1)-hydroxy-1-oxoC.sub.malkyl, 2-(protected
amino)-m-hydroxy-1-oxoC.sub.malkyl, 2-(protected
amino)-m-guanidino-1-oxoC.sub.malkyl,
m-(x-(alkylthio)C.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(hydroxyphenalkylamino)-m-oxoC.sub.malkyl,
m-oxo-m-(phenalkylamino)C.sub.malkyl,
m-(x-(1H-imidazol-4-yl)C.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-carboxyC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(alkylamino)-m-oxoC.sub.malkyl,
m-(x-mercaptoC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-((x-1)-hydroxyC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-hydroxyC.sub.xalkylamino)-m-oxoC.sub.malkyl,
m-(x-aminoC.sub.xalkylamino)-m-oxoC.sub.malkyl, or
m-(x-amino-x-oxoC.sub.xalkylamino)-m-oxoC.sub.malkyl, wherein m is
an integer from 3 to 12, and x is an integer from 1 to 12.
[0065] Some of the amine polymers described herein have a portion
of the nitrogen atoms of the amine polymer substituted with a
ligand of
2-(tert-butoxycarbonylamino)-3-(1H-indol-3-yl)-1-oxopropyl,
5-(2-(4-(nonyloxy)benzamido)ethylamino)-5-oxopentyl,
(4,5-dihydro-1H-imidazolyl, 10-(pyridinium-1-yl)decyl,
2-(1H-indol-3-yl)ethyl,
5-(2-(1H-indol-3-yl)ethylamino)-5-oxopentyl,
2-amino-3-(1H-indol-2-yl)-1-oxopropyl,
3-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)propyl,
10-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)decyl,
10-(1-methyl-1H-imidazol-3-ium-3-yl)decyl,
3-(thiazol-3-ium-3-yl)propyl, 3-aminopropyl, 3-cyclohexylpropyl,
3-phenylpropyl, 3-(trimethylammonio)propyl,
3-(1-methylpyrrolidinium-1-yl)propyl,
3-(2-methylthiazol-3-ium-3-yl)propyl,
3-(benzo[d]thiazol-3-ium-3-yl)propyl,
3-(tetrahydro-1H-thiophenium-1-yl)propyl,
3-(3-methyl-1H-imidazol-3-ium-1-yl)propyl,
3-(1-methyl-1H-imidazol-3-ium-3-yl)propyl,
3-(3-(3-aminopropyl)-1H-imidazol-3-ium-1-yl)propyl,
3-(1-(3-aminopropyl)-1H-imidazol-3-ium-3-yl)propyl,
3-(3-(5-trimethylammonio)pentyl)-1H-imidazol-3-ium-1-yl)propyl,
3-(1-(5-trimethylammonio)pentyl)-1H-imidazol-3-ium-3-yl)propyl,
3-(3-decyl-1H-imidazol-3-ium-1-yl)propyl,
3-(1-decyl-1H-imidazol-3-ium-3-yl)propyl,
3-(3-(9-(3-methyl-1H-imidazol-3-ium-1-yl)nonyl)-1H-imidazol-3-ium-1-yl)pr-
opyl,
3-(1-(9-(1-methyl-1H-imidazol-3-ium-3-yl)nonyl)-1H-imidazol-3-ium-3--
yl)propyl,
3-(1-(9-(3-methyl-1H-imidazol-3-ium-1-yl)nonyl)-1H-imidazol-3-i-
um-3-yl)propyl,
3-(3-(9-(1-methyl-1H-imidazol-3-ium-3-yl)nonyl)-1H-imidazol-3-ium-1-yl)pr-
opyl, 4-(3-decyl-1H-imidazol-3-ium-1-yl)butyl,
4-(1-decyl-1H-imidazol-3-ium-3-yl)butyl,
10-(1-decyl-2-methyl-1H-imidazol-3-ium-3-yl)decyl,
10-(3-decyl-2-methyl-1H-imidazol-3-ium-1-yl)decyl,
3-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)propyl,
3-(2,3-dimethyl-1H-imidazol-3-ium-1-yl)propyl,
10-(2,3-dimethyl-1H-imidazol-3-ium-1-yl)decyl,
10-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)decyl,
10-(1-methyl-1H-imidazol-3-ium-3-yl)decyl,
10-(3-methyl-1H-imidazol-3-ium-1-yl)decyl,
10-(1-butyl-1H-imidazol-3-ium-3-yl)decyl,
10-(3-butyl-1H-imidazol-3-ium-1-yl)decyl,
10-(pyridinium-1-yl)decyl, 10-(1-methylpyrrolidinium-1-yl)decyl,
naphthalen-2-ylmethyl, naphthalen-1-ylmethyl,
4-amino-2-(tert-butoxycarbonylamino)-1,4-dioxobutyl,
2-(tert-butoxycarbonylamino)-1-oxoethyl,
2-(tert-butoxycarbonylamino)-4-(methylthio)-1-oxobutyl,
5-(3-(methylthio)propylamino)-5-oxopentyl,
2-(tert-butoxycarbonylamino)-3-(4-hydroxyphenyl)-1-oxopropyl,
5-(4-hydroxyphenethylamino)-5-oxopentyl,
2-(tert-butoxycarbonylamino)-1-oxo-3-phenylpropyl,
5-oxo-5-(phenethylamino)pentyl,
2-tert-butoxycarbonylamino)-3-(1H-imidazol-4-yl)-1-oxopropyl,
5-(2-(1H-imidazol-4-yl)ethylamino)-5-oxopentyl,
2-(tert-butoxycarbonylamino)-3-carboxy-1-oxopropyl,
5-(2-carboxyethylamino)-5-oxopentyl,
2-tert-butoxycarbonylamino)-3-methyl-1-oxobutyl,
5-(isobutylamino)-5-oxopentyl,(3R)-2-(tert-butoxycarbonylamino)-3-methyl--
1-oxopentyl,(R)-5-(2-methylbutylamino)-5-oxopentyl,
2-tert-butoxycarbonylamino)-3-mercapto-1-oxopropyl,
5-(2-mercaptoethylamino)-5-oxopentyl,(3R)-2-(tert-butoxycarbonylamino)-3--
hydroxy-1-oxobutyl,(R)-5-(2-hydroxypropylamino)-5-oxopentyl,
6-amino-2-(tert-butoxycarbonylamino)-1-oxohexyl,
5-(5-aminopentylamino)-5-oxopentyl,
5-amino-2-(tert-butoxycarbonylamino)-1,5-dioxopentyl,
5-(4-amino-4-oxobutylamino)-5-oxopentyl,
2-tert-butoxycarbonylamino)-5-guanidino-1-oxopentyl,
5-(4-guanidinobutylamino)-5-oxopentyl,
2-(tert-butoxycarbonylamino)-3-hydroxy-1-oxopropyl,
5-(2-hydroxyethylamino)-5-oxopentyl,
2-(tert-butoxycarbonylamino)-4-methyl-1-oxopentyl,
5-(isopentylamino)-5-oxopentyl,
2-(tert-butoxycarbonylamino)-4-carboxy-1-oxobutyl,
5-(3-carboxypropylamino)-5-oxopentyl,
2-(tert-butoxycarbonylamino)-1-oxopropyl,
5-(ethylamino)-5-oxopentyl, a ligand of formula 4
*-R.sub.46-R.sub.47-R.sub.48 (4)
or a combination thereof, wherein R.sub.46 is decylene, R.sub.47 is
1,3-bis(1-methylpiperidin-4-yl)propane, and R.sub.48 is decyl.
[0066] Some of the amine polymers described herein have a portion
of the nitrogen atoms of the amine polymer substituted with a
ligand of
2-(tert-butoxycarbonylamino)-3-(1H-indol-3-yl)-1-oxopropyl,
5-(2-(4-(nonyloxy)benzamido)ethylamino)-5-oxopentyl,
(4,5-dihydro-1H-imidazolyl, 10-(pyridinium-1-yl)decyl,
2-(1H-indol-3-yl)ethyl, 54241H-indol-3-yl)ethylamino)-5-oxopentyl,
2-amino-3-(1H-indol-2-yl)-1-oxopropyl,
3-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)propyl,
10-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)decyl,
10-(1-methyl-1H-imidazol-3-ium-3-yl)decyl,
3-(thiazol-3-ium-3-yl)propyl, 3-aminopropyl, 3-cyclohexylpropyl,
3-phenylpropyl, 3-(trimethylammonio)propyl,
3-(1-methylpyrrolidinium-1-yl)propyl,
3-(2-methylthiazol-3-ium-3-yl)propyl,
3-(benzo[d]thiazol-3-ium-3-yl)propyl,
3-(tetrahydro-1H-thiophenium-1-yl)propyl,
3-(3-methyl-1H-imidazol-3-ium-1-yl)propyl,
3-(1-methyl-1H-imidazol-3-ium-3-yl)propyl,
3-(3-(3-aminopropyl)-1H-imidazol-3-ium-1-yl)propyl,
3-(1-(3-aminopropyl)-1H-imidazol-3-ium-3-yl)propyl,
3-(3-(5-trimethylammonio)pentyl)-1H-imidazol-3-ium-1-yl)propyl,
3-(1-(5-trimethylammonio)pentyl)-1H-imidazol-3-ium-3-yl)propyl,
3-(3-decyl-1H-imidazol-3-ium-1-yl)propyl,
3-(1-decyl-1H-imidazol-3-ium-3-yl)propyl,
3-(3-(9-(3-methyl-1H-imidazol-3-ium-1-yl)nonyl)-1H-imidazol-3-ium-1-yl)pr-
opyl,
3-(1-(9-(1-methyl-1H-imidazol-3-ium-3-yl)nonyl)-1H-imidazol-3-ium-3--
yl)propyl,
3-(1-(9-(3-methyl-1H-imidazol-3-ium-1-yl)nonyl)-1H-imidazol-3-i-
um-3-yl)propyl,
3-(3-(9-(1-methyl-1H-imidazol-3-ium-3-yl)nonyl)-1H-imidazol-3-ium-1-yl)pr-
opyl, 4-(3-decyl-1H-imidazol-3-ium-1-yl)butyl,
4-(1-decyl-1H-imidazol-3-ium-3-yl)butyl,
10-(1-decyl-2-methyl-1H-imidazol-3-ium-3-yl)decyl,
10-(3-decyl-2-methyl-1H-imidazol-3-ium-1-yl)decyl,
3-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)propyl,
3-(2,3-dimethyl-1H-imidazol-3-ium-1-yl)propyl,
10-(2,3-dimethyl-1H-imidazol-3-ium-1-yl)decyl,
10-(1,2-dimethyl-1H-imidazol-3-ium-3-yl)decyl,
10-(1-methyl-1H-imidazol-3-ium-3-yl)decyl,
10-(3-methyl-1H-imidazol-3-ium-1-yl)decyl,
10-(1-butyl-1H-imidazol-3-ium-3-yl)decyl,
10-(3-butyl-1H-imidazol-3-ium-1-yl)decyl,
10-(pyridinium-1-yl)decyl, 10-(1-methylpyrrolidinium-1-yl)decyl,
naphthalen-2-ylmethyl, naphthalen-1-ylmethyl, a ligand of formula
4
*-R.sub.46-R.sub.47-R.sub.48 (4)
or a combination thereof, wherein R.sub.46 is decylene, R.sub.47 is
1,3-bis(1-methylpiperidin-4-yl)propane, and R.sub.48 is decyl.
[0067] In the above ligands having protected amino groups, the
protecting group is independently --C(O)OR.sub.49, --C(O)R.sub.50,
wherein R.sub.49 is alkyl or aryl, and R.sub.50 is amino, hydrogen,
alkyl, or haloalkyl. Protecting groups are well known in the art,
and those known in the art may be used.
[0068] The amine polymers having a portion of the nitrogen atoms of
the amine polymer substituted with a ligand can have about 5 mole %
to about 60 mole % ligand based on the moles of amine monomer,
about 5 mole % to about 50 mole % ligand based on the moles of
amine monomer, or about 10 mole % to about 30 mole % ligand based
on the moles of amine monomer.
[0069] The ratio of primary, secondary, and tertiary amines can be
calculated by assuming complete reaction between the amine monomer
and the crosslinking monomer and comparing the number of moles of
the amine monomer and the crosslinking monomer along with the
number of possible reaction sites on the crosslinking monomer. For
example, when the amine polymer is
N,N,N',N'-tetrakis(3-aminopropyl)-1,4-butanediamine (BTA), the
amine has two tertiary amines and four primary amines before
reacting with a crosslinking monomer. If the crosslinking monomer
is dibromodecane and the mole ratio of BTA to dibromodecane is 1 to
1, two of the primary amine atoms will react with the crosslinking
monomer to convert two of the primary amines to two secondary
amines. Thus, the ratio of the primary to secondary to tertiary
amines is 1 to 1 to 1.
[0070] Also, the amine polymers of the invention can bind various
bile acids such that the concentration of bound taurocholic acid is
greater than 1.5 mmol/g polymer and the concentration of unbound
taurocholic acid is less than 1.0 mmol/g polymer when the polymer
is placed in a buffer solution having a 2.5 mM taurocholic acid
concentration at 37.degree. C. and the concentration of bound
taurocholic acid is greater than 5.0 mmol/g polymer and the
concentration of unbound taurocholic acid is greater than 4.0
mmol/g polymer when the polymer is placed in a buffer solution
having a taurocholic acid concentration of at least 10 mM at
37.degree. C. Additionally, the amine polymers of the invention can
bind bile acids such that the concentration of bound
glycodeoxycholate is greater than 1.0 mmol/g polymer and the
concentration of unbound glycodeoxycholate is less than 0.1 mmol/g
polymer when the polymer is placed in a buffer solution having a
1.25 mM glycodeoxycholate concentration at 37.degree. C. and the
concentration of bound glycodeoxycholate is greater than 6.0 mmol/g
polymer and the concentration of unbound glycodeoxycholate is
greater than 2.0 mmol/g polymer when the polymer is placed in a
buffer solution having a glycodeoxycholate concentration of at
least 10 mM at 37.degree. C.
[0071] Further, the amine polymer can be useful as a bile acid
sequestrant, wherein, in a buffer solution at 37.degree. C.
containing less than 2.6 mM taurocholic acid, the amine polymer
binds more of the acid than sevelamer and in a buffer solution at
37.degree. C. containing more than 5.0 mM taurocholic acid the
amine polymer binds more bile acid that colesevelam. The amine
polymer can have the structure of any one of the amine polymers
disclosed herein. Specifically, the amine polymer is derived from
the polymerization of an amine monomer and a crosslinking monomer
wherein the amine monomer comprises
N,N,N',N'-tetrakis(3-aminopropyl)-1,12-diaminododecane and the
crosslinking monomer comprises 1,3-dichloropropanol.
[0072] Without wishing to be bound by any particular theory, the
invention herein uses a combination of positive charge density and
hydrophobicity to achieve unexpected bile acid binding affinity,
binding capacity, retention and removal. The charge density comes
from a concentration of positively charged nitrogen atoms that are
separated by a hydrophobic segment. Hydrophobicity is expressed by
the calculated log P, as discussed herein. Further, as shown in
FIGS. 1 and 2, the present invention has a unique combination of
high binding affinity at low concentrations of bile acids and high
binding capacity for bile acids at high concentrations of bile
acids. More specifically, at 37.degree. C., in a buffer solution
containing less than 2.6 mM taurocholic acid, the polymers of the
present invention bound more bile acid than sevelamer, and in a
buffer solution containing more than 5.0 mM taurocholic acid, the
polymers of the present invention bound more bile acid than
colesevelam. Even more specifically, at 37.degree. C., in a buffer
solution containing less than 2.0 mM taurocholic acid, the polymers
of the present invention bound more bile acid than sevelamer, and
in a buffer solution containing more than 7.0 mM taurocholic acid,
the polymers of the present invention bound more bile acid than
colesevelam. Yet more specifically, at 37.degree. C., in a buffer
solution containing less than 1.5 mM taurocholic acid, the polymers
of the present invention bound more bile acid than sevelamer, and
in a buffer solution containing more than 10.0 mM taurocholic acid,
the polymers of the present invention bound more bile acid than
colesevelam. In some embodiments, the Langmuir equation known to
those of skill in the art can be used in a linear regression
analysis to determine equilibrium binding constants that reflect
the greater affinity than sevelamer and the greater binding
capacity than colesevelam.
[0073] FIGS. 1 and 2 show graphs of the data from Example 50
plotted as the unbound bile acid in mmol bile acid per g polymer on
the x-axis and bound bile acid in mmol bile acid per g polymer on
the y-axis. With this data graphed in this manner, the trend of the
bile acid binding shows that the polymer of Sample 99 binds more
bile acid than the commercial bile acid sequestrants with the
exception of colesevelam at low bile acid concentrations (i.e.,
less than 2.5 mM) and binds more bile acid than all the commercial
bile acid sequestrants except sevelamer at high bile acid
concentrations (i.e., greater than 5.0 mM).
[0074] Further, the calculated log P (c Log P) of at least one of
R.sub.10 or R.sub.30 of Formula 1 of the amine polymers can be
greater than 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, or 8. The calculated
log P (c Log P)(Clog P) is determined by drawing the structure of
the crosslinker without the leaving groups in Chemdraw Ultra 11.0
(CambridgeSoft, Cambridge Mass.) and replacing the leaving groups
with hydrogen, and selecting the chemical properties tool to
calculate the c Log P. For example, for the crosslinker
1,10-dibromodecane, one would enter the structure of decane into
Chemdraw and select "show chemical properties" from the "view"
toolbar to calculate its c Log P as 5.984. If the crosslinker is a
ring structure that opens during crosslinking, such as
epichlorohydrin, the c Log P is determined by drawing the
ring-opened structure as shown below for epichlorohydrin:
##STR00021##
[0075] For example, the calculated log P (c Log P) for various
segments is detailed in Table 2.
TABLE-US-00002 TABLE 2 Calculated log P (cLog P) of selected
segments Segment Calculated log P ##STR00022## -0.7512 ##STR00023##
-0.5108 ##STR00024## 0.0740 ##STR00025## 0.603 ##STR00026## 0.512
-- 1.752 ##STR00027## 2.28 ##STR00028## 1.006 ##STR00029## 1.57
##STR00030## 2.81 ##STR00031## 3.339 ##STR00032## 2.064
##STR00033## 3.868 ##STR00034## 4.397 ##STR00035## 3.122
##STR00036## 4.926 ##STR00037## 5.455 ##STR00038## 4.67
##STR00039## 5.984 ##STR00040## 7.042 ##STR00041## 8.1 ##STR00042##
9.158
[0076] One method for preparing the amine polymers described herein
is to contact an amine monomer having six, seven or eight possible
reaction sites or an amine monomer of Formulae 2 or 3 with a
crosslinking monomer. The amine monomer and crosslinking monomer
can be contacted in the presence of a solvent; the solvent is
preferably a polar aprotic solvent (e.g., dimethyl formamide (DMF),
dimethyl sulfoxide (DMSO), N,N-dimethylacetamide (DMAC),
tetrahydrofuran (THF), methyltetrahydrofuran, dimethylsulfoxide),
1,4-dioxane, 2-pyrrolidinone, or 1-methyl-2-pyrrolidinone. Polar
protic solvents can also be used (e.g. methanol, ethanol, isopropyl
alcohol, butanol, pentanol, or ethylene glycol). Once the amine
monomer and the crosslinking monomer are contacted, the reaction
mixture is heated to from about 40.degree. C. to about 120.degree.
C. or at about 60.degree. C. to 70.degree. C. for about 12 to 24
hours. After the reaction is complete, the polymer gel product is
washed with a basic solution, followed by water, and then
lyophilized until dry.
[0077] Monomers of the amine as defined in formulas 2 and/or 3 can
be prepared using methods known to those of skill in the art, with
specific examples of such syntheses in the examples below. In
general, however, the desired core (R.sub.3) is prepared or
commercially available and converted into a tetranitrile using
known synthetic routes. For certain embodiments, an alkyl
tetranitrile is prepared by the addition of acrylonitrile to an
alkyldiamine via a Michael-type reaction. An alkyl tetranitrile can
also be prepared by the addition of a dihaloalkyl to
3,3'-iminodipropionitrile. Another approach of preparing an alkyl
tetranitrile is via the synthesis of the primary amine protected
form of bis(3-aminopropyl)amine, (e.g.,
bis(3-(t-butoxycarbonylamino)propyl)amine or
bis((3-benzyloxycarbonylamino)propyl)amine) followed by the
addition of the dihaloalkane, and subsequent deprotection (see for
example, Protective Groups in Organic Synthesis by Theodore Greene,
Wiley-Interscience, 1999). Thereafter, the alkyl tetranitrile
intermediate is then hydrogenated. Hydrogenation can be
accomplished using a variety of techniques including Raney-nickel
and/or Raney-cobalt catalysts followed by washing. A general
hydrogenation procedure with Raney cobalt would combine the alkyl
tetranitrile with hydrogen at a pressure from 100 to 5000 psi
(e.g., about 1300-1500 psi) with or without NH.sub.3 (e.g., about
40 psi NH.sub.3) at a temperature of 50 to 120.degree. C. (e.g.,
about 100.degree. C.) in a solvent (e.g., water, methanol, ethanol,
toluene, etc.) with adequate stirring and reaction time.
[0078] The amine polymers of the invention have various chemical,
structural and physical properties that contribute to their
capacity for binding bile acids and/or their affinity for binding
bile acids preferentially over fatty acids, phosphates and/or other
compounds present in the gastrointestinal tract.
[0079] The amine polymer can be administered in the form of a salt,
or as a partial salt, or as salt free base. The "salt" has nitrogen
atoms or groups in all or some of the repeat units that are
protonated to create a positively charged nitrogen atom associated
with a negatively charged counterion. The anionic counterions can
be selected to minimize adverse effects on the patient. Examples of
suitable counterions include Cl.sup.-, Br.sup.-,
CH.sub.3OSO.sub.3.sup.-, HSO.sub.4.sup.-, SO.sub.4.sup.2-, nitrate,
HCO.sub.3.sup.-, CO.sub.3.sup.2-, acetate, lactate, phosphate,
hydrophosphate, fumarate, malate, pyruvate, malonate, benzoate,
glucuronate, oxalate, acetylglycinate, succinate, propionate,
butyrate, ascorbate, citrate, tartrate, maleate, folate, an amino
acid derivative, a nucleotide, a lipid, a phospholipid, or a
combination thereof. The counterions can be the same as, or
different from, each other. For example, the reaction product can
contain two different types of counterions. In most cases, not all
of the nitrogen atoms will be in a salt form, with the percent of
nitrogen atoms in a salt form being dictated by certain properties,
such as flowability, storage time, and weight.
[0080] To determine the in vitro binding affinity for bile salts
under conditions that are intended to mimic in certain respects
those conditions found in the lower small intestine, the amine
polymer is analyzed using assay A. The A assay combines the polymer
to be analyzed in a desired concentration with a solution that
mimics certain conditions present in the lower small intestine as
described in Protocol 1 in the examples. After a period of time,
the polymers are recovered by centrifugation and the supernatants
are sampled, filtered to remove any remaining particulates and
assayed for ion concentrations by liquid chromatography (LC). By
comparing the equilibrium concentrations of glycocholate
(GC.sub.eq), glycodeoxycholate (GDC.sub.eq), oleyl glycerol
(OG.sub.eq) and/or oleic acid (OA.sub.eq) in the presence of the
polymer to their concentrations in test solution in the absence of
the polymer, the amount of each component bound under these
experimental conditions in mmoles/g polymer is calculated. The in
vitro bile salt binding affinity under the conditions of the A
assay in Protocol 1 results in a maximum of about 0.75 mmol/gram
polymer. Thus, the in vitro bile salt binding affinity for the
amine polymers of this invention is from about 0.34 to about 0.75
mmol/gram polymer, particularly from about 0.46 to about 0.75
mmol/gram polymer, and more particularly, from about 0.55 to about
0.75 mmol/gram polymer when measured in the Assay A solution.
Further, in some embodiments, the in vitro bile salt binding
affinity for the amine polymers of this invention is greater than
0.55 mmol/gram polymer, greater than 0.60 mmol/gram polymer, or
greater than 0.65 mmol/gram polymer.
[0081] In some cases the concentration of phosphate ions was also
determined on a strong anion exchange column by liquid
chromatography using a basic mobile phase in order to measure the
phosphate binding affinity. The polymers of the invention bind
phosphate in vitro in an amount of less than 0.3 mmol/gram of
polymer, particularly less than 0.2 mmol/gram of polymer, more
particularly up to about 0.15 mmol/gram polymer, and even more
particularly, up to about 0.10 mmol/gram polymer when measured
using a B assay.
[0082] To determine the in vitro binding capacity for bile salts
under conditions that are intended to mimic in certain respects
those conditions found in the upper small intestine after a meal,
the amine polymer is analyzed using Assay B. In Assay B, the
polymer to be analyzed is combined in a desired concentration with
a solution that mimics certain conditions present in the upper
small intestine as described in Protocol 2 in the examples. The
same general procedure as described above was used to calculate the
amount of each component bound. The in vitro bile salt binding
capacity under the conditions of the B assay in Protocol 2 results
in a maximum of about 3.7 mmol/gram polymer. Thus, the in vitro
bile salt binding capacity for the amine polymers is from about
0.28 to about 3.7 mmol/gram polymer, particularly from about 2.22
to about 3.7 mmol/gram polymer, and more particularly from about 3
to about 3.7 mmol/gram polymer when measured in the assay B
solution.
[0083] To determine the in vivo binding retention for bile salts,
the amine polymer is analyzed in a hamster model. The hamster model
provides a complex and relevant measure of the polymer's binding
capacity for bile acids, its binding affinity for bile acids over
other anions, and its ability to retain bound bile acids and to
increase the excretion of bile acids and bile acids metabolites
from the gastrointestinal tract into the feces. Preferably, Golden
Syrian hamsters may be used as they have a similar bile acid
profile to that of humans. Male Golden Syrian hamsters are
acclimated and then placed on a high-fat, high-sucrose western
diet, D12079B (Research Diet, New Brunswick, N.J.) for several days
before the study is started. The amine polymers to be analyzed are
blended into western diet at the desired dose to prepare the test
diets. The hamsters are held in individual metabolic cages allowing
the separation and collection of feces. Animals from the test
groups are switched to the test diets, while animals from the
untreated group are kept on western diet without added amine
polymer. Food intake is measured for four consecutive days. For
each hamster, feces from the last three days of the treatment
period are collected, pooled, lyophilized, and then homogenized by
grinding in a mortar and pestle. The feces samples are then
extracted for fecal bile salt analysis. In some cases, a baseline
treatment period is conducted where all groups of animals are
placed in metabolic cages as described above and fed only on
western diet without added test article. Feces are collected as
described above and the effect of the amine polymer on bile salt
fecal excretion is determined by comparing baseline versus
treatment periods. Otherwise, the effect of amine polymers on bile
salt fecal excretion is determined by comparing untreated versus
test groups. Hamster fecal bile salts are analyzed as described in
the examples. The amine polymers can have a calculated in vivo
binding capacity at least 25%, 50%, 75%, 100%, 125%, 150%, 175% or
200% greater than colesevelam hydrochloride when measured at a
dosage of 0.5% of the total feed intake in male Golden Syrian
hamsters fed a Western diet.
[0084] The amine polymers can have a calculated in vivo bile salt
binding capacity of at least about 0.35 mmol bile salt/gram of
polymer when measured in humans. The amine polymers can have an in
vivo binding capacity in a human of at least 0.35 mmol bile salt
per gram of polymer, at least 0.4 mmol bile salt per gram of
polymer, at least 0.5 mmol bile salt per gram of polymer, at least
0.6 mmol bile salt per gram of polymer, or more.
[0085] Polymers of the invention are crosslinked materials, meaning
that they do not generally dissolve in solvents however they can
swell with solvents or absorb the solvent. As used herein,
"swelling ratio" refers to the number of grams of solvent taken up
by one gram of crosslinked polymer when equilibrated in an aqueous
environment. The swelling ratio is sensitive to the polymer solvent
interaction parameter as described in Flory Huggins (Flory P. J.
"Principles of Polymer Chemistry, Cornell Ithica Pub. 1953). When
more than one measurement of swelling is taken for a given polymer,
the mean of the measurements is taken to be the swelling ratio. The
swelling ratio in water, or in physiological isotonic buffer, which
is representative of the gastrointestinal tract (for example United
States Pharmacopeia Simulated Intestinal Fluid or Simulated Gastric
Fluid), is typically in the range of about 1 to about 10 g of
swelling solution (solvent)/g of polymer, particularly about 2 to
6, and more particularly about 2 to about 4. The counterion content
of the polymer can affect the swelling ratio, in the examples
listed below, a chloride counterion is used, and the chloride
content is stated. The counterion content can be as much as 25 wt.
% of the total weight of the polymer and as little as <1% of the
total weight of the polymer.
[0086] The amine polymers can be particles having a mean diameter
from about 10 microns to about 200 microns. In some of the
embodiments, the amine polymer particles are substantially
spherical beads. These beads can have a mean diameter from about 10
microns to about 200 microns. As used herein, the term
"substantially" means generally rounded particles having an average
aspect ratio of about 1.0 to about 2.0. Aspect ratio is the ratio
of the largest linear dimension of a particle to the smallest
linear dimension of the particle. Aspect ratios may be easily
determined by those of ordinary skill in the art. This definition
includes spherical particles, which by definition have an aspect
ratio of 1.0. In some embodiments, the particles have an average
aspect ratio of about 1.0, 1.2, 1.4, 1.6, 1.8 or 2.0. The particles
may be round or elliptical when observed at a magnification wherein
the field of view is at least twice the diameter of the
particle.
[0087] The substantially spherical beads can be prepared using
methods known to a person skilled in the art. For example, a
preferred mode of synthesis is a heterogeneous process. Such
processes are also referred to as polymerization in dispersed media
and include direct or inverse suspension, emulsion, precipitation,
dispersion or micro emulsion polymerization, reaction in aerosol or
using bulk polymerization methods. In inverse suspension, the
continuous phase can be selected from apolar solvents such as
silicone, toluene, benzene, hydrocarbon solvents or oils,
halogenated solvents, supercritical carbon dioxide, and the like.
The discrete phase for the inverse suspension system comprises
solubilizing the monomer and crosslinker in water; this can be
achieved by the addition of an acid such as hydrochloric acid to
form the amine salt, which renders the organic amine substantially
more water soluble and dispersing the amine solution in a
water-immiscible solvent to form an emulsion. With a direct
suspension or emulsion process, water can be used as the continuous
phase, although salt brines are also useful to "salt out" the
monomer and crosslinker into the discrete phase, as described in
U.S. Pat. No. 5,414,068. The monomers can be dispersed either neat
or as a solution in the continuous phase using a cosolvent. The
crosslinking monomer can be added to the reaction in a
semicontinuous fashion (staged addition) allowing the
polymerization reaction to occur. Isolation of the beads can be
carried out by filtration, washing and drying. Size can be further
controlled or modified by reduction processes such as extrusion and
grinding.
[0088] The yield and efficiency of the reaction of crosslinker and
amine monomer can be increased by the addition of a Dean-Stark
process to a suspension polymerization reaction. During the
Dean-Stark process water is removed, which concentrates the
reaction mixture (e.g., amine and crosslinker). Without being
limited by any particular theory, the concentrating process allows
any reactive chain ends on the growing network to react, driving
the reaction to completion. Generally, the temperature also rises
as the water is removed. Increased efficiency in the reaction may
allow for the use of lower amounts of crosslinker and may produce a
product having higher purity.
[0089] Thus, when preparing polymer beads, the ratio of the
crosslinker to amine monomer can change depending on the process
conditions (e.g., salting out or Dean-Stark conditions), monomer
purity and the desired physical properties (e.g., swelling ratio,
particle size, etc.). In various embodiments, the mole ratio of the
amine monomer (e.g., of formula 2 or formula 3) to the crosslinking
monomer is from about 1:1 to about 1:5; preferably, from about 1:1
to about 1:3 and more specifically from about 1:1.1 to about
1:3.
[0090] Polymers can be obtained by methods known to those in the
art, examples of which are illustrated in the Examples herein. The
crosslinked amine polymer particle is generally a reaction product
of a reaction mixture that is subjected to reaction conditions. The
reaction mixture may also generally contain components that are not
chemically incorporated into the product. The reaction mixture
typically comprises monomers.
[0091] In general, the reactions are conducted such that a polymer
network is generated, which is insoluble but can be solvated into a
gel. When the interpenetrating solvent is water, the insoluble
material is described as a hydrogel. The reaction is carried either
in solution, in bulk (i.e. using the neat monomers and crosslinking
compounds) or in dispersed media. The reaction may start with the
introduction of for example, temperature change or irradiation. In
general amine polymers can be prepared by chain growth or step
growth. Step growth polymerization involves the polymerization of
monomers that contain unsaturated functional groups, including
radical polymerization, cationic polymerization and anionic
polymerization. Step growth polymerization involves the reaction of
bifunctional or polyfunctional monomers that grow via, dimers,
trimers to longer oligomers. When using a polyfunctional amine
containing monomer, the growth results in a branched polymer.
Network formation occurs when the polymer chains react with each
other. Parameters that effect the network formation reaction
include temperature, solvent choice, the concentrations of monomers
and crosslinkers, and the ratio of the monomer to the crosslinking
monomer. For polyamines such as that formed from an amine monomer
and multi functional alkyl bromide crosslinker, desirable solvents
have a high dielectric constant and include the following, but are
not limited to, water, methanol, (and alcoholic solvents), N,
N-dimethylformamide, methylpyrrolidone, dimethylsulfoxide,
tetrahydrofuran, methyltetrahydrofuran and acetonitrile. The
addition of a base maybe desired in some cases.
[0092] Polymerization reactions to prepare the amine polymers
include preparing an aqueous solution of the amine monomer,
optionally with a surfactant, and adding an organic phase
containing an organic solvent and optionally, a surfactant, to the
aqueous phase. The crosslinker then can be added in a batch or a
semi-continuous fashion. For example, the crosslinker can be added
to the polymerization all at once or can be added slowly over a
period of time.
[0093] The amine polymer particles have a mean diameter of from
about 10 .mu.m to about 200 .mu.m. Specific ranges are where the
amine polymer particles have a mean diameter of from about 20 .mu.m
to about 200 .mu.m, from about 20 .mu.m to about 150 .mu.m, or from
about 20 .mu.m to about 125 .mu.m. Other ranges include from about
35 .mu.m to about 150 .mu.m, from about 35 .mu.m to about 125
.mu.m, from about 50 .mu.m to about 125 .mu.m, or from about 50
.mu.m to about 100 .mu.m. Particle sizes, including mean diameters,
distributions, etc. can be determined using techniques known to
those of skill in the art. For example, U.S. Pharmacopeia
(USP)<429> discloses methods for determining particle
sizes.
[0094] Various amine polymer particles also have less than about 4
volume percent of the particles that have a diameter of less than
about 10 .mu.m; particularly, less than about 2 volume percent of
the particles that have a diameter of less than about 10 .mu.m;
more particularly, less than about 1 volume percent of the
particles that have a diameter of less than about 10 .mu.m; and
even more particularly, less than about 0.5 volume percent of the
particles that have a diameter of less than about 10 .mu.m. In
other cases, specific ranges are less than about 4 volume percent
of the particles that have a diameter of less than about 20 .mu.m;
less than about 2 volume percent of the particles that have a
diameter of less than about 20 .mu.m; less than about 1 volume
percent of the particles that have a diameter of less than about 20
.mu.m; less than about 0.5 volume percent of the particles that
have a diameter of less than about 20 .mu.m; less than about 2
volume percent of the particles that have a diameter of less than
about 30 .mu.m; less than about 1 volume percent of the particles
that have a diameter of less than about 30 .mu.m; less than about 1
volume percent of the particles that have a diameter of less than
about 30 .mu.m; less than about 1 volume percent of the particles
that have a diameter of less than about 40 .mu.m; or less than
about 0.5 volume percent of the particles that have a diameter of
less than about 40 .mu.m. In various embodiments, the amine polymer
has a particle size distribution wherein not more than about 5
volume % of the particles have a diameter less than about 30 .mu.m
(i.e., D(0.05)<30 .mu.m), not more than about 5 volume % of the
particles have a diameter greater than about 250 .mu.m (i.e.,
D(0.05)>250 .mu.m), and at least about 50 volume % of the
particles have a diameter in the range from about 70 to about 150
.mu.m.
[0095] The particle distribution of the amine polymer can be
described as the span. The span of the particle distribution is
defined as (D(0.9)-D(0.1))/D(0.5), where D(0.9) is the value
wherein 90% of the particles have a diameter below that value,
D(0.1) is the value wherein 10% of the particles have a diameter
below that value, and D(0.5) is the value wherein 50% of the
particles have a diameter above that value and 50% of the particles
have a diameter below that value as measured by laser diffraction.
The span of the particle distribution is typically from about 0.5
to about 1, from about 0.5 to about 0.95, from about 0.5 to about
0.90, or from about 0.5 to about 0.85. Particle size distributions
can be measured using Niro Method No. A 8 d (revised September
2005), available from GEA Niro, Denmark, using the Malvern
Mastersizer.
[0096] It has now been found that when using the amine polymers and
the compositions of the present invention, a once-a-day dose is
substantially equivalent to a twice-a-day dose, which is also
substantially equivalent to a three-times-a-day dose. Generally,
the once per day or twice per day administration of a daily amount
of the polymer or the composition has a bile acid removal that is
not statistically significantly different from the removal of the
same polymer or composition at the same daily amount administered
three times per day.
[0097] Additionally, the invention is directed to methods of
removing bile acids from an animal subject by administering an
amine polymer or a pharmaceutical composition comprising an amine
polymer, wherein less than 25% of subjects taking the polymer or
composition once per day experience mild or moderate
gastrointestinal adverse events at a dose of 6.0 grams/day or less.
Gastrointestinal adverse events may include flatulence, diarrhea,
abdominal pain, constipation, stomatitis, nausea and/or vomiting.
In some aspects, the polymer or composition is administered twice a
day and less than 25% of subjects taking the polymer or composition
twice per day experience mild or moderate gastrointestinal adverse
events. In some instances, the subjects taking the polymer or
composition once per day or twice per day experience no severe
gastrointestinal adverse events. The amine polymers or
pharmaceutical compositions of the present invention have about 50%
or more tolerability as compared to the same polymer or composition
of the same daily amount administered three times a day. For
example, for every two patients in which administration of the
polymer three times a day is well tolerated, there is at least one
patient in which administration of the polymer once a day or twice
a day is well tolerated.
[0098] When administration is well tolerated, there should be
little or no significant dose modification or dose discontinuation
by the subject. In some embodiments, well tolerated means there is
no apparent dose response relationship for gastrointestinal adverse
events. In some of these embodiments, well tolerated means that the
following gastrointestinal adverse effects are not reported from a
statistically significant number of subjects, including those
effects selected from the group consisting of flatulence, diarrhea,
abdominal pain, constipation, stomatitis, nausea and vomiting.
[0099] In other embodiments, the present invention provides a
method of removing bile acids from the gastrointestinal tract of an
animal subject in need thereof, comprising administering an
effective amount of an amine polymer or a composition comprising an
amine polymer, wherein the polymer or composition is as well
tolerated as administering substantially the same amount of the
same polymer or composition three times per day. In some instances,
the subject is experiencing hypercholesteremia and thus the method
treats hypercholesteremia. In other instances, the method lowers
serum cholesterol.
[0100] Without wanting to be bound by any particular theory, the
tolerability of the polymer or composition comprising the polymers
results from physical properties that the amine polymers may
possess, including a viscosity when hydrated and sedimented of from
about 10,000 Pas to about 2,500,000 Pas, from about 10,000 Pas to
about 2,000,000 Pas, from about 10,000 Pas to about 1,500,000 Pas,
from about 10,000 Pas to about 1,000,000 Pas, from about 10,000 Pas
to about 500,000 Pas, or from about 10,000 Pas to about 250,000
Pas, from about 30,000 Pas to about 3,000,000 Pas, from about
30,000 Pas to about 2,000,000 Pas, or from about 30,000 Pas to
about 1,000,000 Pas, the viscosity being measured at a shear rate
of 0.01 sec.sup.-1. This viscosity is measured using a wet polymer
prepared by mixing the polymer thoroughly with a slight excess of
simulated intestinal fluid (per USP <26>), allowing the
mixture to sediment for 3 days at 37.degree. C., and decanting free
liquid from the sedimented wet polymer. The steady state shear
viscosity of this wet polymer can be determined using a Bohlin VOR
Rheometer (available from Malvern Instruments Ltd., Malvern, U.K.)
or equivalent with a parallel plate geometry (upper plate of 15 mm
diameter and lower plate of 30 mm diameter, and gap between plates
of 1 mm) and the temperature maintained at 3TC.
[0101] The amine polymers may further have a hydrated and
sedimented yield stress of from about 150 Pa to about 4000 Pa, from
about 150 Pa to about 3000 Pa, from about 150 Pa to about 2500 Pa,
from about 150 Pa to about 1500 Pa, from about 150 Pa to about 1000
Pa, from about 150 Pa to about 750 Pa, or from about 150 Pa to
about 500 Pa, from about 200 Pa to about 4000 Pa, from about 200 Pa
to about 2500 Pa, from about 200 Pa to about 1000 Pa, or from about
200 Pa to about 750 Pa. Dynamic stress sweep measurements (i.e.,
yield stress) can be made using a Reologica STRESSTECH Rheometer
(available from Reologica Instruments AB, Lund, Sweden) or
equivalent in a manner known to those of skill in the art. This
rheometer also has a parallel plate geometry (upper plate of 15 mm
diameter, lower plate of 30 mm diameter, and gap between plates of
1 mm) and the temperature is maintained at 37.degree. C. A constant
frequency of 1 Hz with two integration periods can be used while
the shear stress is increased from 1 to 10.sup.4 Pa.
[0102] Amine polymers used in this invention may also have
desirable compressibility and bulk density when in the form of a
dry powder. Some of the particles of the amine polymers in the dry
form have a bulk density of from about 0.8 g/cm.sup.3 to about 1.5
g/cm.sup.3, from about 0.82 g/cm.sup.3 to about 1.5 g/cm.sup.3,
from about 0.84 g/cm.sup.3 to about 1.5 g/cm.sup.3, from about 0.86
g/cm.sup.3 to about 1.5 g/cm.sup.3, from about 0.8 g/cm.sup.3 to
about 1.2 g/cm.sup.3, or from about 0.86 g/cm.sup.3 to about 1.2
g/cm.sup.3. The bulk density affects the volume of amine polymer
needed for administration to a patient. For example, a higher bulk
density means that a lower volume will provide the same number of
grams of amine polymer. This lower volume can improve patient
compliance by allowing the patient to perceive they are taking a
smaller amount due to the smaller volume.
[0103] A powder composed of the particles of the amine polymer in
dry form has a compressibility index of from about 3 to about 30,
from about 3 to about 25, from about 3 to about 20, from about 3 to
about 15, from about 3 to about 13, from about 5 to about 25, from
about 5 to about 20, or from about 5 to about 15. The
compressibility index is defined as 100*(TD-BD)/TD, wherein BD and
TD are the bulk density and tap density, respectively. Bulk density
(BD) and tapped density (TD) are used to calculate a
compressibility index (CI). Standardized procedures for this
measurement are specified as USP <616>. A quantity of the
powder is weighed into a graduated cylinder. The mass M and initial
(loosely packed) volume V.sub.o are recorded. The cylinder is then
placed on an apparatus which raises and then drops the cylinder,
from a height of 3 mm.+-.10%, at a rate of 250 times (taps) per
minute. The volume is measured after 500 taps and then again after
an additional 750 taps (1250 total). If the difference in volumes
after 500 and 1250 taps is less than 2%, then the final volume is
recorded as V.sub.f and the experiment is complete. Otherwise,
tapping is repeated in increments of 1250 taps at a time, until the
volume change before and after tapping is less than 2%. The
following quantities are calculated from the data:
Bulk Density (BD)=M/V.sub.o
Tapped Density (TD)=M/V.sub.f
Compressibility Index (CI, also called Carr's
Index)=100*(TD-BD)/TD.
[0104] The powder form of the amine polymers settles into its
smallest volume more easily than polymers conventionally used to
treat hypercholesteremia. This makes the difference between the
bulk density and the tap density (measured powder density after
tapping a set number of times) from about 3% to about 30%, from
about 3% to about 25%, from about 3% to about 20%, from about 3% to
about 15%, from about 3% to about 10%, from about 5% to about 35%,
from about 5% to about 30%, or from about 5% to about 20% of the
bulk density.
[0105] The polymers and pharmaceutical compositions described
herein retain a significant amount of the bound bile salts
throughout the small intestine, and specifically, the bile salts
bound by the polymer are not released prior to entry into the colon
or excretion of the polymer in the feces. The term "significant
amount" as used herein is not intended to mean that the entire
amount of the bound bile salt are retained prior to fecal excretion
or entry in to the colon. A sufficient amount of the bound bile
salts are retained, such that a therapeutic and/or prophylactic
benefit is obtained. For example, it may be sufficient for a
polymer to retain bile acids such that there is a significant
increase in the amount of bile acids entering the colon. The bile
acids may then be released from the polymer but may still
substantially be excreted either intact or as metabolites in the
feces and thus for purposes of this invention have been
sufficiently retained. Retention of bile acids may be measured by
measuring the amounts of bile acids in the feces or in colonic
aspirates or extracts above baseline levels (i.e., above the amount
of bile acids retained in the feces when no polymer is administered
to the animal subject). Particular amounts of bound bile salts that
can be retained range from about 5% to about 100% above baseline
levels. The polymer or pharmaceutical composition should retain at
least about 5% of the bound bile salts, more particularly at least
about 10%, even more particularly at least about 25% and most
particularly at least about 50% of the bound bile salts above
baseline levels. Retention of bile acids by the polymer can be
calculated either directly by in vitro methods or indirectly by in
vivo methods. The period of retention is generally during the time
that the polymer or composition is being used therapeutically or
prophylactically. When the polymer or composition is used to bind
and remove bile salts from the gastrointestinal tract, the
retention period is the time of residence of the polymer or
composition in the gastrointestinal or the average residence time
of the polymer or composition in the small intestine.
[0106] The polymers and pharmaceutical compositions described
herein may result in an increased ratio of primary to secondary
bile acids excreted in the feces. Bile acids may be characterized
by their site of synthesis and modification; primary bile acids
(for example cholic acid and chenodeoxycholic acid) are synthesized
in hepatocytes from cholesterol and secondary or tertiary bile
acids (for example deoxycholic acid and lithocholic acid) are the
products of bacterial dehydroxylation in the terminal ileum and
colon. Primary bile acids may be deconjugated and/or dehydroxylated
to convert them to secondary or tertiary bile acids; for example
deoxycholate (from cholate) and lithocholate (from
chenodeoxycholate). A change in the ratio of excreted bile acids
towards primary or unmetabolized bile acids is a measure of in vivo
retention of bile acids by polymers. The amine polymers, in an in
vivo measurement, can produce on average at least 11% primary bile
acids in the feces based on total bile acids in the feces. In
various embodiments, the amine polymers bind at least 15% or at
least 20% primary bile acids in the feces based on the total bile
acids in the feces.
[0107] Generally, the amine polymers are not significantly absorbed
from the gastrointestinal tract. Depending upon the size
distribution of the amine polymer particles, clinically
insignificant amounts of the polymers may be absorbed. More
specifically, about 90% or more of the polymer is not absorbed,
about 95% or more is not absorbed, even more specifically about 97%
or more is not absorbed, and most specifically about 98% or more of
the polymer is not absorbed.
[0108] The amine polymers can be used to remove bile salts from an
animal subject by administering an effective amount of the polymer
to an animal subject in need thereof. The bile salts can be bound
and retained by the amine polymer and then removed from the
gastrointestinal tract in the feces. Further, the amine polymers
can be used to reduce serum LDL-cholesterol, or serum
non-HDL-cholesterol, in an animal subject. In some instances, the
mean serum LDL can be decreased by at least 15%, at least 20%, at
least 25%, at least 30% or more after 2, 4, 12, 26, 52 or more
weeks of treatment with the amine polymer at a daily dose at which
the subject experiences no severe gastrointestinal adverse events.
In some instances, the daily dose of the amine polymer is about 6.0
g/day, 5.0 g/day, 4.0 g/day, 3.0, 2.5, or 2.0 g/day or less.
[0109] Further, the amine polymers can be administered to improve
glycemic control in a human subject with Type II diabetes mellitus.
Preferably, when a human subject with Type II diabetes mellitus is
treated, glycated hemoglobin (Hb.sub.A1c) can be decreased by at
least 0.5%, at least 0.6%, at least 0.7%, at least 0.8%, at least
0.9%, at least 1.0% or more after 18, 26, 52 or more weeks of
treatment with the amine polymer at a daily dose at which the
subject experiences no severe gastrointestinal adverse events. In
some instances, the daily dose of the amine polymer is about 6.0
g/day, 5.0 g/day, 4.0 g/day, 3.0, 2.5, or 2.0 g/day or less. Also,
the fasting plasma glucose can be decreased by at least 14 mg/dL
(0.8 mmol/L), at least 16 mg/dL (0.9 mmol/L), at least 18 mg/dL (1
mmol/L), at least 20 mg/dL (1.1 mmol/L) or more after 2, 4, 12, 26,
52 or more weeks of treatment with the amine polymer at a daily
dose at which the subject experiences no severe gastrointestinal
adverse events. In some instances, the daily dose of the amine
polymer is about 6.0 g/day, 5.0 g/day, 4.0 g/day, 3.0, 2.5, or 2.0
g/day or less.
[0110] Further, the amine polymers can be used to ameliorate, treat
or slow progression of Alzheimer's disease.
[0111] The amine polymers can also be used to treat non-alcoholic
statohepatitis, cholestatic pruritus, irritable bowel syndrome with
diarrhea (IBS-D), idiopathic bile acid malabsorption, genetic or
congenital Fibroblast Growth Factor 19 (FGF19) deficiency or a
combination thereof. When the amine polymers are used to treat
cholestatic pruritus, they can be used in combination with an oral
or topical antipruritic containing, for example, an antihistamine,
a corticosteroid, a local anesthetic, a counterirritant, an opioid,
an opioid receptor antagonist, or other therapies including but not
limited to crotamiton, doxepin, mirtazapine, capsaicin, tacrolimus,
linoleic acid, gabapentin, activated charcoal, thalidomide,
naltrexone, erythropoietin, nicergoline, naltrexone, nalmefene,
butorphanol, naloxone, rifampin, ondansetron, ursodeoxycholate,
S-adenosyl-L-methionine, serotonin-selective reuptake inhibitors,
phenobarbital, dronabinol, phototherapy, or a combination
thereof
[0112] When the amine polymers are used to treat IBS-D, they can be
used in combination with antidiarrheals such as opiates, opioid or
opioid analogs including loperamide, codeine, diphenoxylate,
serotonin receptor antagonists such as alosetron, ramosetron and
cilansetron, serotonin-selective reuptake inhibitors, tricyclic
antidepressants such as amitriptyline and desipramine or drugs
reducing the levels of serotonin (5-HT), antispasmodic drugs
including anticholinergics such as hyoscyamine or dicyclomine,
chloride secretion blockers such as crofelemer and probiotics.
[0113] As used herein, an animal subject can be a human or other
mammal in need of either bile salt removal, reduction of serum
LDL-cholesterol, or non HDL-cholesterol concentration, increase in
HDL-C or improved glycemic control.
[0114] The methods, polymers and compositions described herein are
suitable for removal of bile salts from an animal subject wherein
the subject is in need of such bile salt removal. For example,
patients experiencing hypercholesterolemia or hyperlipidemia
benefit from such bile salt removal. The methods described herein
are applicable to these patients regardless of the underlying
condition that is causing the high serum cholesterol levels or need
for bile acid removal.
[0115] The amine polymers can be administered once, twice, or three
times a day. If the amine polymer is administered once a day, it
may be administered just before, with, or just after the largest
meal of the day. Also, if administered once a day, it may be
administered in connection with the largest, on average during a
twenty-four hour period, release of bile acids from the gall
bladder, which is typically in the morning. Further, it is
preferred that the amine polymer is administered at least 3 hours
before or after any agents that might have an adverse interaction
with the amine polymers.
[0116] The dosage regimen to treat hypercholesterolemia,
atherosclerosis, diabetes, Alzheimer's disease, non-alcoholic
steatohepatits, cholestatic pruritus, IBS-D, idiopathic bile acid
malabsorption or reduce plasma cholesterol with the combination
therapy and pharmaceutical compositions of the present invention
can be selected using a variety of factors. These include the type,
age, weight, sex, diet, and medical condition of the patient, the
severity of the disease, the route of administration,
pharmacological consideration such as the activity, efficacy,
pharmacokinetics and toxicology profiles of the particular compound
employed, whether a drug delivery system is utilized, and whether
the amine polymer is administered as part of a drug combination.
Thus, the dosage regimen actually employed may vary widely.
[0117] Initial treatment of a patient suffering from a
hyperlipidemic condition such as hypercholesterolemia and/or
atherosclerosis can begin with the dosages indicated above.
Treatment should generally be continued as necessary over a period
of several weeks to several months or years until the condition has
been controlled or eliminated. Patients undergoing treatment with
the amine polymers disclosed herein can be routinely monitored by,
for example, measuring serum LDL and total cholesterol levels by
any of the methods well known in the art, to determine the
effectiveness of the combination therapy. Repeated analysis of such
data permits modification of the treatment regimen during therapy
so that optimal effective amounts of each type of agent are
administered at any point in time, and so that the duration of
treatment can be determined as well. In this way, the treatment
regimen/dosing schedule can be rationally modified over the course
of therapy so that the lowest amount of amine polymer and
optionally, combination treatment, is administered and so that
administration is continued only so long as is necessary to
successfully treat the hyperlipidemic condition such as
hypercholesterolemia and atherosclerosis.
[0118] If necessary, the amine polymers or pharmaceutical
compositions may be administered in combination with other
therapeutic agents. The choice of therapeutic agents that can be
co-administered with the compounds of the invention will depend, in
part, on the condition being treated. For example, various agents
can be co-administered with the amine polymer, including agents
used in reducing serum LDL-cholesterol or non-HDL-cholesterol,
which comprise a hydroxymethyl-glutaryl-coenzyme A (HMG CoA)
reductase inhibitor, a fibrate, a cholesterol absorption inhibitor,
niacin (i.e. nicotinic acid or derivatives thereof), a phytosterol,
an intestinal lipase inhibitor, an intestinal or secreted
phospholipase A2 inhibitor, inhibitors of the synthesis or normal
activity of Apo-B100, agonists of the synthesis or normal activity
of ApoA, or any agent that modulates cholesterol absorption or
metabolism, or a combination thereof. In some instances, the HMG
CoA reductase inhibitor comprises a statin, such as atorvastatin,
cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin,
pravastatin, rosuvastatin, simvastatin, or a combination thereof.
The cholesterol absorption inhibitor can comprise ezetimibe. The
fibrate can be benzafibrate, ciprofibrate, clofibrate, gemfibrozil,
fenofibrate, or a combination thereof. The intestinal lipase
inhibitor can comprise orlisatat. In some instances, the amine
polymers or pharmaceutical compositions may be administered in
combination with a HMG CoA reductase inhibitor and niacin (e.g.,
lovastatin and niacin), or a HMG CoA reductase inhibitor and a
cholesterol absorption inhibitor (e.g., simvastatin and ezetimibe),
or a HMG CoA reductase inhibitor and an intestinal lipase
inhibitor.
[0119] In another example, other agents can be co-administered with
the amine polymer, including agents used in preventing or treating
diabetes, obesity or other dyslipidemias, such as a sulfonylurea, a
biguanidine, a glitazone, a thiazolidindione, an activator of
peroxisome poliferator-activated receptors (PPARs), an
alpha-glucosidase inhibitor, a potassium channel antagonist, an
aldose reductase inhibitor, a glucagon antagonist, a retinoid X
receptor (RXR) antagonist, a farnesoid X receptor (FXR) agonist, a
FXR antagonist, glucagon-like peptide-1 (GLP-1), a GLP-1 analog, a
dipeptidyl peptidase IV (DPP-IV) inhibitor, amylin, an amylin
analog, an SGLT2 inhibitor, insulin, an insulin secretagogue, a
thyroid hormone, a thyroid hormone analog, an alpha glucosidase
inhibitor or a combination thereof. The biguanidine can be
metformin, buformin, phenformin, or a combination thereof. The
thiazolidindione can be pioglitazone, rivoglitazone, rosiglitazone,
troglitazone, or a combination thereof. The sulfonylurea can be
acetohexamide, chlorpropamide, tolbutamide, tolazamide, glipizide,
gliclazide, glibenclamide, gliquidone, glyclopyramide, glimepiride,
or a combination thereof. The DPP-IV inhibitor can be alogliptin,
linagliptin, saxagliptin, sitagliptin, vildagliptin, or a
combination thereof. The GLP-1 analog can be exenatide,
liraglutide, albiglutide, or a combination thereof. The alpha
glucosidase inhibitor can be acarbose, miglitol or voglibose.
[0120] The term dyslipidemia is taken to mean a deviation in at
least one of total serum cholesterol, LDL-cholesterol, non-HDL
cholesterol, HDL-cholesterol or triglyceride from that considered
normal by the National Cholesterol Education Program or other
suitable bodies. In another example, other agents can be
co-administered with the amine polymer, including an anti-platelet
agent, a beta-blocker, a renin-angiotensin-aldosterone system
(RAAS) inhibitor, a RAAS modulator (e.g., angiotensin converting
enzyme inhibitors, renin inhibitors, angiotensin receptor blockers,
aldosterone antagonists or sodium channel blockers, including
amiloride, triamterene, trimethoprim, and pentamidine) or a
combination thereof
[0121] The amine polymers can also be administered with other
cholesterol-lowering agents such as acifran, azacosterol,
benfluorex, .beta.-benzalbutyramide, carnitine, chondroitin
sulfate, clomestrone, detaxtran, dextran sulfate sodium,
5,8,11,14,17-eicosapentaenoic acid, eritadenine, furazabol,
meglutol, melinamide, mytatrienediol, ornithine, .gamma.-oryzanol,
pantethine, pentaerythritol tetraacetate, .alpha.-phenybutyramide,
priozadil, probucol, .beta.-sitosterol, sultosilic acid, piperazine
salt, tiadenol, triparanol, xenbucin, or a combination thereof
[0122] Other agents that can be advantageously used for treatment
in combination with the amine polymers are a squalene epoxidase
inhibitor, a squalene synthetase inhibitor (or squalene synthase
inhibitor), an acyl-coenzyme A, cholesterol acyltransferase (ACAT)
inhibitor (including selective inhibitors of ACAT-1 or ACAT-2, as
well as dual inhibitors of ACAT-1 and ACAT-2), a microsomal
triglyceride transfer protein (MTP) inhibitor, probucol, a
cholesterol absorption inhibitor (e.g., ezetimibe and
1-(4-fluorophenyl)-3(R)-3(S)-(4-fluorophenyl)-3-hydroxypropyl),
4(S)-4-hydroxyphenol (-2-azetidinone) described in U.S. Pat. Nos.
5,727,115 and 5,846,966), a LDL receptor inducer, a platelet
aggregation inhibitor (e.g., a glycoprotein IIb/IIa fibrinogen
receptor antagonist), aspirin, vitamin B.sub.6 (or pyridoxine),
vitamin B.sub.12 (or cyanocobalamin), a water-soluble
pharmaceutical salt or ester of folic acid (e.g., sodium salt and
the methylglucamine salt), an anti-oxidant vitamin (e.g., vitamin C
and E and beta-carotene), or a combination thereof
[0123] The term "treating" as used herein includes achieving a
therapeutic benefit. By therapeutic benefit is meant eradication,
amelioration, or prevention of the underlying disorder being
treated. For example, in a hypercholesterolemia patient,
therapeutic benefit includes eradication or amelioration of the
underlying hypercholesterolemia. Also, a therapeutic benefit is
achieved with the eradication, amelioration, or prevention of one
or more of the physiological symptoms associated with the
underlying disorder such that an improvement is observed in the
patient, notwithstanding that the patient may still be afflicted
with the underlying disorder. In some treatment regimens, the amine
polymer or composition of the invention may be administered to a
patient at risk of developing hypercholesterolemia or diabetes or
to a patient reporting one or more of the physiological symptoms of
hypercholesterolemia or diabetes, even though a diagnosis of
hypercholesterolemia or diabetes may not have been made.
[0124] The pharmaceutical compositions of the present invention
include compositions wherein the amine polymers are present in an
effective amount, i.e., in an amount effective to achieve
therapeutic or prophylactic benefit. The actual amount effective
for a particular application will depend on the patient (e.g., age,
weight, etc.), the condition being treated, and the route of
administration. Determination of an effective amount is well within
the capabilities of those skilled in the art, especially in light
of the disclosure herein. The effective amount for use in humans
can be estimated from animal models. For example, a dose for humans
can be formulated to achieve gastrointestinal concentrations that
have been found to be effective in animals. In various embodiments,
the human patient takes about 0.5 g to about 10 g per day,
preferably about 0.5 g to about 5 g per day, more preferably, about
0.5 g to about 3 g per day, about 0.5 g to about 2.5 g per day, and
most preferably about 0.5 g to about 2.0 g per day.
[0125] The polymers and compositions described herein can be used
as food products and/or food additives. They can be added to foods
prior to consumption or during packaging.
[0126] The amine polymers or pharmaceutically acceptable salts
thereof, or compositions described herein, can be delivered to the
patient using a wide variety of routes or modes of administration.
The most preferred routes for administration are oral, intestinal,
or rectal. Rectal routes of administration are known to those of
skill in the art. Intestinal routes of administration generally
refer to administration directly into a segment of the
gastrointestinal tract, e.g., through a gastrointestinal tube or
through a stoma. The most preferred route for administration is
oral.
[0127] The polymers (or pharmaceutically acceptable salts thereof)
may be administered per se or in the form of a pharmaceutical
composition wherein the active compound(s) is in admixture or
mixture with one or more pharmaceutically acceptable excipients.
Pharmaceutical compositions for use in accordance with the present
invention may be formulated in a conventional manner using one or
more pharmaceutically acceptable excipients comprising carriers,
diluents, and auxiliaries which facilitate processing of the active
compounds into preparations which can be used physiologically.
Proper composition is dependent upon the route of administration
chosen.
[0128] For oral administration, the polymers or compositions of the
invention can be formulated readily by combining the polymer or
composition with pharmaceutically acceptable excipients well known
in the art. Such excipients enable the compositions of the
invention to be formulated as powders, tablets, pills, dragees,
capsules, liquids, gels, syrups, slurries, suspensions, wafers, and
the like, for oral ingestion by a patient to be treated.
Pharmaceutical preparations for oral use can be obtained as a solid
excipient, optionally grinding a resulting mixture, and processing
the mixture of granules, after adding suitable auxiliaries, if
desired, to obtain tablets or dragee cores. Suitable excipients
are, in particular, fillers such as sugars, including lactose or
sucrose; cellulose preparations such as, for example, maize starch,
wheat starch, rice starch, potato starch, gelatin, gum tragacanth,
methyl cellulose, hydroxypropyl methylcellulose, sodium
carboxymethylcellulose, and/or polyvinyl pyrrolidone (PVP); and
various flavoring agents known in the art. If desired,
disintegrating agents may be added, such as the cross-linked
polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such
as sodium alginate.
[0129] Additionally, the amine polymer composition can comprise one
or more fat-soluble vitamins such as vitamin A, D, E, K, or a
combination thereof. An amount of the fat-soluble vitamin can be
added to the composition sufficient to deliver about the daily
dietary intake level (i.e., the Reference Daily Intake (RDI)),
which is currently 3000 IU, 400 IU, 30 IU, 80 .mu.g, respectively,
for vitamin A, D, E, and K.
[0130] In various embodiments, the active ingredient (e.g.,
polymer) constitutes over about 20%, more particularly over about
50%, even more particularly over about 75%, and most particularly
more than about 90% by weight of the oral dosage form, the
remainder comprising suitable excipient(s).
[0131] The amine polymers or pharmaceutical compositions can be
administered in the form of a chewable or mouth-disintegrating
tablet, a liquid, a powder, a powder contained within a sachet, a
soft gelatin capsule, or a hard gelatin capsule. In some
embodiments, the polymers of the invention are provided as
pharmaceutical compositions in the form of liquid compositions. In
various embodiments, the pharmaceutical composition contains an
amine polymer dispersed in a suitable liquid excipient. Suitable
liquid excipients are known in the art; see, e.g., Remington's
Pharmaceutical Sciences.
[0132] An effective amount of the polymers of the invention can be
administered to the animal subject in less than four unit doses per
day, such as in less than four tablets per day. The "dosage unit"
or "unit dose" is a tablet, capsule or other oral dosage form
containing an amount of the amine polymer. The polymer is generally
administered in 4, 3, 2 or 1 unit doses in a 24-hour period, which
provides a daily dose of the polymer to the subject under
treatment.
[0133] Unless otherwise indicated, an "alkyl" group as described
herein alone or as part of another group is an optionally
substituted linear saturated monovalent hydrocarbon radical
containing from one to twenty carbon atoms and preferably one to
twelve carbon atoms, or an optionally substituted branched
saturated monovalent hydrocarbon radical containing three to twenty
carbon atoms, and preferably three to eight carbon atoms. Examples
of unsubstituted alkyl groups include methyl, ethyl, n-propyl,
i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, i-pentyl,
s-pentyl, t-pentyl, and the like.
[0134] The term "amide" as used herein represents a bivalent (i.e.,
difunctional) amido linkage (i.e.,
##STR00043##
[0135] The term "aryl" as used herein alone or as part of another
group denotes an optionally substituted monovalent aromatic
hydrocarbon radical, preferably a monovalent monocyclic or bicyclic
group containing from 6 to 12 carbons in the ring portion, such as
phenyl, biphenyl, naphthyl, substituted phenyl, substituted
biphenyl or substituted naphthyl. Phenyl and substituted phenyl are
the more preferred aryl groups. The term "aryl" also includes
heteroaryl.
[0136] The term "cycloalkyl" as used herein denotes optionally an
optionally substituted cyclic saturated monovalent bridged or
non-bridged hydrocarbon radical containing from three to eight
carbon atoms in one ring and up to 20 carbon atoms in a multiple
ring group. Exemplary unsubstituted cycloalkyl groups include
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl,
cyclooctyl, adamantyl, norbornyl, and the like.
[0137] The term "-ene" as used as a suffix as part of another group
denotes a bivalent radical in which a hydrogen atom is removed from
each of two terminal carbons of the group, or if the group is
cyclic, from each of two different carbon atoms in the ring. For
example, alkylene denotes a bivalent alkyl group such as methylene
(--CH.sub.2--) or ethylene (--CH.sub.2CH.sub.2--), and arylene
denotes a bivalent aryl group such as o-phenylene, m-phenylene, or
p-phenylene. For clarity, addition of the -ene suffix is not
intended to alter the definition of the principal word other than
denoting a bivalent radical. Thus, continuing the example above,
alkylene denotes an optionally substituted linear saturated
bivalent hydrocarbon radical.
[0138] The term "ether" as used herein represents a bivalent (i.e.,
difunctional) ether linkage (i.e., --O--).
[0139] The term "ester" as used herein represents a bivalent (i.e.,
difunctional) ester linkage (i.e., --C(O)O--).
[0140] The term "heteroaryl," as used herein alone or as part of
another group, denotes an optionally substituted monovalent
monocyclic or bicyclic aromatic radical of 5 to 10 ring atoms in
protonated or unprotonated form, where one or more, preferably one,
two, or three, ring atoms are heteroatoms independently selected
from N, O, and S, and the remaining ring atoms are carbon.
Exemplary heteroaryl moieties include benzofuranyl,
benzo[d]thiazolyl, benzo[d]thiazolium, isoquinolinyl,
isoquinolinium, quinolinyl, quinolinium, thiophenyl, imidazolyl,
imidazolium, oxazolyl, oxazolium, furanyl, thiazolyl, thiazolium,
pyridinyl, pyridinium, furyl, thienyl, pyridyl, pyrrolyl,
pyrrolidinium, indolyl, indolinium, and the like.
[0141] The term "heterocyclo," as used herein alone or as part of
another group, denotes a saturated or unsaturated monovalent
monocyclic group of 4 to 8 ring atoms in protonated or unprotonated
form, in which one or two ring atoms are heteroatom(s),
independently selected from N, O, and S, and the remaining ring
atoms are carbon atoms. Additionally, the heterocyclic ring may be
fused to a phenyl or heteroaryl ring, provided that the entire
heterocyclic ring is not completely aromatic. Exemplary heterocyclo
groups include the heteroaryl groups described above, pyrrolidino,
pyrrolidinium, piperidino, piperidinium, morpholino, morpholinium,
piperazino, piperazinium, and the like.
[0142] The term "hydrocarbon" as used herein describes a compound
or radical consisting exclusively of the elements carbon and
hydrogen.
[0143] The term "substituted" as in "substituted aryl,"
"substituted alkyl," and the like, means that in the group in
question (i.e., the alkyl, aryl or other group that follows the
term), at least one hydrogen atom bound to a carbon atom is
replaced with one or more substituent groups such as hydroxy
(--OH), alkylthio, phosphino, amido (--CON(R.sub.A)(R.sub.B),
wherein R.sub.A and R.sub.B are independently hydrogen, alkyl, or
aryl), amino (--N(R.sub.A)(R.sub.B), wherein R.sub.A and R.sub.B
are independently hydrogen, alkyl, or aryl), halo (fluoro, chloro,
bromo, or iodo), silyl, nitro (--NO.sub.2), an ether (--OR.sub.A
wherein R.sub.A is alkyl or aryl), an ester (--OC(O)R.sub.A wherein
R.sub.A is alkyl or aryl), keto (--C(O)R.sub.A wherein R.sub.A is
alkyl or aryl), heterocyclo, and the like. When the term
"substituted" introduces a list of possible substituted groups, it
is intended that the term apply to every member of that group. That
is, the phrase "optionally substituted alkyl or aryl" is to be
interpreted as "optionally substituted alkyl or optionally
substituted aryl."
[0144] As used herein "possible reaction sites" in the amine
monomers are nitrogen atoms bonded to one or more hydrogen
atoms.
[0145] Having described the invention in detail, it will be
apparent that modifications and variations are possible without
departing from the scope of the invention defined in the appended
claims.
EXAMPLES
[0146] The following non-limiting examples are provided to further
illustrate the present invention. The following assays were used
for the in vitro and in vivo testing detailed in the examples
below.
[0147] Protocol 1: Conditions Mimicking the Lower Small Intestine
(A Assay).
[0148] Amine polymers were measured in conditions mimicking those
found in the lower small intestine (Northfield, T C and McColl, I
(1973) "Postprandial concentrations of free and conjugated bile
salts down the length of the normal human small intestine", Gut 14:
513-518, Borgstrom, B, et al. (1957) "Studies of intestinal
digestion and absorption in the human", J Clin Invest 36:
1521-1536.)
[0149] The following test solution was prepared: 50 mM
N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES), 50 mM
sodium BES, 6.5 mM sodium phosphate, 0.93 mM sodium glycocholate,
0.93 mM sodium glycodeoxycholate, 150 mM sodium chloride, pH 7.0.
The test solution was stored at -20.degree. C. Before use the test
solution was thawed in a 37.degree. C. water bath, stirred
vigorously on a stir plate for greater than 20 minutes, and
filtered through a Nalgene 0.45 micron cellulose nitrate filter
unit. This was found to provide reproducible results. Amine
polymers to be analyzed were freeze-dried a minimum of 18 hours and
were accurately dispensed into 16.times.100 mm borosilicate test
tubes, with each tube containing between 23 and 28 mg of test
sample. The precise weight was noted and the above solution was
added using a 10 mL disposable pipette, so that the polymer
concentration was 2.5 mg/mL. The tubes were covered with a sheet of
Teflon, clamped and tumbled end-over-end (30-40 revolutions per
minute) inside an atmospheric chamber at 37.degree. C. for three
hours. The polymers were recovered by centrifugation at 500.times.g
for 10 minutes and the supernatants were sampled, filtered through
a 96 well 0.45 micron Whatman Unifilter 800 by centrifugation at
1000.times.g for 10 minutes to remove any remaining particulates.
Filtrates were transferred to either glass IC vials with rubber
septa or 96 well polypropylene deep well sample plates.
[0150] To determine the concentration of glycocholate (GC) and
glycodeoxycholate (GDC) in the filtrate, 50 .mu.L of the sample
solution was injected onto a HPLC system, equipped with Phenomenex
Luna C8 (2) column (100 .ANG., 5 .mu.m, 50.times.2.00 mm), and a UV
detector. The sample was analyzed using a gradient of water, 25 mM
phosphate buffer (pH=3) and acetonitrile at a flow rate of 0.4
mL/min. The signal of GC and GDC was detected at a wavelength of
205 nm from the UV detector. Calibration solutions comprised of GC
and GDC standards of different concentrations were also injected
onto the same HPLC system. The calibration curve of each component
was then constructed by plotting the peak area vs. concentration.
Based on the peak area of the GC and GDC found in the sample and
the corresponding calibration curve, the concentration of each
component in the sample was calculated in mM.
[0151] By comparing the equilibrium concentrations of glycocholate
(GC.sub.eq) and glycodeoxycholate (GDC.sub.eq), in the presence of
the polymer to their concentrations in test solution in the absence
of the polymer, the amount of each component bound under these
experimental conditions in mmoles/g polymer was calculated.
[0152] In some cases, the concentration of phosphate was also
determined by injection of 20 uL of filtrate onto strong anion
exchange columns (Dionex AG11-HC 50.times.4 mm ID and Dionex
AS11-HC 250.times.4 mm ID) using a Waters Alliance 2795 Separation
Module equipped with a 6 column switching valve installed inside a
column oven and a Dionex Conductivity Detector CD25 (with DS3 flow
cell and ASRS Ultra 11 4 mm Suppressor). The mobile phase was 30 mM
KOH buffer with a 1 mL/min flow rate and a run time of 15 minutes
per sample. Phosphate standards of different concentrations were
also injected onto the same system and the calibration curve was
then constructed by plotting the peak area vs. concentration. Based
on the peak area found in the sample and the corresponding
calibration curve, the concentration of phosphate in the sample was
calculated in mM.
[0153] By comparing the equilibrium concentrations of phosphate
(P.sub.eq) and in the presence of the polymer to their
concentrations in test solution in the absence of the polymer, the
amount of phosphate bound under these experimental conditions in
mmoles/g polymer was calculated.
[0154] Protocol 2: Conditions Mimicking the Upper Small Intestine
(Assay B).
[0155] Amine polymers were also measured in conditions mimicking
those found in the upper small intestine after a meal (Fordtran, J
S and Locklear, T W (1966) "Ionic constituents and osmolality of
gastric and small-intestinal fluids after eating", Am J Dig Dis 11:
503-521; Northfield, T C and McColl, I (1973) "Postprandial
concentrations of free and conjugated bile salts down the length of
the normal human small intestine", Gut 14: 513-518; Evans, D F, et
al. (1988) "Measurement of gastrointestinal pH profiles in normal
ambulant human subjects", Gut 29: 1035-1041). The bile salt binding
performance of test polymers was evaluated at a polymer
concentration of 2.5 mg/mL in the manner described in Protocol 1
above, with the exception that the following test solution was
used: 50 mM N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid
(BES), 50 mM sodium BES, 6.5 mM sodium phosphate, 4.6 mM sodium
glycocholate, 4.6 mM sodium glycodeoxycholate, 1.2 mM oleyl
glycerol, 9 mM oleic acid, 150 mM sodium chloride, pH 7.0.
Freeze-dried polymer was precisely dispensed into the 16.times.100
mm borosilicate test tubes, with each tube containing between 28
and 33 mg of test sample. In certain cases, the concentration of
polymer was adjusted from 2.5 mg/mL to 1 mg/mL. Otherwise the
procedure was identical to that described in Protocol 1 above,
except filtrates submitted for analytical analysis were only
dispensed into glass IC vials.
[0156] To determine the concentration of glycocholate (GC),
glycodeoxycholate (GDC), oleyl glycerol (OG) and oleic acid (OA)
concentrations in filtrate samples, 20 .mu.L was injected onto a
HPLC system that was equipped with a Phenomenex Luna C8 (2) column
(100 .ANG., 5 .mu.m, 50.times.2.00 mm) and a UV detector. The
sample was analyzed using a gradient of water, 25 mM phosphate
buffer (pH=3) and acetonitrile at a flow rate of 0.4 mL/min. The
signal of GC, GDC, OG and OA is detected at a wavelength of 205 nm
from the UV detector. Calibration solutions comprised of GC, GDC,
OG and OA standards of different concentrations were also injected
onto the same HPLC system. The calibration curve of each component
was then constructed by plotting the peak area vs. concentration.
Based on the peak area of the GC, GDC, OG or OA found in the sample
and the corresponding calibration curve, the concentration of each
component in the sample is calculated in mM.
[0157] By comparing the equilibrium concentrations of glycocholate
(GCeq), glycodeoxycholate (GDCeq), oleyl glycerol (OGeq) and/or
oleic acid (OAeq) in the presence of the polymer to their
concentrations in test solution in the absence of the polymer, the
amount of each component bound under these experimental conditions
in mmoles/g polymer was calculated.
[0158] Hamster Model. To collect in vivo data, Male Golden Syrian
hamsters (8-9 weeks old) were obtained from Charles River
Laboratories (Wilmington, Mass.). Upon arrival, the animals were
placed on rodent diet Teklad 2018 (Madison, Wis.). Food and water
were provided ad libitum throughout the course of the study.
Animals were acclimated for at least seven days, and then
randomized by body weight into groups of at least five animals
each. All animals were then placed on a high-fat, high-sucrose
western diet, D12079B (Research Diet, New Brunswick, N.J.) for
three days before the study started. Amine polymers were blended
into western diet at a dose of 0.5% to prepare the test diets. To
initiate the study, all hamsters were moved into individual
metabolic cages allowing the separation and collection of feces.
Animals from the test groups were switched to the test diets, while
animals from the untreated group were kept on western diet without
added amine polymer. Food intake was measured for the next four
consecutive days. For each hamster, feces from the last three days
of the treatment period were collected, pooled, lyophilized, and
then homogenized by grinding in a mortar and pestle. The feces
samples were then extracted for fecal bile salt analysis.
[0159] In some cases, a baseline treatment period was conducted
where all groups of animals were placed in metabolic cages as
described above and fed only on western diet without added test
article. Feces were collected as described above and the effect of
amine polymer on bile salt fecal excretion was determined by
comparing baseline versus treatment periods. Otherwise, the effect
of amine polymer on bile salt fecal excretion was determined by
comparing untreated versus test groups.
[0160] Hamster fecal bile salts were analyzed using a modification
of the procedure reported by Porter and colleagues (Porter, J L. et
al. 2003. Accurate enzymatic measurement of fecal bile salts in
patients with malabsorption. J Lab Clin Med. 141:411-8). For each
extraction, a 100 mg aliquot of dry feces was weighed into a
16.times.100 mm Pyrex test tube. Ethylene glycol (1 mL) with 0.7N
NaOH was then added. The test tube was capped with a marble and
heated at 190-200.degree. C. for 2 h. After cooling, 1 mL of 20%
NaCl and 0.2 mL 6N HCl were added. After brief mixing, 6 ml diethyl
ether was added. The tube was capped, vortexed for 5 minutes, and
then centrifuged at 1,000.times.g for 5 minutes. The diethyl ether
phase was transferred into a 20 mL glass vial. Two additional
extractions with 6 mL diethyl ether were performed and the extracts
were pooled. The ether was completely evaporated under a stream of
air. The residue was then dissolved in 3 mL methanol and bile salts
(cholic acid, 3-OH-12-oxo-cholanic acid, chenodeoxycholic acid,
deoxycholic acid, and lithocholic acid) were quantified by
LC-MS.
Example 1: N,N,N',N'-tetrakis(3-aminopropyl)-1,4-butanediamine
(C.sub.4 BTA) Polymers with Dihaloalkane Crosslinkers
[0161] Synthesis of crosslinked
N,N,N',N'-tetrakis(3-aminopropyl)-1,4-butanediamine materials were
conducted using parallel synthesis. A solution of
N,N,N',N'-tetrakis(3-aminopropyl)-1,4-butanediamine (C.sub.4 BTA)
(40 wt. % of a N,N-dimethylformamide (DMF) solution) was dispensed
into 40 mL glass vials. The crosslinking monomer of formula
X-R.sub.1-X, wherein X was bromo and R.sub.1 was as listed in the
table below, were added to each vial. Additional DMF and methanol
(MeOH) were added resulting in a total solid content of 40 wt. %
where the solvents are in at a ratio of 1:1 (by volume). The vials
were capped and heated for 17 hours at 58.degree. C. The resulting
polymer gel was swollen and ground in MeOH, washed in MeOH (twice),
ammonium hydroxide (10 vol. %, twice) then water (three times) and
lyophilized until dry. Bile acid (BA) binding capacity, affinity,
and retention for each resulting polymer were determined via the A
assay, B assay and hamster model as described above, and results
are reported below.
[0162] Synthesis of
N,N,N',N'-tetrakis(3-aminopropyl)-1,4-butanediamine. To a mixture
of 1,4-diamino butane and acrylonitrile in dioxane was added 40%
KOH solution under nitrogen. The reaction was stirred at room
temperature over night and HPLC was used to monitor the reaction.
After the completion of reaction, the mixture was diluted with
tert-butyl methyl ether. The organic phase was washed with brine,
then dried over anhydrous sodium sulfate. After concentration of
the solution,
3,3',3'',3'''-(butane-1,4-diylbis(azanetriyl))tetrapropanenitrile
was obtained. A suspension of
3,3',3'',3'''-(butane-1,4-diylbis(azanetriyl))tetrapropanenitrile
in 1:1 methanol:water was placed in a Parr hydrogenation apparatus.
To the mixture was charged wet Raney cobalt catalyst. The mixture
was hydrogenated under 700 psi at 70.degree. C. for 18 hours. After
cooling to room temperature, the reaction was filtered through
celite. The filtrate was concentrated to yield
N,N,N',N'-tetrakis(3-aminopropyl)-1,4-butanediamine (C.sub.4 BTA)
as a pale yellow oil.
[0163] N,N,N',N'-tetrakis(3-aminopropyl)-1,8-octanediamine (C.sub.8
BTA), N,N,N',N'-tetrakis(3-aminopropyl)-1,10-decanediamine
(C.sub.10 BTA), and
N,N,N',N'-tetrakis(3-aminopropyl)-1,12-dodecanediamine (C.sub.12
BTA) were synthesized following same procedure.
TABLE-US-00003 BA BA BA BA binding Cross- Monomer:Cross- Cross-
Binding binding Binding % Primary linking linking linking affinity
capacity retention Bile Sam- monomer Monomer Monomer C.sub.4 BTA
MeOH DMF A assay B assay Hamster Acids in Swelling ple # (R.sub.1)
Molar Ratio (mg) (uL) (uL) (uL) (mmol/g) (mmol/g) (mmol/g) feces*
(g/g) 1-A1 C.sub.8 alkylene 1:1.6 6705 5080 11126 11126 0.44 3.34
0.41 5.9 1.42 1-A2 C.sub.8 alkylene 1:2.2 6358 3503 9338 9338 0.50
3.29 0.79 1-A3 C.sub.10 alkylene 1:1.6 6868 4717 10947 10947 0.58
3.24 0.66 13.9 0.67 1-A4 C.sub.10 alkylene 1:2.2 6537 3265 9291
9291 0.65 2.95 0.52 25.0 0.60 1-A5 C.sub.10 alkylene 1:2.8 6083
2387 8045 8045 0.64 1.86 1.13 1-A6 C.sub.12 alkylene 1:1.6 7011
4403 10795 10795 0.68 3.25 0.77, 0.81 23.4, 20.0 0.41 1-B1 C.sub.12
alkylene 1:2.2 6694 3057 9250 9250 0.68 2.66 0.47 22.1 0.50
.dagger.average of 2 studies *% Primary Bile Acids in feces as % of
total measured: i.e. (Cholic acid + chenodeoxycholic acid) .times.
100/(Cholic acid + chenodeoxycholic acid + 3-OH-12Oxo-Cholanic Acid
+ deoxycholic acid + lithocholic acid)
Example 2: N,N,N',N'-tetrakis(3-aminopropyl)-1,4-butanediamine
(C.sub.4 BTA) Polymers with Bisacrylamide Crosslinkers
[0164] Synthesis of crosslinked
N,N,N',N'-tetrakis(3-aminopropyl)-1,4-butanediamine materials were
conducted using parallel synthesis. A solution of
N,N,N',N'-tetrakis(3-aminopropyl)-1,4-butanediamine (40 wt. % of a
dimethyl sulfoxide (DMSO) solution) was dispensed into 40 mL glass
vials. The bisacrylamide crosslinking monomer listed in the table
below was added to each vial. Additional DMSO was added resulting
in a total solid content of 40 wt. %. The vials were capped and
heated for 17 hours at 58.degree. C. The resulting polymer gel was
swollen and ground in MeOH, washed in MeOH (twice), NaOH (0.5M
once) then water (three times) and lyophilized until dry. Bile acid
(BA) binding capacity, affinity, and retention for each resulting
polymer were determined via the A assay, B assay and hamster model
as described above, and results are reported in the table
below.
TABLE-US-00004 Monomer:Cross- Cross- Bisacrylamide linking linking
Sam- Crosslinking Monomer Monomer C.sub.4 BTA DMSO ple # Monomer
Molar Ratio (mg) (uL) (uL) 2-C3 N,N'-Octylene 1:2.2 1911 1135 5450
bis(acrylamide) 2-D2 N,N'-Decylene 1:1.6 1759 1293 5450
bis(acrylamide) BA BA BA BA Binding binding binding binding %
Primary affinity capacity retention Bile Sam- A assay B assay
Hamster Acids in Swelling ple # (mmol/g) (mmol/g) (mmol/g) feces*
(gm/gm) 2-C3 0.60 2.97 0.39 21.5 2.00 2-D2 0.69 3.00 0.44 49.7 1.52
*% Primary Bile Acids in feces as % of total measured: i.e. (Cholic
acid + chenodeoxycholic acid) .times. 100/(Cholic acid +
chenodeoxycholic acid + 3-OH-12Oxo-Cholanic Acid + deoxycholic acid
+ lithocholic acid)
Example 3: N,N,N',N'-tetrakis(3-aminopropyl)-1,4-butanediamine
(C.sub.4 BTA) Polymers with Epichlorohydrin (ECH)--Comparative
Example
[0165] Synthesis of crosslinked
N,N,N',N'-tetrakis(3-aminopropyl)-1,4-butanediamine materials were
conducted using parallel synthesis. A solution of
N,N,N',N'-tetrakis(3-aminopropyl)-1,4-butanediamine (40 wt. % of a
N,N-dimethylformamide (DMF) solution) was dispensed into 40 mL
glass vials. Epichlorohydrin (ECH) was added to each vial.
Additional DMF and methanol were added resulting in a total solid
content of 40 wt. % where the solvents are in at a ratio of 1:1 (by
volume). The vials were capped and heated for 17 hours at
58.degree. C. The resulting polymer gel was swollen and ground in
MeOH, washed in MeOH (twice), NaOH (0.5M once) then water (three
times) and lyophilized until dry. Bile acid binding capacity,
affinity, and retention for each resulting polymer were determined
via the A assay, B assay and hamster model as described above, and
results are reported in the table below.
TABLE-US-00005 Monomer:Cross- Cross- Cross- linking linking Sam-
linking Monomer Monomer C.sub.4 BTA Methanol DMF ple # Monomer
Molar Ratio (mg) (uL) (uL) (uL) 3-A1 ECH 1:1.6 39829 88720 72046
72046 BA Bile acid Bile acid Bile acid binding binding binding
binding % Primary affinity capacity retention Bile Sam- A assay B
assay Hamster Acids in Swelling ple # (mmol/g) (mmol/g) (mmol/g)
feces* g/g 3-A1 0.34 3.15 0.12 4.7 52.06 *% Primary Bile Acids in
feces as % of total measured: i.e. (Cholic acid + chenodeoxycholic
acid) .times. 100/(Cholic acid + chenodeoxycholic acid +
3-OH-12Oxo-Cholanic Acid + deoxycholic acid + lithocholic acid)
Example 4: N,N,N',N'-tetrakis(3-aminopropyl)-1,12-dodecanediamine
(C.sub.12 BTA) Polymers with
1,3-bis(3-iodopropyl)-1H-imidazol-3-ium
[0166] Synthesis of crosslinked
N,N,N',N'-tetrakis(3-aminopropyl)-1,4-butanediamine materials were
conducted using parallel synthesis.
N,N,N',N'-tetrakis(3-aminopropyl)-1,12-dodecanediamine was
dispensed into a 40 mL glass vial.
1,3-bis(3-iodopropyl)-1H-imidazol-3-ium and N-methylpyrrolidone
(NMP) was added to the vial. The vial was capped and heated for 17
hours at 58.degree. C. The resulting polymer gel was swollen and
ground in MeOH, washed in MeOH (twice), hydrochloric acid (1M,
three times) then water (three times) and lyophilized until dry.
Bile acid binding capacity, affinity, and retention for each
resulting polymer were determined via the A assay, B assay and
hamster model as described above, and results are reported in the
table below.
TABLE-US-00006 Monomer:Cross- 1,3-bis(3-iodopropyl)-1H- linking
imidazol-3-ium Sam- Monomer C.sub.12 BTA Crosslinking monomer NMP
ple # Molar Ratio (mg) (mg) (uL) 4-B3 1:1.26 2080 3253 5666 BA Bile
acid Bile acid Bile acid binding binding binding binding % Primary
affinity capacity retention Bile Sam- A assay B assay Hamster Acids
in Swelling ple # (mmol/g) (mmol/g) (mmol/g) feces* (g/g) 4-B3 0.51
2.99 0.48 18.5 11.45 *% Primary Bile Acids in feces as % of total
measured: i.e. (Cholic acid + chenodeoxycholic acid) .times.
100/(Cholic acid + chenodeoxycholic acid + 3-OH-12Oxo-Cholanic Acid
+ deoxycholic acid + lithocholic acid)
Example 5: Preparation of
1,3-bis(3-iodopropyl)-1H-imidazol-3-ium
[0167] A slurry of imidazole sodium salt (18.3 g, 0.2 mol) and
1-bromo-3-chloropropane (50 mL, 0.5 mol) in 200 mL of THF was
stirred at room temperature overnight. The mixture was then
refluxed for 8 hours and concentrated to dryness. Acetone (250 mL)
was added to the residue, followed by sodium iodide (150 g, 1 mol).
The slurry was stirred under refluxing overnight. Solvent was
removed under reduced pressure. To the residue was added 300 mL of
10% methanol in dichloromethane. Solid was removed by filtration.
The filtrate was concentrated and purified by chromatography
(silica gel, 10-15% methanol in dichloromethane). 11.5 g of desired
product was obtained as a brown oil. MS m/e (MH.sup.+), calcd
404.93, found 404.73. .sup.1H NMR confirmed the structure.
TABLE-US-00007 Crosslinking monomer Structure C.sub.10 bisimidazol-
ium ##STR00044## C.sub.12 bisimidazol- ium ##STR00045## C.sub.12
core, C.sub.3 bisimidazol- ium ##STR00046## C.sub.3 bisimidazol-
ium ##STR00047##
TABLE-US-00008 Amine Monomer Structure C.sub.4 BTA ##STR00048##
C.sub.8 BTA ##STR00049## C.sub.10 BTA ##STR00050## C.sub.12 BTA
##STR00051##
Example 6: C.sub.4 BTA and C.sub.10 BTA Monomers with Bis
Imidazolium Crosslinking Monomers
[0168] Synthesis of
N,N,N',N'-tetrakis(3-aminopropyl)-1,4-butanediamine (C.sub.4 BTA),
N,N,N',N'-tetrakis(3-aminopropyl)-1,10-decanediamine (C.sub.10 BTA)
polymers materials were conducted using dispensing robots with
liquid and powder dispensing capacities. C.sub.4 BTA or C.sub.10
BTA monomer was dispensed into 8 mL glass vials. Solutions of the
crosslinking monomer of formula X-R.sub.1-X wherein X is halo such
as chloro or bromo and R.sub.1 is a imidazolium hydrocarbon chain
listed in the examples below. Crosslinkers were dispensed as 40 wt.
% in dimethyl sulfoxide (DMSO). Solvent was added to each vial to
make the final solid content concentration at 40 wt. %. Vials were
equipped with magnetic stirrer, capped and heated for 17 hours at
70.degree. C. Most vials contained a solid plug of polymer. The
polymer was swollen and ground in dimethyl formamide (DMF), washed
with aqueous hydrochloric acid (1 M), water, saturated solution
sodium bicarbonate (NaHCO.sub.3) three times, water (two times) and
lyophilized until dry.
TABLE-US-00009 BA binding Cross- BA binding % Primary
monomer/cross- linking Capacity Affinity Retention Bile Sam- linker
weight Monomer Weight DMSO B assay A assay Hamster Acids in ple #
mole ratio Monomer (mg) (R.sub.1) (mg) (mg) (mmol/g) (mmol/g)
(mmol/g) feces* 5-A1 1:1.6 C.sub.4 BTA 200.0 C.sub.10
bisimidazolium 879.7 1619.6 5-A2 1:2.2 C.sub.4 BTA 200.0 C.sub.10
bisimidazolium 1209.6 2114.4 2.59 0.59 6-A1 1:1.sup. C.sub.4 BTA
200.0 C.sub.10 bisimidazolium 549.8 1124.7 2.68 0.58 6-A2 1:1.3
C.sub.4 BTA 200.0 C.sub.10 bisimidazolium 714.8 1372.1 2.57 0.50
6-A3 1:1.6 C.sub.4 BTA 200.0 C.sub.10 bisimidazolium 879.7 1619.6
2.82 0.54 7-A1 1:1.3 C.sub.4 BTA 1049.4 C.sub.10 bisimidazolium
3750.6 7200.0 2.71 0.57 7-A2 1:1.6 C.sub.4 BTA 1037.3 C.sub.10
bisimidazolium 4562.7 8400.0 2.91 0.56 0.48 12.1 8-A1 1:1.sup.
C.sub.4 BTA 200.0 C.sub.12 bisimidazolium 603.0 1084.0 2.82 0.58
8-A2 1:1.6 C.sub.4 BTA 200.0 C.sub.12 bisimidazolium 964.7 1572.4
2.69 0.66 8-B1 1:1.sup. C.sub.10 BTA 200.0 C.sub.12 bisimidazolium
476.3 913.0 2.61 0.67 8-B2 1:1.6 C.sub.10 BTA 200.0 C.sub.12
bisimidazolium 762.1 1298.9 2.61 0.62 8-B3 1:1.6 C.sub.10 BTA 200.0
C.sub.12 bisimidazolium 762.1 1298.9 2.68 0.66 9-A1 1:1.sup.
C.sub.4 BTA 1494.5 C.sub.12 bisimidazolium 4505.0 8100.0 2.62 0.67
9-A2 1:1.6 C.sub.4 BTA 786.9 C.sub.12 bisimidazolium 3796.2 6187.3
2.62 0.66 0.44 10 9-B1 1:1.sup. C.sub.10 BTA 1537.7 C.sub.12
bisimidazolium 3662.3 7020.0 2.70 0.68 9-B2 1:1.6 C.sub.10 BTA
838.9 C.sub.12 bisimidazolium 3197.0 5448.6 3.17 0.56 9-B3 1:1.6
C.sub.10 BTA 838.9 C.sub.12 bisimidazolium 3197.0 5448.6 2.7 0.63
0.47 16.4 10-A1 1:1.6 C.sub.4 BTA 1138.0 C.sub.12 core, C.sub.3
4062.0 7800.0 3.17 0.59 0.47 17.5 bisimidazolium 10-A2 1:1.6
C.sub.10 BTA 1361.3 C.sub.12 core, C.sub.3 3838.7 7800.0 3.12 0.58
0.47 27.5 bisimidazolium *% Primary Bile Acids in feces as % of
total measured: i.e. (Cholic acid + chenodeoxycholic acid) .times.
100/(Cholic acid + chenodeoxycholic acid + 3-OH-12Oxo-Cholanic Acid
+ deoxycholic acid + lithocholic acid)
Example 7: N,N,N',N'-tetrakis(3-aminopropyl)-1,4-butanediamine
(C.sub.4 BTA) Terpolymers with 1-(3-aminopropyl)imidazole (API) as
Comonomer, and 1,10-dibromodecane (DBD), as Crosslinking
Monomer
[0169] Synthesis of crosslinked
N,N,N',N'-tetrakis(3-aminopropyl)-1,4-butanediamine materials were
conducted using parallel synthesis. A solution of
N,N,N',N'-tetrakis(3-aminopropyl)-1,4-butanediamine (40 wt. % of a
N,N-dimethylformamide (DMF) solution) was dispensed into 40 mL
glass vials. 1,10-Dibromodecane (DBD), the crosslinking monomer and
1-(3-aminopropyl)imidazole (API), the comonomer, were added to each
vial in the amounts described in the table below. Additional DMF
and methanol were added resulting in a total solid content of 40
wt. % where the solvents were in at a ratio of 1:1 (by volume). The
vials were capped and heated for 17 hours at 58.degree. C. The
resulting polymer gel was swollen and ground in MeOH, washed in
MeOH (twice), NaOH (0.1M three times) then water (three times) and
lyophilized until dry. Bile acid binding capacity, affinity, and
retention for each resulting polymer were determined via the A
assay, B assay and hamster model, and results are reported in the
table below.
TABLE-US-00010 Monomer:Como- nomer:Cross- linking Sam- Monomer DBD
C.sub.4 BTA API DMF methanol ple # Mole Ratio (mg) (uL) (uL) (uL)
(uL) 11-D1 0.75:0.25:1.6 2588 1421 129 3426 3426 11-D2 0.5:0.5:1.6
3261 1119 405 3758 3758 11-D3 0.25:0.75:1.6 4406 605 876 4323 4323
BA BA BA BA binding binding binding binding % Primary affinity
capacity retention Bile Sam- A assay B assay Hamster Acids in
Swelling ple # (mmol/g) (mmol/g) (mmol/g) feces* g/g 11-D1 0.52
3.00 0.56 7.6 63.63 11-D2 0.56 2.92 0.62 10.4 49.36 11-D3 0.58 2.66
0.52 10.7 *% Primary Bile Acids in feces as % of total measured:
i.e. (Cholic acid + chenodeoxycholic acid) .times. 100/(Cholic acid
+ chenodeoxycholic acid + 3-OH-12Oxo-Cholanic Acid + deoxycholic
acid + lithocholic acid)
Example 8: N,N,N',N'-tetrakis(3-aminopropyl)-1,4-butanediamine
(C.sub.4 BTA) with Guanidine Hydrochloride as a Crosslinking
Monomer
[0170] Synthesis of polymers with guanidine hydrochloride as a
crosslinker consisted of three components:
N,N,N',N'-tetrakis(3-aminopropyl)-1,4-butanediamine monomer
(C.sub.4 BTA), guanidine hydrochloride, and a comonomer. All the
reactions were carried out using an appropriate size round bottom
flask with a nitrogen inlet port and hot plates equipped with
silicon oil baths.
[0171] In a typical reaction,
N,N,N',N'-tetrakis(3-aminopropyl)-1,4-butanediamine monomer was
dispensed into a round bottom flask with a nitrogen inlet port.
Then guanidine hydrochloride and comonomer (if present) were added
to the flask. The reaction flasks were capped using a rubber septum
and nitrogen flow was introduced from the nitrogen inlet port. The
reaction flask were then heated for 18 hours at 120.degree. C. and
then for 4 hours at 180.degree. C. The polymer formed was swollen
and ground in 1M hydrochloric acid solution and then washed with
ethanol (two times), water, 3M sodium hydroxide (two times) and
water (three times) and lyophilized until dry. Bile acid binding
capacity, affinity, and retention for each resulting polymer were
determined via the A assay, B assay and hamster model and results
are reported in the table below.
TABLE-US-00011 C.sub.4 Crosslinking C.sub.4
BTA:crosslinker:Comonomer BTA Crosslinker Sample # Monomer
Comonomer (mol ratio) (g) (g) 12-B5 Guanidine None 1:2:0 20.00
12.07 HCl 13-A1 Guanidine 1,6- 1:1.56:1.56 3.49 1.64 HCl diamino-
hexane 13-A2 Guanidine 1,8- 1:1.56:1.56 2.81 1.32 HCl diamino-
octane 13-A3 Guanidine 1,10- 1:1.56:1.56 2.36 1.11 HCl diamino-
decane 13-A4 Guanidine 1,12- 1:1.56:1.56 2.03 0.95 HCl diamino-
dodecane 13-B1 Guanidine 1,12- 1:3.57:3.57 1.33 1.43 HCl diamino-
dodecane BA binding BA binding BA binding BA binding % Primary
Comonomer A assay B assay Hamster Bile Acids Swelling Sample # (g)
(mmol/g) (mmol/g) (mmol/g) in feces* g/g 12-B5 0 0.48 3.39 0.43
20.9 13-A1 2.00 0.48 3.27 0.5 15.5 4.03 13-A2 2.00 0.54 3.2 0.495
20.8 2.76 13-A3 2.00 0.60 3.08 0.46 25.3 2.44 13-A4 2.00 0.65 3.21
0.595 22.2 2.41 13-B1 3.00 0.69 2.17 0.37 52.3 1.05 *% Primary Bile
Acids in feces as % of total measured: i.e. (Cholic acid +
chenodeoxycholic acid) .times. 100/(Cholic acid + chenodeoxycholic
acid + 3-OH-12Oxo-Cholanic Acid + deoxycholic acid + lithocholic
acid)
TABLE-US-00012 Crosslinking monomer Structure TMBMP- DBD
##STR00052## TBMP- DBDD ##STR00053## TMBMP- DBUD ##STR00054##
Example 9: Synthesis of Polymers of
N,N,N',N'-tetrakis(3-aminopropyl)-1,4-butanediamine (C.sub.4 BTA)
and with Dihalo Bis Piperidinium as Crosslinkers and Ligands
[0172] Synthesis of polymers with dihalobis piperidinium as
crosslinkers consisted of two components:
N,N,N',N'-tetrakis(3-aminopropyl)-1,10-dacanediamine monomer
(C.sub.10 BTA) or
N,N,N',N'-tetrakis(3-aminopropyl)-1,4-butanediamine (C.sub.4 BTA)
and dihalobis piperidinium (TMBMP-DBD). The reactions were carried
out using a 250 mL size round bottom flask with a nitrogen inlet
port and hot plates equipped with silicon oil baths.
[0173] In a typical reaction, a BTA monomer was dissolved in
methanol to make a 50 wt. % solution and then dispensed into a
round bottom flask. Then TMBMP-DBD or TMBMP-DBDD was added to the
flask as a 50 wt. % solution in methanol. The reaction flasks were
capped using a rubber septum and nitrogen flow was introduced from
the nitrogen inlet port. The reaction flasks were then heated for
18 hours at 55.degree. C. The polymers formed with C.sub.4 BTA were
swollen and ground in methanol and washed with methanol (two
times), 1M hydrochloric acid, and water (three times) and
lyophilized until dry. The polymers formed with C.sub.10 BTA were
swollen and ground in methanol and washed with methanol (two
times), 0.5M hydrochloric acid, water, 0.5M sodium bicarbonate (two
times) and water (three times) and lyophilized until dry. Bile acid
binding capacity, affinity, and retention for each resulting
polymer were determined via the A assay, B assay and hamster model
and results are reported in the table below.
TABLE-US-00013 Cross- Cross- Monomer:cross- linking Sam- Amine
linking linker BTA CH.sub.3OH monomer ple # monomer Monomer (mol
ratio) (g) (g) (g) 14-A1 C.sub.4 BTA TBMP-DBD 1:2.sup. 1.58 9.96
8.38 15-A1 C.sub.10 BTA TBMP-DBD 1:1.6 1.2 5.22 4.02 15-A2 C.sub.10
BTA TBMP-DBDD 1:1.6 1.2 5.49 4.29 BA Bile acid Bile acid Bile acid
binding binding binding binding % Primary affinity capacity
retention Bile Sam- A assay B assay Hamster Acids in Swelling ple #
(mmol/g) (mmol/g) (mmol/g) feces* g/g 14-A1 0.55 2.73 0.37 14.0 7.6
15-A1 0.54 2.90 11.18 15-A2 0.66 2.79 0.53 18.8 1.83 *% Primary
Bile Acids in feces as % of total measured: i.e. (Cholic acid +
chenodeoxycholic acid) .times. 100/(Cholic acid + chenodeoxycholic
acid + 3-OH-12Oxo-Cholanic Acid + deoxycholic acid + lithocholic
acid)
Example 10: Ligand Modification
[0174] Polymer synthesized with BTA and dihalobis piperidinium
crosslinker were further modified by reacting with alkyl halides to
attach a pendant alkyl ligand to the scaffold. In a typical
reaction, polymer scaffold was first soaked in methanol in a 250 mL
round bottom flask and then different amount of alkyl halide ligand
(as listed in table below) was added to the flask. The reactions
were carried out at 55.degree. C. for 18 hours. The polymer were
then washed with methanol (2 times), 1 M hydrochloric acid, 1 M
sodium chloride (2 times), and water (3 times) and lyophilized
until dry. Bile acid binding capacity, affinity, and retention for
each resulting polymer were determined via the A assay, B assay and
hamster model and results are reported in the table below.
TABLE-US-00014 Polymer Polymer Sam- Polymer scaffold:Ligand
scaffold Methanol Ligand ple # scaffold Ligand (mol ratio) (g) (g)
(g) 16-A1 C.sub.4 BTA/ C.sub.10 alkyl 1:0.95 2.8 31.6 1.2 TMBMP/DBD
16-A2 C.sub.4 BTA/ C.sub.10 alkyl 1:1.75 2.2 27.69 1.8 TMBMP/DBD
16-A3 C.sub.4 BTA/ C.sub.10 alkyl 1:3.45 1.6 23.73 2.4 TMBMP/DBD BA
binding BA BA BA Hamster binding binding binding % Primary affinity
capacity retention Bile Sam- A assay B assay Hamster Acids in
Swelling ple # (mmol/g) (mmol/g) (mmol/g) feces* g/g 16-A1 0.65
2.25 0.38 4.6 3.22 16-A2 0.62 2.11 2.29 16-A3 0.671 1.98 0.4 4.4
2.11 *% Primary Bile Acids in feces as % of total measured: i.e.
(Cholic acid + chenodeoxycholic acid) .times. 100/(Cholic acid +
chenodeoxycholic acid + 3-OH-12Oxo-Cholanic Acid + deoxycholic acid
+ lithocholic acid)
Example 11: Synthesis of a Crosslinker,
Bis-1-bromo-decane-4,4'-trimethylenebis(1-methylpiperidine)
[0175] Into a round bottomed flask was weighed 60 g (0.20 moles) of
dibromodecane and 20 mL of methanol. The flask was heated to
55.degree. C. for 15-20 minutes. Then 10.0 g (0.041 mol) of
4,4'-Trimethylenebis(1-methylpiperidine) was added to the solution.
The reaction mixture was allowed to stir for 12 hours and the
reaction was stopped by the removal of heat and cooling to room
temperature. The product was isolated by precipitation of the
reaction solution into a solution of acetone:hexane 3:1 followed by
filtration and washing with hexanes. The yield was 24.6 g 91%
yield. The product was identified by .sup.1H NMR and mass spec.
Example 12: Preparation of TMBMP-DBUD
[0176] A mixture of 11-bromoundecanol (31.65 g, 0.126 mol) and
4,4'-trimethylenebis(1-methylpiperidine) (5 g, 0.021 mol) in
methanol (50 mL) was refluxed for 17 hours. Methanol was removed by
rotary evaporation. To the residue was added toluene (100 mL) and
the mixture was stirred at 50.degree. C. for 2 hours. Solvent was
removed by filtration. The solid was washed with toluene (100 mL)
and ether (2.times.100 mL). After drying under high vacuum,
4,4'-(propane-1,3-diyl)bis(1-(11-hydroxyundecyl)-1-methylpiperidinium)
was obtained as a white powder (15.5 g, 100%). MS m/e (M.sup.2+),
calculated 290.3, found 290.5.
[0177]
4,4'-(propane-1,3-diyl)bis(1-(11-hydroxyundecyl)-1-methylpiperidini-
um) (15.5 g, 0.21 mol) was placed in a pressure flask. Hydrobromic
acid (50 mL, 48 wt. % in water) was added and the flask was
tightened to seal. The reaction was stirred at 120.degree. C. for
17 hours. The reaction mixture was azeotroped with THF and toluene
to remove excess hydrobromic acid. The residue was dried in vacuum
oven at 35.degree. C. for 24 hours to give 17.27 g crude product as
a light brown powder (94.9% yield).
[0178] The crude product (4.02 g) was recrystallized in isopropanol
(20 mL) to give
4,4'-(propane-1,3-diyl)bis(1-(11-bromoundecyl)-1-methylpiperidinium)
as an off-white solid (3.11 g, 77.4% recovery). MS m/e (M.sup.2+),
calculated 353.2, found 353.3.
Example 13: N,N,N',N'-tetrakis(3-aminopropyl)-1,3-propanediamine
(C.sub.3 BTA), N,N,N',N'-tetrakis
(3-aminopropyl)-1,8-octaneanediamine (C.sub.8 BTA),
N,N,N',N'-tetrakis(3-aminopropyl)-1,10-decanediamine (C.sub.10 BTA)
and N,N,N',N'-tetrakis (3-aminopropyl)-1,12-dodecanediamine
(C.sub.12 BTA) Gel Synthesis
[0179] Synthesis of
N,N,N',N'-tetrakis(3-aminopropyl)-1,3-propanediamine,
N,N,N',N'-tetrakis (3-aminopropyl)-1,8-octaneanediamine,
N,N,N',N'-tetrakis(3-aminopropyl)-1,10-decanediamine and
N,N,N',N'-tetrakis (3-aminopropyl)-1,12-dodecanediamine polymers
materials were conducted using dispensing robots with liquid and
powder dispensing capacities.
N,N,N',N'-tetrakis(3-aminopropyl)-1,3-propanediamine or
N,N,N',N'-tetrakis (3-aminopropyl)-1, 8-octaneanediamine or
N,N,N',N'-tetrakis(3-aminopropyl)-1,10-decanediamine or
N,N,N',N'-tetrakis (3-aminopropyl)-1,12-dodecanediamine monomer was
dispensed into 8 mL glass vials. Solutions of the crosslinking
monomer of formula X-R.sub.1-X wherein X is halo such as chloro or
bromo and R.sub.1 is a hydrocarbon chain listed in the examples
below, 1,10-dibromodecane was dispensed at 40 wt. % in dimethyl
sulfoxide (DMSO) and 1,12-dibromododecane was neat. Solvent was
added to each vial to make the final solid content concentration at
40 wt %. Vials were equipped with magnetic stirrer, capped and
heated for 17 hours at 60.degree. C. Most vials contained a solid
plug of polymer. The polymer was swollen and ground in dimethyl
formamide (DMF), washed with aqueous hydrochloric acid (1 M),
water, sodium hydroxide (0.01 M, three times), water (two times)
and lyophilized until dry.
TABLE-US-00015 Bile acid Bile acid binding binding Capacity
Affinity Retention % Primary Monomer:cosslinker Wt. Cross-linker wt
DMSO B assay A assay Hamster Bile Acids Sample # mole ratio monomer
(mg) (R.sub.1) (mg) (mg) (mmol/g) (mmol/g) (mmol/g) in feces* 17-A1
1:0.5 C.sub.8 BTA 300.0 C.sub.10 alkylene 120.8 631.2 17-A2 1:0.5
C.sub.10 BTA 300.0 C.sub.10 alkylene 112.3 618.5 17-A3 1:0.5
C.sub.12 BTA 300.0 C.sub.10 alkylene 105.0 607.5 17-B1 1:1 C.sub.8
BTA 300.0 C.sub.10 alkylene 241.6 812.4 3.33 17-B2 1:1 C.sub.10 BTA
300.0 C.sub.10 alkylene 224.7 787.0 3.22 17-B3 1:1 C.sub.12 BTA
300.0 C.sub.10 alkylene 210.0 764.9 3.32 17-C1 1:1.6 C.sub.8 BTA
300.0 C.sub.10 alkylene 386.6 1029.8 3.21 17-C2 1:1.6 C.sub.10 BTA
300.0 C.sub.10 alkylene 359.5 989.2 2.91 17-C3 1:1.6 C.sub.12 BTA
300.0 C.sub.10 alkylene 335.9 953.9 2.98 17-D1 1:2.2 C.sub.8 BTA
300.0 C.sub.10 alkylene 531.5 1247.3 2.93 17-D2 1:2.2 C.sub.10 BTA
300.0 C.sub.10 alkylene 494.3 1191.4 2.74 17-D3 1:2.2 C.sub.12 BTA
300.0 C.sub.10 alkylene 461.9 1142.9 2.61 18-A1 1:1.6 C.sub.10 BTA
6368.8 C.sub.10 alkylene 7631.2 21000.0 3.07 0.68 19-A1 1:1.6
C.sub.10 BTA 2911.5 C.sub.10 alkylene 3488.5 9600.0 3.15 0.68 0.49
25.1 19-A2 1:1.6 C.sub.12 BTA 3019.1 C.sub.10 alkylene 3380.9
9600.0 3.00 0.70 0.56 28.3 20-A2 1:1.6 C.sub.8 BTA 150.0 C.sub.10
alkylene 193.3 514.9 20-B2 1:2.2 C.sub.8 BTA 150.0 C.sub.10
alkylene 265.8 623.6 2.77 20-C2 1:2.8 C.sub.8 BTA 150.0 C.sub.10
alkylene 338.2 732.4 2.54 20-D2 1:3.4 C.sub.8 BTA 150.0 C.sub.10
alkylene 410.7 841.1 2.24 21-A1 1:1.6 C.sub.3 BTA 150.0 C.sub.10
alkylene 238.2 582.3 3.32 0.61 21-B1 1:2.2 C.sub.3 BTA 150.0
C.sub.10 alkylene 327.5 716.3 3.24 21-C1 1:2.8 C.sub.3 BTA 150.0
C.sub.10 alkylene 416.8 850.3 3.10 0.69 21-D1 1:3.4 C.sub.3 BTA
150.0 C.sub.10 alkylene 506.2 984.3 2.86 0.71 22-A1 1:1.6 C.sub.3
BTA 2923.5 C.sub.12 alkylene 5076.5 12000.0 3.03 0.68 0.64 26.2 *%
Primary Bile Acids in feces as % of total measured: i e. (Cholic
acid + chenodeoxycholic acid) .times. 100/(Cholic acid +
chenodeoxycholic acid + 3-OH-12Oxo-Cholanic Acid + deoxycholic acid
+ lithocholic acid)
Example 14: BTA Monomers with Different Core Structures
##STR00055##
[0181] Synthesis of
N.sup.1,N.sup.1'-(1,3-phenylenebis(methylene))bis(N.sup.1-(3-aminopropyl)-
propane-1,3-diamine) (R.sub.3=1,3-phenylenedimethyl),
N.sup.1,N.sup.1'-(1,4-phenylenebis(methylene))bis(N.sup.1-(3-aminopropyl)-
propane-1,3-diamine) (R.sub.3=1,4-phenylenedimethyl),
N.sup.2,N.sup.2,N.sup.6,N.sup.6-tetrakis(3-aminopropyl)pyridine-2,6-dicar-
boxamide (R.sub.3=2,6-diformylpyridine),
N.sup.1,N.sup.1,N.sup.6,N.sup.6-tetrakis(3-aminopropyl)adipamide
(R.sub.3=1,6-dioxohexane-1,6-diyl),
N.sub.1,N.sup.1,N.sup.4,N.sup.4tetrakis(3-aminopropyl)succinamide
(R.sub.3=succinyl) and
1,3-bis(3-(bis(3-aminopropyl)amino)propyl)-1H-imidazol-3-ium
(R.sub.3=3,3'-(1H-imidazole-3-ium-1,3-diyl)dipropyl) crosslinked
materials were conducted using dispensing robots with liquid and
powder dispensing capacities. The selected monomer was dispensed
into 8 mL glass vials. Solutions of the crosslinking monomer of
formula X-R.sub.1-X wherein X is halo such as chloro or bromo and
R.sub.1 is a hydrocarbon chain as listed in the table below was
dispensed as 40 wt. % in dimethyl sulfoxide (DMSO). Solvents and
K.sub.2CO.sub.3 were added to each vial. The vials were equipped
with magnetic stirrer, capped and heated for 17 hours at 60.degree.
C. Most vials contained a solid plug of polymer. The polymer was
swollen and ground in methanol, washed with aqueous hydrochloric
acid (1 M), water, sodium hydroxide (0.01 M, three times), water
(two times) and lyophilized until dry.
TABLE-US-00016 BA binding % Mono- 1,10- BA binding Primary Cross-
mer:cross- Dibromo Affinity Capacity Retention Bile Sample linking
linker decane K.sub.2CO.sub.3 DMSO A assay B assay Hamster Acids in
# monomer mole ratio Monomer R.sub.3 value wt (mg) (mg) (mg) (mg)
(mmol/g) (mmol/g) (mmol/g) feces* 23-B1 C.sub.10 alkylene 1:0.5
1,3-phenylenedimethyl 400 102.9 568.6 754.3 0.672 2.7324 23-B2
C.sub.10 alkylene 1:1 1,3-phenylenedimethyl 400 205.8 568.6 908.6
0.6636 1.3948 23-C1 C.sub.10 alkylene 1:0.5 2,6-diformylpyridine
400 104.2 480 756.3 23-C2 C.sub.10 alkylene 1:1
2,6-diformylpyridine 400 208.4 480 912.7 0.6592 2.3176 23-D1
C.sub.10 alkylene 1:0.5 1,6-dioxohexane-1,6-diyl 400 115.8 426.6
773.7 23-D2 C.sub.10 alkylene 1:1 1,6-dioxohexane-1,6-diyl 400
231.5 426.6 947.3 0.6404 2.2948 24-A1 C.sub.10 alkylene 1:1.6
1,3-phenylenedimethyl 329.1 270.9 467.9 900 0.6586 1.3198 24-A2
C.sub.10 alkylene 1:1.6 2,6-diformylpyridine 327.2 272.8 392.7 900
0.6938 1.8654 24-A3 C.sub.10 alkylene 1:1.6
1,6-dioxohexane-1,6-diyl 311.5 288.5 332.2 900 0.6846 1.9758 25-A1
C.sub.10 alkylene 1:1.6 1,3-phenylenedimethyl 3949.4 3250.5 5614.3
10799.8 0.366 0.2862 25-A2 C.sub.10 alkylene 1:1.6
1,3-phenylenedimethyl 3926.3 3273.7 4711.9 10800 0.583 0.849 0.2
26.3 25-A3 C.sub.10 alkylene 1:1.6 1,6-dioxohexane-1,6-diyl 3983.9
3689.8 4248.7 11510.6 0.6502 1.495 0.25, 0.51 36.3, 29.2 26-A1
C.sub.10 alkylene 1:0.5 1,3-phenylenedimethyl 4600.6 1183.3 6540.1
8675.9 0.64905 2.7082 27-A1 C.sub.10 alkylene 1:0.5
1,3-phenylenedimethyl 2409.9 619.8 3425.8 4544.5 0.6652 2.6874
27-A2 C.sub.10 alkylene 1:1 2,6-diformylpyridine 2998.3 1562.4
3598.2 6841.1 0.5532 1.2818 28-A2 C.sub.10 alkylene 1:1
1,3-phenylenedimethyl 300 154.3 426.5 681.5 0.6668 2.8324 28-A3
C.sub.10 alkylene 1:0.5 1,3-phenylenedimethyl 300 231.5 426.5 797.2
0.6716 2.0856 29-A1 C.sub.10 alkylene 1:0.5 1,3-phenylenedimethyl
3943.4 1014.2 5605.8 7436.5 0.6628 2.1736 29-A2 C.sub.10 alkylene
1:1 1,3-phenylenedimethyl 2880.4 1481.7 4094.7 6543.2 0.67 1.8818
30-A1 C.sub.10 alkylene 1:0.8 3,3'-(1H-imidazole-3-ium- 300 108.2
373.6 612.2 0.573 2.889 1,3-diyl)dipropyl 30-A2 C.sub.10 alkylene
1:1.2 3,3'-(1H-imidazole-3-ium- 300 162.2 373.6 693.3 0.617 2.7334
1,3-diyl)dipropyl 31-A1 C.sub.10 alkylene 1:0.8
3,3'-(1H-imidazole-3-ium- 2001.4 721.5 2492.5 4084.5 0.6018 2.9138
1,3-diyl)dipropyl 31-A2 C.sub.10 alkylene 1:1.2
3,3'-(1H-imidazole-3-ium- 2001.4 1082.1 2492.5 4624.8 0.6374 2.4926
0.5 16.2 1,3-diyl)dipropyl 32-A1 C.sub.10 alkylene 1:0.8
3,3'-(1H-imidazole-3-ium- 4700 1694.4 5853.3 9591.6 0.638 2.3254
0.5 19.8 1,3-diyl)dipropyl 33-A1 C.sub.10 alkylene 1:0.8 Succinyl
400 195.83 450.99 795.1 0.62 2.86 33-A2 C.sub.10 alkylene 1:1.2
Succinyl 400 293.74 450.99 892.9 0.66 2.48 33-A3 C.sub.10 alkylene
1:1.6 Succinyl 400 391.66 450.99 990.7 0.66 1.78 33-A4 C.sub.10
alkylene 1:1.2 Succinyl 4000 2937.42 4509.85 8929.3 0.65 2.71 0.59
14.5 33-B1 C.sub.12 alkylene 1:0.8 Succinyl 400 214.14 450.99 813.4
0.68 1.83 33-B2 C.sub.12 alkylene 1:1.2 Succinyl 400 321.21 450.99
920.4 0.68 2.31 33-B3 C.sub.12 alkylene 1:1.6 Succinyl 400 428.28
450.99 1027.3 0.66 1.33 33-B4 C.sub.12 alkylene 1:1.2 Succinyl 4000
3212.11 4509.85 9203.7 0.68 1.95 0.39 25.0 *% Primary Bile Acids in
feces as % of total measured: i.e. (Cholic acid + chenodeoxycholic
acid) .times. 100/(Cholic acid + chenodeoxycholic acid +
3-OH-12Oxo-Cholanic Acid + deoxycholic acid + lithocholic acid)
Example 15:
N.sup.1,N.sup.1'-(1,3-phenylenebis(methylene))bis(N.sup.1-(3-aminopropyl)-
propane-1,3-diamine)
##STR00056##
[0183] Tert-butyl 3,3'-azanediylbis(propane-3,1-diyl)dicarbamate
(14.0 g, 0.038 mol) was dissolved in 150 mL of acetonitrile. To the
solution was added 1,3-bis(chloromethyl)benzene (3.34 g, 0.019
mol), followed by diisopropylethylamine (13.2 mL, 0.076 mol). The
reaction was stirred at 60.degree. C. for 20 hours. The solvent was
removed and the residue was purified by flash chromatography
(silica gel, 15% methanol in dichloromethane) to give 7.56 g (52%)
of pure
tert-butyl-3,3',3'',3'''-(1,3-phenylenebis(methylene))bis(azanetriyl)tetr-
akis(propane-3,1-diyl)tetracarbamate as a brown oil. MS m/e
(MH.sup.+), calculated 765.55, found 765.67.
[0184] Tert-butyl
3,3',3'',3'''-(1,3-phenylenebis(methylene))bis(azanetriyl)tetrakis-(propa-
ne-3,1-diyl)tetracarbamate (7.56 g, 0.099 mol) was dissolved in 40
mL of dichloromethane. To the solution was added trifluoroacetic
acid (30.5 mL, 0.396 mol). The reaction was stirred at room
temperature for 16 hours. Solvent was removed under reduced
pressure and toluene (100 mL) was added to the residue to form a
heteroazeotrope. After removal of toluene and remaining
trifluoroacetic acid, a brown semi-solid was formed. To the residue
was added 4N hydrochloric acid in dioxane (40 mL) and the mixture
was stirred at room temperature for 30 minutes. A light brown solid
formed. Ethyl ether (150 mL) was added to the mixture and the solid
was filtered, washed with ethyl ether and dried under high vacuum
to give 5.78 g
N.sup.1,N.sup.1'-(1,3-phenylenebis(methylene))bis(N.sup.1-(3-amino-
propyl)propane-1,3-diamine) as a hexahydrochloride salt in
quantitative yield. MS m/e (MH.sup.+), calculated 365.33, found
365.39.
Example 16:
N.sup.2,N.sup.2,N.sup.6,N.sup.6-tetrakis(3-aminopropyl)pyridine-2,6-dicar-
boxamide
##STR00057##
[0186] A solution of tert-butyl
3,3'-azanediylbis(propane-3,1-diyl)dicarbamate (9.94 g, 0.03 mol)
and diisopropylethyl amine (7.82 mL, 0.045 mol) in 200 mL of
dichloromethane was cooled to 4.degree. C. in an ice bath.
Pyridine-2,6-dicarbonyl dichloride (3.06 g, 0.015 mol) was
dissolved in 50 mL of dichloromethane and was added to the solution
of tert-butyl 3,3'-azanediylbis(propane-3,1-diyl)dicarbamate
dropwise. The internal temperature remained at or below 4.degree.
C. during the addition. After the addition, the reaction was warmed
to room temperature and stirred for 3 hours. The reaction solution
was washed with 1N HCl (2.times.150 mL), brine (150 mL), saturated
NaHCO.sub.3 solution (150 mL), and brine (150 mL). The organic
phase was dried over MgSO.sub.4 and concentrated. The crude product
was passed through a silica gel plug (15% methanol in
dichloromethane) to give 11.2 gram of tetra-Boc-protected
N.sup.2,N.sub.2,N.sup.6,N.sup.6-tetrakis(3-aminopropyl)pyridine-2,6-dicar-
boxamide as a white solid (94%). MS m/e (MH.sup.+), calculated
794.50, found 794.71.
[0187] To a solution of tetra-Boc-protected
N.sup.2,N.sup.2,N.sup.6,N.sup.6-tetrakis(3-aminopropyl)pyridine-2,6-dicar-
boxamide (11.1 g, 0.014 mol) in 80 mL of dichloromethane was added
trifluoroacetic acid (21.6 mL, 0.28 mol). The reaction was stirred
at room temperature for 3 hours. Solvent was removed under reduced
pressure and toluene (100 mL) was added to the residue to form a
heteroazeotrope. Solvent and remaining trifluoroacetic acid were
removed under reduced pressure. To the residue was added 4N HCl in
dioxane (25 mL). The mixture was stirred at room temperature for 30
minutes and a white solid formed. Ethyl ether (150 mL) was added to
the mixture and the solid was filtered, washed with ethyl ether and
dried under high vacuum to give
N.sup.2,N.sup.2,N.sup.6,N.sup.6-tetrakis(3-aminopropyl)pyridine-2,6-dicar-
boxamide as penta-hydrochloride salt in quantitative yield (8.02
g). MS m/e (MH.sup.+), calculated 394.29, found 394.3.
Example 17:
N.sup.1,N.sup.1,N.sup.6,N.sup.6-tetrakis(3-aminopropyl)adipamide
##STR00058##
[0189] The title compound was prepared using same procedure
described above for
N.sup.2,N.sup.2,N.sup.6,N.sup.6-tetrakis(3-aminopropyl)pyridine-
-2,6-dicarboxamide. After drying under high vacuum, 6.03 g of
N.sup.1,N.sup.1,N.sup.6,N.sup.6-tetrakis(3-aminopropyl)adipamide
tetra-hydrochloride salt was obtained as a white solid (78%). MS
m/e (MH.sup.+), calculated 373.33, found 373.4.
Example 18:
N.sup.1,N.sup.1,N.sup.4,N.sup.4-tetrakis(3-aminopropyl)succinamide
##STR00059##
[0191] A solution of tert-butyl
3,3'-azanediylbis(propane-3,1-diyl)dicarbamate (15.0 g, 0.045 mol)
and diisopropylethyl amine (8.6 mL, 0.0495 mol) in 200 mL of
dichloromethane was cooled to 4.degree. C. in ice bath. Succinyl
chloride (2.68 mL, 0.0226 mol) was dissolved in 50 mL of
dichloromethane and was added to the solution of tert-butyl
3,3'-azanediylbis(propane-3,1-diyl)dicarbamate dropwise. The
internal temperature remained at or below 4.degree. C. during the
addition. After the addition, the reaction was warmed to room
temperature and stirred for 2 hours. The reaction solution was
washed with 1:1 mixture of 1N HCl and brine (2.times.150 mL),
saturated NaHCO.sub.3 solution (200 mL), and brine (200 mL).
Organic phase was dried over MgSO.sub.4 and concentrated. The crude
product was purified on silica gel column (5-10% methanol in
dichloromethane) to give 14.92 gram of t-Boc-protected
N.sup.1,N.sup.1,N.sup.4,N.sup.4-tetrakis(3-aminopropyl)succinamide
as a brown solid (88.6%).
[0192] A solution of tetra-Boc-protected
N.sup.1,N.sup.1,N.sup.4,N.sub.4-tetrakis(3-aminopropyl)succinamide
(14.9 g, 0.02 mol) in 4N HCl in dioxane (100 mL, 0.4 mol) was
stirred at room temperature overnight. Precipitate formed in the
solution. Diethylether (100 mL) was added to the reaction mixture.
The slurry was stirred at room temperature for 30 min. Solid was
filtered under nitrogen blanket and washed with diethylether
(3.times.100 mL). After removal of residue solvent, desired product
was obtained in quantitative yield as a tetrahydrochloride salt. MS
m/e (MH.sup.+), calculated 345.29, found 345.3.
Example 19:
1,3-bis(3-(bis(3-aminopropyl)amino)propyl)-1H-imidazol-3-ium
##STR00060##
[0194] To a solution of 1,3-bis(3-iodopropyl)-1H-imidazol-3-ium
iodide (5.02 g, 9.4 mmol) in 100 mL of acetonitrile was added
tert-butyl 3,3'-azanediylbis(propane-3,1-diyl)dicarbamate (6.25 g,
18.8 mmol), followed by diisopropylethylamine (4.08 mL, 23.5 mmol).
The reaction was stirred at 60.degree. C. for 16 hours. Solvent was
removed under reduced pressure. The crude product was purified by
flash chromatography (silica gel, 15% methanol in dichloromethane
containing 1% trimethylamine).
1,3-bis(3-(bis(3-(tert-butoxycarbonylamino)propyl)amino)propyl)-1H-imidaz-
ol-3-ium iodide was obtained as white solid (5.8 g, 66%). MS m/e
(MH.sup.+), calculated 811.6, found 811.7.
[0195] A mixture of
1,3-bis(3-(bis(3-(tert-butoxycarbonylamino)propyl)amino)propyl)-1H-imidaz-
ol-3-ium iodide (5.5 g, 5.8 mmol) in 4N HCl in dioxane (58.6 mL,
234 mmol) was stirred at room temperature overnight. Solvent was
removed under reduced pressure. Toluene (3.times.100 mL) was added
to form a heteroazeotrope. After removal of toluene and residue
solvent, the desired product was obtained as a hexahydrochloride
salt in quantitative yield. MS m/e (MH.sup.+), calculated 411.39,
found 411.4.
Example 20: Synthesis of Imidazolium Crosslinkers
[0196] Synthesis of Bis imiazole-n-alkane. A solution of
Na-imidazole (0.1 mol) (imidazole sodium derivative, Aldrich
197637, CAS 5587-42-8) in 100 mL THF was prepared. An appropriate
amount of the dialkyl bromide was added and the mixture was stirred
overnight at room temperature. The solids were filtered off and the
filtrate was dried under vacuum. The product was purified by column
chromatography using 500 g of silica and ethyl acetate. The
resulting yield was 50-80%. The product was identified by .sup.1H
NMR and mass spec.
[0197] Synthesis of 1-alkyl-3-(1-bromoalkyl) imidazolium bromide.
Dibromoalkane (0.3 mol) was placed into a 3-necked flask that was
fitted with an overhead stirrer. Acetone was added such that the
resulting solution was 3 M. Alkyl imidazole (0.03 mol) was
dissolved in acetone to result in a 2M solution. This was added to
the flask and the reaction was stirred overnight at 45-50.degree.
C. The next day, the acetone was vacuumed off and the product was
purified by column chromatography using 500 g of silica gel and
90:10 CH.sub.2Cl.sub.2:MeOH. The yield was in the range of 60-70%
of materials that ranged from a clear oil to a white sold. Product
was identified by .sup.1H NMR and mass spec.
[0198] Synthesis of polymer modified with 1,3-dialkylimidazolium
bromide. The desired polyamine scaffold gel was dissolved in water
and neutralized with an equimolar solution of NaOH. An appropriate
amount of a solution of 1,3-dialkylimidazolium bromide in methanol
was added to the polyamine solution. The mixture was heated to
75.degree. C. for 24 hours. After cooling to room temperature the
modified polyamine gel was washed by exposing the gel to a 2.times.
methanol wash, 0.5 M HCl wash and 2.times. water washes. Each wash
consisted of a process where the gel was stirred for 30 minutes,
exposed to the washing solvent, centrifuged and the supernatant
liquid was decanted off, and the wash solvent was added. After the
final water wash, the gel was placed into a lyophilizer to remove
the water. The gel was isolated as a white fluffy material.
[0199] Synthesis of n-alkyl bisimidazole. Imidazole sodium
derivative (27 g, 0.29 moles) and tetrabutyl ammonium hydrogen
sulfate (2.2 g, 6 mmol) (both commercially available from Aldrich)
was weighed into a 1 L, 3 necked flask. An overhead stirrer, a
condenser with a feed of dry, inert atmosphere was fitted to the
flask. The remaining neck was fitted with a rubber septa. Anhydrous
THF (250 mL) was added to the flask and stirred for 1 hour at room
temperature. An appropriate amount of alkyl dibromide (1, 12
dibromododecane, 16.g, 0.049 mol) in 50 mL THF was added. After
stirring for 3-5 days and monitoring the progress with TLC, the
solids were filtered off and the filtrate was dried under reduced
pressure to generate an oil. The product was purified by adding
CH.sub.2Cl.sub.2 and washing five times with water and then washing
the organic layer with anhydrous magnesium sulfate. The purity was
monitored by TLC (10% MeOH, 90% CH.sub.2Cl.sub.2), until no
starting imidazole was present. The resulting yields were in the
range of 80-90%. .sup.1H NMR (CD.sub.3OD, 25.degree. C., .delta.
(ppm): 7.62 (s), 7.1, 6.90 (imidazole), 4.0 (tr), 1.8 (br), 1.25
(br, alkane). A similar synthesis procedure was used for
1,10-dibromodecane.
[0200] Synthesis of bis(1-bromoalkyl imidazolium bromide) alkane.
In a dry sealed round bottomed flask, an appropriate amount of
dibromoalkane (dibromododecane 48.7 g, 0.14 mol) was taken and 49 g
of acetone, 1 g of MeOH was added as solvent. To this, freshly
prepared n-alkyl bisimidazole (10 g, 0.033 mol) was added dropwise.
It was heated at 55.degree. C. for 2-3 days. The product was
isolated by precipitating the product. The reaction solution was
allowed to cool to room temperature and then this was added slowly
to a glass beaker containing 250 mL of hexanes being rapidly
stirred. The product form a precipitate oil. The hexanes were
removed and the precipitate was stirred/washed with the following
solvents to remove excess dibromoalkane; ethylacetate and diethyl
ether. The white precipitate was placed in a vacuum oven to remove
excess organic solvent.
[0201] The yields were in the range of 60%. .sup.1H NMR
(CD.sub.3OD, 25.degree. C., .delta. (ppm): 9.1 (s), 7.7
(imidazolium), 4.21 (tr, --CH.sub.2-imidazolium), 3.4
(--CH.sub.2Br), 1.9 (br), 1.4 (br, alkane). A similar synthesis
procedure was used to prepare all bisimidazolium alkylhalide
crosslinkers e.g. bis imidazolium C.sub.10 crosslinker, bis
imidazolium C.sub.12 crosslinker, bis imidazolium C.sub.12 core
C.sub.3 crosslinker.
Example 21: Synthesis of a Crosslinker,
Bis-1-alkyl-4,4'-Trimethylenebis(1-methylpiperidine) Ligand
[0202] Into a round bottomed flask was weighed 42.34 g (0.20 moles)
of dibromopropane and 20 mL of methanol. The flask was heated to
55.degree. C. for 15-20 minutes. Then 10.0 g (0.041 mol) of
4,4'-trimethylenebis(1-methylpiperidine) was added to the solution.
The reaction mixture was allowed to stir for 12 hours and the
reaction was stopped by the removal of heat and cooling to room
temperature. The product was isolated by precipitation of the
reaction solution into a solution of acetone:hexane 3:1 followed by
filtration and washing with hexanes. The yield was 24.6 g (91%
yield). The product was identified by .sup.1H NMR and mass
spectrometry.
Example 22: Monomer Approach Towards the Synthesis of
Ligand-Containing
N,N,N',N'-tetrakis(3-aminopropyl)-1,4-butanediamine (C.sub.4 BTA)
polymers
[0203] Synthesis of ligand-containing BTA polymers by the monomer
approach was conducted in a 4.times.6 library format with 8 mL
vials. N-alpha-(tert-butoxycarbonyl)-L-tryptophan N-succinimidyl
ester (Boc-Trp-Osu) was obtained commercially (TCI America CAS
3392-11-8). The synthesis was conducted in a two step process.
[0204] Step 1 (Recipe for BTA modified with ligand). A 75 wt. %
solution of N,N,N',N'-tetrakis(3-aminopropyl)-1,4-butanediamine
(C.sub.4 BTA) in N-methylpyrrolidone (NMP) was dispensed into the
vials, followed by a solution of ligand (20 wt. % in NMP). The
vials were sealed and the mixture was stirred at 80.degree. C.,
stirring at 500 RPM for 18 hours, then cooled to room temperature.
Attachment of the ligand to C.sub.4 BTA was confirmed using MS. The
amounts of the C.sub.4 BTA, NMP, and Boc-Trp-OSu use are listed in
the table below.
[0205] Step 2 (Crosslinking the modified BTA monomer). The C.sub.4
BTA-ligand mixture was subsequently treated with neat
1,10-dibromodecane (DBD) or epichlorohydrin (ECH). The reactions
were sealed and heated at 80.degree. C. for 18 hours with stirring
at 500 RPM until the reaction mixture gelled. Samples that gelled
were washed with methanol (2.times.), 1M NaOH solution, water
(3.times.), then lyophilized dry. The amounts for the reactants are
listed in the table below.
TABLE-US-00017 Recipe # C.sub.4 BTA NMP Boc-Trp-OSu 100-A1 911.14
1459.15 288.86 100-A2 734.37 2107.32 465.63 100-A3 529.07 2860.07
670.93 100-A4 339.34 3555.74 860.66 BA BA binding binding
Amine:Cross- Ligand:Amine affinity capacity linker Mol Cross- A
assay B assay Sample Amine Cross- Mol Ratio to 100- 100-A2 100-A3
100-A4 linker (mmol/ (mmol/ # Monomer Ligand linker Ratio BTA A1
(mg) (mg) (mg) (mg) (mg) g) g) 34-A1 BTA Boc-Trp-Osu ECH 1:2 1:0.25
650.435 0 0 0 130.28 0.47 2.95 34-A2 BTA Boc-Trp-Osu ECH 1:4 1:0.25
650.435 0 0 0 260.56 0.41 0.62 34-A3 BTA Boc-Trp-Osu ECH 1:6 1:0.25
650.435 0 0 0 390.85 0.37 0.68 34-A4 BTA Boc-Trp-Osu ECH 1:8 1:0.25
650.435 0 0 0 521.13 0.36 1.01 34-B1 BTA Boc-Trp-Osu ECH 1:2 1:0.5
0 0 0 0 104.69 0.44 2.42 34-B2 BTA Boc-Trp-Osu ECH 1:4 1:0.5 0 0 0
0 209.38 0.42 1.26 34-B3 BTA Boc-Trp-Osu ECH 1:6 1:0.5 0 806.535 0
0 314.06 0.38 1.23 34-B4 BTA Boc-Trp-Osu ECH 1:8 1:0.5 0 806.535 0
0 418.75 0.37 1.15 35-A1 BTA Boc-Trp-Osu DBD 1:1 1:0.5 0 806.535 0
0 211.27 0.57 3.20 35-A2 BTA Boc-Trp-Osu DBD 1:2 1:0.25 0 806.535 0
0 422.54 0.65 2.31 35-A3 BTA Boc-Trp-Osu DBD 1:3 1:0.25 0 0 0 0
633.81 0.55 1.06 35-A4 BTA Boc-Trp-Osu DBD 1:4 1:0.25 0 0 0 0
845.09 N/A 1.81 35-B1 BTA Boc-Trp-Osu DBD 1:1 1:0.5 0 0 1013.94 0
169.77 0.58 2.80 35-B2 BTA Boc-Trp-Osu DBD 1:2 1:0.5 0 0 1013.94 0
339.54 0.63 1.74 35-B3 BTA Boc-Trp-Osu DBD 1:3 1:0.5 0 0 1013.94 0
509.30 0.46 0.63 35-B4 BTA Boc-Trp-Osu DBD 1:4 1:0.5 0 0 1013.94 0
679.07 0.48 0.76 35-C1 BTA Boc-Trp-Osu DBD 1:1 1:1 0 167.56 0 0
125.25 N/A 1.12 35-C2 BTA Boc-Trp-Osu DBD 1:2 1:1 0 167.56 0 0
250.51 0.54 0.88 35-C3 BTA Boc-Trp-Osu DBD 1:3 1:1 0 167.56 0
1119.4693 375.76 0.54 0.83 *Boc-Trp-Osu is
2-(tert-butoxycarbonylamino)-3-1H-indol-3-yl)-1 oxopropanyl Animal
samples prepared by the monomer approach follow. BA BA BA BA
binding binding Amine:Cross- Ligand:Amine Cross- binding binding
Hamster % Primary Swell- Sample linker Mol BTA Ligand NMP linker A
assay B assay (mmol/ Bile Acids ing # Ligand Mol Ratio Ratio (mg)
(mg) (uL) (mg) (mmol/g) (mmol/g) g) in feces* (g/g) 36-A1
Boc-Trp-Osu 1 0.25 3037.1 962.9 4731.4 2879.1 0.57 3.20 0.62 12.0
0.92 37-A1 Boc-Trp-Osu 1 0.25 5315 1685 1685 5038.4 0.58 3.28 0.51
17.7 0.80 38-B1 Trp (De-Boc 1 0.25 3037.1 962.9 4731.4 2879.1 0.59
3.27 0.55 14.8 0.62 of 36-A1) 39-A1 Amphiphilic 0.33 0.25 2994.77
1005.2 18579.1 N/A 0.67 1.57 0.28 31.9 0.81 *% Primary Bile Acids
in feces as % of total measured: i.e. (Cholic acid +
chenodeoxycholic acid) .times. 100/(Cholic acid + chenodeoxycholic
acid + 3-OH-12Oxo-Cholanic Acid + deoxycholic acid + lithocholic
acid)
[0206] Preparation of de-Boc Trp animal sample (38-B1). Following
the attachment of Boc-Trp-OSu ligand onto the polymer as described
above, the polymer was treated with two additional washes of HCl in
dioxane (4M). The polymer was then washed with water, 10 vol. %
NH.sub.4OH (2.times.), and water (3.times.) before lyophilizing
dry.
Example 23: Scaffold Approach Towards the Synthesis of
Ligand-Containing C.sub.4 BTA Polymers
[0207] The scaffold was prepared by mixing C.sub.4 BTA neat with a
50 wt. % 1,10-dibromodecane (DBD) in N-methylpyrrolidone (NMP).
Additional NMP was added to give a total concentration of
crosslinker and C.sub.4 BTA equal to 37.5 wt. %. The mixture was
heated at 70.degree. C. stirring at 400 RPM until the mixture
formed a gel. The gel was continued to be heated for a total of 22
hours before cooling. The solid was ground in methanol, washed with
methanol, 1M NaCl, MeOH, water (3.times.), then lyophilized dry to
give tacky particles.
[0208] The scaffold was portioned out into a 4.times.6 library
plate with 8 mL vials. To this was added a 20 wt. % solution of
ligand (thiazolium) in NMP. The vials were filled with NMP to
achieve a total volume of 2.5 mL. The mixture was stirred at
80.degree. C. for 18 hours, stirring at 500 RPM. Reactions were
cooled, washed with methanol, 1M NaOH, and water, then lyophilized
dry. The amounts used for the reactions follow.
TABLE-US-00018 BTA- BA binding BA binding DBD affinity capacity
Sample Amine Amine:Crosslinker Ligand:Amine Scaffold Ligand A assay
B assay # Monomer Ligand Crosslinker Mol Ratio Mol Ratio (mg) (mg)
NMP (uL) (mmol/g) (mmol/g) 40-A1 BTA None DBD 0.625 0 300 0 2380
0.60 3.29 40-A2 BTA Thiazolium DBD 0.625 0.04 300 5.78 2374.22 0.60
3.29 40-A3 BTA Thiazolium DBD 0.625 0.08 300 11.56 2368.44 0.61
3.27 40-A4 BTA Thiazolium DBD 0.625 0.12 300 17.33 2362.67 0.60
3.23 40-A5 BTA Thiazolium DBD 0.625 0.16 300 23.11 2356.89 0.60
3.21 40-A6 BTA Thiazolium DBD 0.625 0.2 300 28.89 2351.11 0.61 3.20
40-B1 BTA Thiazolium DBD 0.625 0.25 300 36.11 2343.89 0.60 3.23
40-B2 BTA Thiazolium DBD 0.625 0.3 300 43.33 2336.67 0.60 3.17
40-B3 BTA Thiazolium DBD 0.625 0.35 300 50.56 2329.44 0.61 3.22
40-B4 BTA Thiazolium DBD 0.625 0.4 300 57.78 2322.22 0.60 3.20
40-B5 BTA Thiazolium DBD 0.625 0.45 300 65.00 2315 0.59 3.12 40-B6
BTA Thiazolium DBD 0.625 0.5 300 72.22 2307.78 0.61 3.16
Animal samples prepared by the scaffold approach are listed
below:
TABLE-US-00019 BTA- Ligand:Amine DBD Amine:Crosslinker Mol Scaffold
Ligand Solvent Sample # Ligand Solvent Mol Ratio Ratio (mg) (mg)
(uL) 41-A2 Amphiphilic NMP 0.625 0.25 3000 399.4 28410.6 41-A1
Amphiphilic NMP 0.625 0.1 3000 159.8 28650.2 41-B2 Boc-Trp-Osu NMP
0.625 0.25 3000 377.3 28432.7 42-A1 Tryptamine NMP 0.625 0.25 3000
261.4 18548.6 43-A3 Thiazolium NMP 0.625 0.25 3000 358.1 18451.9
37-A3 Thiazolium NMP 0.625 0.5 3000 716.2 18093.8 44-B6 C.sub.10
Pyridinium NMP 0.625 0.25 3000 356.4 38453.6 43-A2 3-(2-Bromoethyl
NMP 0.625 0.1 3000 84.2 18725.8 Indole) 44-A1 C.sub.3 thiophenium
DMSO 0.625 0.25 3000 361 18449 44-A2 C.sub.3 thiophenium DMSO 0.625
0.5 3000 721.9 18088.1 45-A1 (3-Bromopropyl) DMSO 0.625 0.25 5000
408.77 17608.23 trimethylammonium bromide 45-A2 C.sub.3 methyl DMSO
0.625 0.25 5000 447.92 17569.08 imidazolium 45-A3 C.sub.3
pyrrolidinium DMSO 0.625 0.25 5000 435.44 17581.56 45-A4 C.sub.3
benz- DMSO 0.625 0.25 5000 527.87 17489.13 thiazolium 45-A5 C.sub.3
methyl DMSO 0.625 0.25 5000 620.35 17396.65 thiazolium BA binding
BA binding BA binding Bile acid binding affinity capacity retention
% Primary A assay B assay Hamster Bile Acids Swelling Sample #
(mmol/g) (mmol/g) (mmol/g) in feces* (g/g) 41-A2 0.65 3.17 0.58 4.3
1.29 41-A1 0.64 3.25 0.62 5.7 1.00 41-B2 0.64 3.11 0.51 3.0 1.50
42-A1 0.62 3.25 0.60 8.1 0.64 43-A3 0.62 3.23 0.73, 0.42 6.4, 5.2
1.33 37-A3 0.59 2.99 0.35 6.4 8.30 44-B6 0.59 3.04 0.55 9.0 24.20
43-A2 0.62 3.25 0.67 6.1 N/A 44-A1 0.62 3.26 1.23 44-A2 0.63 3.16
0.75 45-A1 0.62 3.26 0.59 45-A2 0.62 3.27 0.56 45-A3 0.62 3.23 0.89
45-A4 0.62 3.23 0.40 45-A5 0.62 3.20 0.52 *% Primary Bile Acids in
feces as % of total measured: i.e. (Cholic acid + chenodeoxycholic
acid) .times. 100/(Cholic acid + chenodeoxycholic acid +
3-OH-12Oxo-Cholanic Acid + deoxycholic acid + lithocholic acid)
Example 24: Thiazolium: 3-(3-iodopropyl)thiazol-3-ium
##STR00061##
[0210] The titled compound was prepared using same procedure
described above. Thiazole (4 g, 0.047 mol) and diiodopropane (27.2
mL, 0.24 mol) were refluxed in acetonitrile (15 mL) for 5 hours,
then stirring was continued at room temperature overnight. The
white precipitate was removed by filtration. To the filtrate was
added diethyl ether 100 mL. The mixture was cooled in refrigerator
overnight. The solid was filtered and washed with acetonitrile (20
mL) then ether (3.times.30 mL). After drying under reduced
pressure, 17 g (95%) of desired product was obtained as a yellow
solid. MS m/e (MH.sup.+), calculated 253.95, found 254.0. .sup.1H
NMR confirmed the structure.
Example 25: C.sub.3 Methyl Thiazolium:
3-(3-iodopropyl)-2-methylthiazol-3-ium
##STR00062##
[0212] To a solution of 2-methylthiazole (3.0 g, 0.03 mol) in
acetonitrile (15 mL) was added diiodopropane (17.4 mL, 0.15 mol).
The reaction was refluxed for 5 hours, then stirring was continued
at room temperature overnight. White precipitate was removed by
filtration. To the filtrate was added diethyl ether (100 mL). White
crystals formed. The mixture was cooled in refrigerator overnight.
The solid was filtered and washed with acetonitrile (20 mL) then
ether (3.times.30 mL). After drying under reduced pressure, 8.41 g
product was obtained as a white solid (71%). MS m/e (MH.sup.+),
calculated 267.97, found 268.0. .sup.1H NMR confirmed the
structure.
Example 26: C.sub.3 Benzthiazolium:
3-(3-bromopropyl)benzo[d]thiazol-3-ium
##STR00063##
[0214] The titled compound was prepared using same procedure
described above. Benzothiazole (22.5 mL, 0.2 mol) and
1,3-dibromopropane (102 mL, 1 mol) were refluxed for 48 hours to
afford 35.5 g desired product as a yellow solid (69%). MS m/e
(MH.sup.+), calculated 257.98, found 258.0. .sup.1HNMR confirmed
the structure.
Example 27: C.sub.3 Thiophenium Ligand:
1-(3-iodopropyl)tetrahydro-1H-thiophenium
##STR00064##
[0216] A mixture of tetrahydrothiophene (3.0 g, 0.034 mol) and
diiodopropane (7.86 mL, 0.068 mol) in acetonitrile (3.4 mL) was
stirred at 65.degree. C. overnight. The solid was filtered and
washed with acetonitrile (3.times.10 mL). After drying under high
vacuum, the desired product was obtained as a white solid (6.13 g,
47%). MS m/e (MH.sup.+), calculated 256.99, found 257.0. .sup.1H
NMR confirmed the structure.
Example 28: C.sub.10 Pyridinium Ligand: Synthesis of
1-bromodecyl-N-pyridinium bromide
[0217] To a vigorously stirring flask of 1,10-dibromodecane (337.2
mL; 1.5 mmol) was added pyridine in acetone (50 vol. %; 16.2 mL;
0.1 mmol) dropwise over 5 hours at 30.degree. C. After the addition
was complete, the mixture was heated to 45.degree. C. for 18 hours.
The reaction mixture was allowed to cool slightly and the resulting
white precipitate was filtered over a Buchner funnel. The product
was washed thoroughly with hexanes (3.times.100 mL) and vacuum
dried. The product was identified by .sup.1H NMR and mass
spectrometry.
Example 29: Synthesis of Bis Imiazole-N-Alkane Ligand
[0218] A solution of Na-imidazole (0.1 mol) (imidazole sodium
derivative, Aldrich 197637, CAS 5587-42-8) in 100 mL THF. An
appropriate amount of the dialkyl bromide was added and the mixture
was stirred overnight at room temperature. The solids were filtered
off and the filtrate was dried under vacuum. The product was
purified by column chromatography using 500 g of silica and ethyl
acetate. The resulting yield was 50-80%. The product was identified
by .sup.1H NMR and mass spectrometry.
Example 30: C.sub.3 Methyl Imidazole Ligand: Synthesis of
1-methyl-3-(1-bromopropyl) imidazolium bromide ligand
[0219] Dibromoalkane (0.3 mol) was placed into a 3-necked flask
that was fitted with an overhead stirrer. Acetone was added such
that the resulting solution was 3 M. Methyl imidazole (0.03 mol)
was dissolved in acetone to result in a 2M solution. This was added
to the flask and the reaction was stirred overnight at
45-50.degree. C. The next day, the acetone was vacuumed off and the
product was purified by column chromatography using 500 g of silica
gel and 90:10 CH.sub.2Cl.sub.2:MeOH. The yield was in the range of
60-70% of materials that ranged from a clear oil to a white sold.
The product was identified by .sup.1H NMR and mass
spectrometry.
Example 31: Synthesis of 1-Alkyl Methyl Pyrrolidine Ligand
[0220] Dibromoalkane (0.3 mol) was placed into a 3-necked flask
that was fitted with an overhead stirrer. Acetone was added such
that the resulting solution was 3M. A 1-methylpyrrolidine solution
(0.03 mol) was dissolved in acetone to result in a 2M solution.
This was added to the flask and the reaction was stirred overnight
at 55.degree. C. The isolation method depended on the form of the
product, for example, when the product precipitated out of
solution, the solid was filtered and washed with acetone and when
the product was an oil, the acetone was vacuumed off and the
product was purified either by column chromatography using 500 g of
silica gel and CH.sub.2Cl.sub.2:MeOH. The yield was in the range of
60-70% of materials that ranged from a clear oil to a white sold.
The product was identified by .sup.1H NMR and mass
spectrometry.
Example 32: Synthesis of Polymer Modified with
1,3-Dialkylimidazolium Bromide Ligand
[0221] The desired polyamine scaffold gel was dissolved in water
and neutralized with an equimolar solution of NaOH. An appropriate
amount of a solution of 1,3-dialkylimidazolium bromide in methanol
was added to the polyamine solution. The mixture was heated to
75.degree. C. for 24 hours. After cooling to room temperature the
modified polyamine gel was washed by exposing the gel to a methanol
wash (2.times.), 0.5 M HCl wash and water wash (2.times.). In each
wash, the gel was stirred for 30 minutes, exposed to the washing
solvent, and centrifuged; the supernatant liquid was decanted and
the wash solvent was added to the gel. After the final water wash,
the gel was placed into a lyophilizer to remove the water. The gel
was isolated as a white fluffy material.
Example 33: Amphiphilic Ligand:
N-(2-(5-chloropentanamido)ethyl)-4-(nonyloxy)benzamide ligand
##STR00065##
[0223] Step A: 1. 4-(nonyloxy)benzoyl chloride. To a suspension of
4-(nonyloxy)benzoic acid (6.02 g, 0.0228 mol) in 100 mL of
dichloromethane was added DMF (0.176 mL, 0.00228 mol), followed by
thionyl chloride (2.5 mL, 0.0342 mol). The reaction was stirred at
room temperature for 2 hours and became a clear solution. The
solvent was removed under reduced pressure. The residue was dried
under high vacuum overnight. The product (6.54 gram) was obtained
as a brown oil which was used for next step directly.
[0224] Step B: tert-butyl 2-(4-(nonyloxy)benzamido)ethylcarbamate.
A solution of tert-butyl-2-aminoethylcarbamate (3.65 g, 0.0228 mol)
and diisopropylethylamine (4.76 mL, 0.0274 mol) in 100 mL of
dichloromethane was cooled to 4.degree. C. in an ice bath.
4-(Nonyloxy)benzoyl chloride (6.54 g, 0.0228 mol) was dissolved in
50 mL of dichloromethane and was added to
tert-butyl-2-aminoethylcarbamate solution dropwise. The internal
temperature remained at or below 4.degree. C. during the addition.
After the addition, the reaction was warmed to room temperature and
stirred for 2 hours. The mixture was washed with 1N HCl
(2.times.150 mL), brine (150 mL), saturated NaHCO.sub.3 solution
(150 mL), and brine (150 mL). Organic phase was dried over
MgSO.sub.4 and concentrated. The crude product was passed through a
silica gel plug (15% methanol in dichloromethane). The pure product
(9.1 gram) was obtained as a white solid (98%).
[0225] Step C: tert-butyl 2-(4-(nonyloxy)benzamido)ethylcarbamate.
To a solution of tert-butyl-2-(4-(nonyloxy)benzamido)ethylcarbamate
(9.1 g, 0.0224 mol) in 100 mL of dichloromethane was added
trifluoroacetic acid (17.25 mL, 0.224 mol). The reaction was
stirred at room temperature for 16 hours. Solvent was removed under
reduced pressure. Toluene (100 mL) was added to the residue to form
a heteroazeotrope. Solvent and remaining trifluoroacetic acid were
removed under reduced pressure. The residue was dried under high
vacuum until no further weight change (2 days). The product was
obtained as a trifluoroacetate salt, which was used directly for
next step.
[0226] Step D:
N-(2-(5-chloropentanamido)ethyl)-4-(nonyloxy)benzamide. A solution
of tert-butyl-2-(4-(nonyloxy)benzamido)ethylcarbamate
trifluoroacetate salt from previous step and diisopropylethylamine
(11.7 mL, 0.0672 mol) in 150 mL of dichloromethane was cooled to
4.degree. C. in an ice bath. 5-Chloro-valeroyl chloride (2.88 mL,
0.0224 mol) was dissolved in 50 mL of dichloromethane and was added
to the above solution dropwise. The internal temperature remained
at or below 4.degree. C. during the addition. After the addition,
the reaction was warmed to room temperature and stirred for 2
hours. It was then taken up with 150 mL of dichloromethane. The
mixture was washed with 1N HCl (2.times.300 mL), brine (300 mL),
saturated NaHCO.sub.3 solution (300 mL), and brine (300 mL).
Organic phase was dried over MgSO.sub.4 and concentrated. The crude
product was recrystallized in acetonitrile to give pure
N-(2-(5-chloropentanamido)ethyl)-4-(nonyloxy)benzamide as a white
solid (9.36 g, 98%). MS (EI) m/e (MNa.sup.+), calculated (for
C.sub.23H.sub.37ClN.sub.2O.sub.3Na.sup.+) 447.24, found 447.21.
Example 34: Tryptamine Ligand:
N-(2-(1H-indol-3-yl)ethyl)-5-chloropentanamide
##STR00066##
[0228] A solution of 2-(1H-indol-3-yl)ethanamine (5.10 g, 0.032
mol) and diisopropylethyl amine (7.23 mL, 0.042 mol) in 100 mL of
dichloromethane was cooled to 4.degree. C. in ice bath.
5-Chloro-valeroyl chloride (4.2 mL, 0.32 mol) was dissolved in 50
mL of dichloromethane and was added to the solution of
2-(1H-indol-3-yl)ethanamine dropwise. The internal temperature
remained at or below 4.degree. C. during the addition. After the
addition, the reaction was warmed to room temperature and stirred
for 2 hours. The mixture was washed with 1N HCl (2.times.150 mL),
brine (150 mL), saturated NaHCO.sub.3 solution (150 mL), and brine
(150 mL). The organic phase was dried over MgSO.sub.4 and
concentrated. The crude product was purified by flash
chromatography (silica gel, 15% methanol in dichloromethane). Pure
product (7.9 gram) was obtained as a yellow solid (89%). MS m/e
(MH.sup.+), calculated 279.13, found 279.16. This synthesis can be
used to make other amino acid-based ligands by substituting the
appropriate amine reactant for 2-(1H-indol-3-yl)ethanamine (e.g.,
use of 3-methylbutan-1-amine to make a Leu-based ligand).
Example 35: DMP 504 Comparative Example
[0229] Dibromodecane (12.10 g, 0.039 mol) was dispensed with
methanol (13 mL) and N,N-dimethylformamide (13 mL) into a round
bottom flask (100 mL) under nitrogen with a mechanical stirrer and
reflux condenser. Diaminohexane (4.55 g, 0.039 mol) was added to
the flask and the mixture was brought to reflux while stirring.
After 35 minutes gelation occurred and mechanical stirring was
stopped. The resulting gel was cured at 85.degree. C. for 17 hours.
The polymer formed was swollen and ground in water (two times, 80
mL), methanol (two times, 80 mL), water (two times, 80 mL), ethanol
(once, 500 mL), water (once, 100 mL), HCl (1M, 80 mL) ethanol (500
mL) and water (100 mL) and lyophilized until dry.
TABLE-US-00020 Bile acid Bile acid Bile acid binding binding
binding affinity capacity retention A assay B assay Hamster Sample
# (mmol/g) (mmol/g) (mmol/g) 46-A1 0.52 2.60 6.22 4.6
Example 36: N,N,N',N'-Tetrakis(3-aminopropyl)-1,12-diaminododecane
(C.sub.12 BTA),
N,N,N',N'-Tetrakis(3-aminopropyl)-1,10-diaminodecane (C.sub.10
BTA), N,N,N',N'-Tetrakis(3-aminopropyl)-1,8-diaminooctane (C.sub.8
BTA), N,N,N',N'-Tetrakis(3-aminopropyl)-1,4-diaminobutane (C.sub.4
BTA) beads synthesis with 1,3-dichloropropanol (DCP)
[0230] The synthesis of C.sub.12 BTA-DCP, C.sub.10 BTA-DCP, C.sub.8
BTA-DCP, C.sub.4 BTA-DCP beads were conducted in a Semi-Continuous
Parallel Polymerization Reactor (SCPPR). C.sub.4 BTA, C.sub.8 BTA,
C.sub.10 BTA, and C.sub.12 BTA monomers were dispensed into 11 mL
glass tubes and cooled to 5.degree. C. in an ice bath and water was
added. Hydrochloric acid (HCl, 37 wt. % in water) was added slowly
to this solution followed by mixing for 2 minutes.
Dodecylbenzenesulfonic acid sodium salt (DDS) (molecular weight
(MW) 348.48, 15 wt. % in water) and the crosslinker
1,3-dichloropropanol (DCP) (MW 128.99) were added to the solution
followed by mixing for 5 minutes. The organic layer of heptanes and
Span 80 (MW 428.60, 15 wt. % in heptanes) was then added to the
aqueous solution. The test tubes were loaded into the SCPPR,
sealed, and pressurized to 70 pounds/square inch (psi)
(4.83.times.105 Pa). The reaction was allowed to react at
75.degree. C. with stirring (400 rpm) for 17 hours. The resulting
solid polymer beads were then swollen in ethanol, washed with (1)
aqueous HCl (1 M), (2) water, (3) NaOH (1M), (4) water (3.times.)
and lyophilized until dry. Various synthesis experiments are
detailed in the table below.
TABLE-US-00021 Aqueous Layer Organic layer Monomer Solvent Acid
Surfactant Crosslinker solvent Surfactant BTA BTA water HCl DDS DCP
heptanes span 80 Polymer Sample # Core wt. (mg) (mg) (mg) (mg) (mg)
(Mg) (mg) Product 47-A1 C.sub.10 400 949.2 0.0 6.8 218.9 1947.7
155.8 Beads 47-A2 C.sub.10 400 965.5 0.0 13.8 218.9 1981.2 158.5
Beads 47-A3 C.sub.10 400 982.5 0.0 21.1 218.9 2016.0 161.3 Beads
47-A4 C.sub.10 400 1000.0 0.0 28.6 218.9 2052.0 164.2 Gel 47-A5
C.sub.10 400 1035.6 36.4 7.4 218.9 2125.1 170.0 Beads 47-A6
C.sub.10 400 1053.5 36.4 15.0 218.9 2161.7 172.9 Beads 47-B1
C.sub.10 400 1071.9 36.4 23.0 218.9 2199.6 176.0 Beads 47-B2
C.sub.10 400 1091.1 36.4 31.2 218.9 2238.9 179.1 Beads 47-B3
C.sub.10 400 1363.9 36.4 18.2 218.9 2798.6 223.9 Gel 47-B4 C.sub.10
400 1053.5 36.4 15.0 218.9 2161.7 172.9 Beads 47-B5 C.sub.10 400
834.4 36.4 12.8 218.9 1712.1 137.0 Beads 47-B6 C.sub.10 400 671.4
36.4 11.2 218.9 1377.8 110.2 Gel 47-C1 C.sub.10 400 1122.1 72.9 8.0
218.9 2302.5 184.2 Beads 47-C2 C.sub.10 400 1141.4 72.9 16.3 218.9
2342.2 187.4 Gel 47-C3 C.sub.10 400 1161.4 72.9 24.9 218.9 2383.2
190.7 Beads 47-C4 C.sub.10 400 1182.2 72.9 33.8 218.9 2425.8 194.1
Beads 48-A1 C.sub.12 400 1047.7 34.1 15.0 120.3 2149.9 172.0 Beads
48-A2 C.sub.12 400 1047.7 34.1 15.0 180.5 2149.9 172.0 Beads 48-A3
C.sub.12 400 1047.7 34.1 15.0 240.7 2149.9 172.0 Beads 48-A4
C.sub.12 400 1047.7 34.1 15.0 300.9 2149.9 172.0 Beads 48-A5
C.sub.12 400 1047.7 34.1 15.0 204.6 2149.9 172.0 Beads 48-A6
C.sub.12 400 1047.7 34.1 15.0 204.6 2149.9 172.0 Beads 48-B1
C.sub.12 400 1047.7 34.1 15.0 204.6 2149.9 172.0 Beads 48-B2
C.sub.12 400 1047.7 34.1 15.0 204.6 2149.9 172.0 Gel 48-B3 C.sub.12
400 949.2 0.0 6.8 204.6 1947.7 155.8 Gel 48-B4 C.sub.12 400 965.5
0.0 13.8 204.6 1981.2 158.5 Gel 48-B5 C.sub.12 400 982.5 0.0 21.1
204.6 2016.0 161.3 Gel 48-B6 C.sub.12 400 1000.0 0.0 28.6 204.6
2052.0 164.2 Beads 48-C1 C.sub.12 400 1030.0 34.1 7.4 204.6 2113.5
169.1 Beads 48-C2 C.sub.12 400 1047.7 34.1 15.0 204.6 2149.9 172.0
Beads 48-C3 C.sub.12 400 1066.1 34.1 22.8 204.6 2187.6 175.0 Gel
48-C4 C.sub.12 400 1085.1 34.1 31.0 204.6 2226.7 178.1 Gel 48-C5
C.sub.12 400 1047.7 34.1 15.0 204.6 2149.9 10.7 Gel 48-C6 C.sub.12
400 1047.7 34.1 15.0 204.6 2149.9 50.2 Gel 48-D1 C.sub.12 400
1047.7 34.1 15.0 204.6 2149.9 89.6 Beads 48-D2 C.sub.12 400 1047.7
34.1 15.0 204.6 2149.9 129.0 Beads 48-D3 C.sub.12 400 1110.8 68.1
7.9 204.6 2279.3 182.3 Beads 48-D4 C.sub.12 400 1129.9 68.1 16.1
204.6 2318.6 185.5 Beads 48-D5 C.sub.12 400 1149.7 68.1 24.6 204.6
2359.3 188.7 Beads 48-D6 C.sub.12 400 1170.3 68.1 33.4 2401.4 192.1
204.6 Gel 49-A1 C.sub.4 400 1076.9 46.1 15.4 277.1 2209.7 176.8
gel/beads 49-A2 C.sub.4 400 1128.7 46.1 37.6 277.1 2316.2 185.3
gel/beads 49-A3 C.sub.4 400 1185.9 46.1 62.1 277.1 2433.5 194.7
Beads 49-A4 C.sub.4 400 1249.1 46.1 89.2 277.1 2563.2 205.1
Beads
Example 37: C.sub.12 BTA-DCP, C.sub.10 BTA-DCP, C.sub.8 BTA-DCP,
C.sub.4 BTA-DCP Beads Synthesis for In Vivo Study
[0231] A 250 mL 3-neck round bottom flask equipped with overhead
stirrer, condenser, and thermometer was charged with C.sub.12 BTA
(5.0 g, 11.66 mmol) and water (11.39 mL). The resulting mixture was
stirred in an ice bath for 5 minutes. Hydrochloric acid (1.15 ml,
11.66 mmol, 37 wt. % in water) was added slowly over a 2 minute
period. The mixture was stirred for an extra 2 minutes in the ice
bath before removing it. DDS (1.24 mL, 15 wt. % in water) was then
added to the above mixture and stirred for 2 minutes.
1,3-Dichloro-2-propanol (2.56 g, 19.83 mmol) was added. Heptanes
(21.59 mL) and Span 80 solution (20.32 mL, 15 wt. % in heptanes)
were then added. The final mixture was stirred at 220 rpm with an
overhead stirrer and heated in oil bath at 75.degree. C. The
internal temperature of the reaction was at 70.degree. C. After 3
hours, a Dean-Stark treatment was performed to remove the water
using the azeotrope of heptanes and water (at 80.degree. C.). The
reaction was ended after the mixture temperature reached
100.degree. C. or when all the water in the reaction mixture was
collected.
[0232] The reaction mixture was cooled to ambient temperature,
stirring was stopped, and the organic layer was decanted. The beads
were washed with 150 mL isopropyl alcohol, followed by one wash
with HCl (150 ml, 1.0 M), one wash with water, two washes with
NH.sub.4OH (150 mL, 10 wt. % in water), one wash saturated aqueous
NaCl solution, and three washes with water. The beads were
lyophilized for 48 hours. The final product was isolated in 80%
yield (4.9 g). Various synthesis experiments are detailed
below.
[0233] Acid loading of sample 51-D1. The isolated dry bead prepared
from 51-D1 (example 37) was placed into a flask. Using 1 M HCl
solution in water, an appropriate amount of HCl was added to the
bead such that the resulting beads contained 5, 10, 15 and 20
weight percent of chloride. The chloride content in the bead was
later confirmed by elemental analysis and found to be 5, 9, 12, and
19 wt. % respectively. The sample ID's for these compounds were
given 79-A1, 79-A2, 79-A3 and 79-A4 respectively.
TABLE-US-00022 Aqueous Layer Organic layer Monomer Solvent Acid
Surfactant Crosslinker solvent Surfactant BTA BTA wt water HCl DDS
DCP heptanes span 80 Polymer Sample # Core (mg) (mg) (mg) (mg) (mg)
(Mg) (mg) Product 50-A1 C.sub.12 1600 4191 136 60 818 8600 688
beads 50-A2 C.sub.12 1600 4599 272 99 818 9437 755 beads 51-A1
C.sub.4 2000 5678 231 203 1385 11651 932 beads 51-B1 C.sub.8 2000
5300 196 76 1177 10877 870 beads 51-C1 C.sub.10 2000 5267 182 75
1094 10808 865 beads 51-D1 C.sub.12 2000 5239 170 75 1023 10750 860
beads 52-A1 C.sub.8 7460 19770 731 282 4390 40568 3245 beads 53-A1
C.sub.12 8250 21609 702 309 4219 44342 3547 beads 54-A1 C.sub.12
4312 11294 367 161 1427 23176 1854 beads 55-A1 C.sub.12 5000 13096
425 187 2106 26874 2150 beads 56-A1 C.sub.12 4312 11294 367 161
2595 23176 1854 beads 57-A1 C.sub.12 25000 65482 2128 935 12786
134369 10750 beads 58-A1 C.sub.12 5000 13096 426 187 3761 26874
2150 beads 59-A1 C.sub.4 5000 14731 577 737 3464 30227 2418 beads
60-A1 C.sub.12 10000 26193 851 374 5115 53748 4300 beads 61-A1
C.sub.12 5000 13096 426 187 2557 26874 2150 beads 62-A1 C.sub.12
5000 13096 426 187 2557 26874 2150 beads 63-A1 C.sub.12 4312 11294
367 161 1427 23176 1854 beads 64-A1 C.sub.12 5000 13096 425 187
2106 26874 2150 beads 65-A1 C.sub.12 4312 11294 367 161 2595 23176
1854 beads 66-A1 C.sub.12 10000 26193 851 374 5115 53748 4300 beads
67-A1 C.sub.12 5000 13096 426 187 1956 26874 2150 beads 68-A1
C.sub.12 5000 13096 426 187 2256 26874 2150 beads 69-A1 C.sub.12
5000 13096 426 187 2407 26874 2150 beads 70-A1 C.sub.12 25000 65480
2125 935 10530 134370 10750 beads 80-A1 C.sub.12 5000 13096 425 187
2557 26874 2150 beads 81-A2 C.sub.12 5000 13096 425 187 2106 26874
2150 beads
Bile acid binding capacity, affinity, and retention for each
resulting polymer were determined via the A assay, B assay and
hamster model and results are reported in the table below.
TABLE-US-00023 BA BA binding binding Phosphate capacity affinity BA
binding % binding B Assay A Assay retention Primary B Assay
Swelling BTA Data Data Hamster Bile Acid Data Swelling Library Core
(mmol/g) (mmol/g) (mmol/g) in feces (mmol/g) (g/g) Tackiness* 50-A1
C.sub.12 3.34 0.64 0.50 10.9 0.65 2 50-A2 C.sub.12 3.33 0.64 0.43
12.8 0.97 2 51-A1 C.sub.4 3.19 0.37 0.15 10.5 5.98 0 51-B1 C.sub.8
3.28 0.45 0.33 3.5 0.99 0 51-C1 C.sub.10 3.26 0.54 0.40 5.7 0.27 1
51-D1 C.sub.12 3.32 0.64 0.34 8.5 0.38 2 52-A1 C.sub.8 3.24 0.46
0.24 2.5 0.26 1.15 0 53-A1 C.sub.12 3.18 0.66 0.36 6.5 0.69 2 54-A1
C.sub.12 3.25 0.65 0.35 14.8 0.28 2.16 2 55-A1 C.sub.12 3.27 0.67
0.52 17.3 0.23 0.39 2 56-A1 C.sub.12 3.01 0.66 0.34 20.4 0.08, 0.10
0.82 0 57-A1 C.sub.12 3.03 0.67 0.38 18.8, 16.4 0.07 0.41 1 58-A1
C.sub.12 2.87 0.67 0.32 25.9 0.07 0.50 0 59-A1 3.17 0.39 0.61 3.09
79-A1 C.sub.12 2.99 0.66 0.55 18.6 0.64 0 79-A2 C.sub.12 2.95 0.65
0.54 17.3 0.64 0 79-A3 C.sub.12 2.85 0.62 0.51 14.3 0.64 0 79-A4
C.sub.12 2.74 0.64 0.64 0 60-A1 C.sub.12 3.08 0.67 0.41 11.6 0.60 0
61-A1 C.sub.12 3.16 0.64 12.7 1.08 0 62-A1 C.sub.12 3.15 0.66 0.26
0 63-A1 C.sub.12 3.30 0.63 3.00 2 64-A1 C.sub.12 3.20 0.66 1.30 1
65-A1 C.sub.12 2.83 0.66 0.41 1 66-A1 C.sub.12 2.98 0.67 0.50 1
67-A1 C.sub.12 3.13 0.65 0.73 2 68-A1 C.sub.12 2.99 0.66 0.37 2
69-A1 C.sub.12 3.15 0.66 0.41 1 70-A1 C.sub.12 0.65 2 80-A1
C.sub.12 3.12 0.66 0.15 0.65 22 81-A2 C.sub.12 3.14 0.66 0.20 0.97
2 *tackiness number 0 = free flowing beads, 1 = slightly soft
beads, 2 = slightly sticky beads, 3 = sticky and soft
Example 38: C.sub.12 BTA, C.sub.10 BTA, C.sub.8 BTA, C.sub.4 BTA
Beads Synthesis with
1,1'-(dodecane-1,12-diyl)bis(3-bromopropyl)-1H-imidazol-3-ium
(C.sub.12 Core, C.sub.3 Bisimidazolium) Crosslinker
[0234] The synthesis of C.sub.12 BTA-C.sub.12 core, C.sub.3
bisimidazolium, C.sub.10 BTA-C.sub.12 core, C.sub.3 bisimidazolium,
and C.sub.4 BTA-C.sub.12 core, C.sub.3 bisimidazolium beads were
conducted in a SCPPR. C.sub.4 BTA, C.sub.8 BTA, C.sub.10 BTA, and
C.sub.12 BTA monomers were dispensed into 11 mL glass tubes and
cooled to 5.degree. C. in an ice bath and water was added.
Hydrochloric acid (HCl, 37 wt. % in water) was added slowly to this
solution followed by mixing for 2 minutes. DDS (15 wt. % in water)
and a solution of the designated crosslinking monomer (40 wt. % in
water) of formula X-R.sub.1-X (wherein X is halo such as chloro or
bromo and R.sub.1 is C.sub.12 core/C.sub.3 bisimidazolium) were
added. This solution was mixed for 5 minutes and the organic layer
of heptanes and Span 80 (15 wt. % in heptanes) was added to the
aqueous layer. The test tubes were loaded into the SCPPR, sealed,
and pressurized to 70 psi. The reaction was run at 75.degree. C.
with stirring (400 rpm) for 17 hours. The solid polymer beads were
then swollen in ethanol, washed with aqueous HCl (1 M), water
(3.times.) and lyophilized until dry. Various synthesis experiments
are detailed in the table below.
TABLE-US-00024 Aqueous Layer Monomer Crosslinker Organic layer BTA
Solvent Acid Surfactant C.sub.12 core/C.sub.3 solvent Surfactant
BTA wt water HCl DDS bisimidazolium heptanes span 80 Polymer Sample
# Core (mg) (mg) (mg) (mg) (mg) (mg) (mg) Product 71-A1 C.sub.4 100
867 12 37 357 2600 208 Gel 71-A2 C.sub.4 100 867 12 37 357 2600 208
Gel 71-A3 C.sub.4 100 867 12 37 357 2600 208 Gel 71-A4 C.sub.4 100
867 12 37 357 2600 208 Gel 71-B1 C.sub.4 100 867 12 37 357 2600 208
Gel 71-B2 C.sub.4 100 867 12 37 357 2600 208 Gel 71-B3 C.sub.4 100
867 12 37 357 2600 208 Gel 71-B4 C.sub.4 100 867 12 37 357 2600 208
Gel 71-C1 C.sub.4 100 867 12 37 357 2600 208 Gel 71-C2 C.sub.4 100
995 12 42 424 2986 239 Gel 71-C3 C.sub.4 100 1124 12 48 491 3372
270 Gel 71-C4 C.sub.4 100 1253 12 53 558 3758 301 Gel 71-D1 C.sub.4
100 890 12 14 357 2670 214 Gel 71-D2 C.sub.4 100 872 12 32 357 2615
209 Gel 71-D3 C.sub.4 100 853 12 50 357 2560 205 Beads 71-D4
C.sub.4 100 835 12 69 357 2505 200 Gel 72-C1 C.sub.10 100 502 9 9
282 1507 15 Gel 72-C2 C.sub.10 100 619 9 10 282 1857 68 Gel 72-C3
C.sub.10 100 806 9 12 282 2419 153 Gel 72-C4 C.sub.10 100 1156 9 16
282 3468 312 Gel 72-D1 C.sub.10 100 960 9 0 282 2880 230 Gel 72-D2
C.sub.10 100 1057 9 40 282 3172 254 Beads 72-D3 C.sub.10 100 1177 9
88 282 3530 282 Gel 72-D4 C.sub.10 100 1326 9 149 282 3979 318 Gel
73-B1 C.sub.12 100 690 9 29 264 2071 166 Beads 73-B2 C.sub.12 100
690 9 29 264 2071 166 Beads 73-B3 C.sub.12 100 880 9 37 362 2640
211 Beads 73-B4 C.sub.12 100 880 9 37 362 2640 211 Beads 73-D1
C.sub.12 100 690 9 29 264 2071 166 Beads 73-D2 C.sub.12 100 690 9
29 264 2071 166 Beads 73-D3 C.sub.12 100 880 9 37 362 2640 211
Beads 73-D4 C.sub.12 100 880 9 37 362 2640 211 Beads
Example 39: C.sub.12 BTA-C.sub.12 Core, C.sub.3 Bisimidazolium and
C.sub.4 BTA-C.sub.12 Core, C.sub.3 Bisimidazolium Beads for In Vivo
Study
[0235] A 500 mL 3-neck round bottom flask equipped with overhead
stirrer, condenser, and thermometer was charged with C.sub.12 BTA
(5.0 g 11.66 mmol) and 5.67 mL water. The resulting mixture was
stirred in an ice bath for 5 minutes. Hydrochloric acid (1.15 mL,
11.66 mmol, 37 wt. % in water) was added slowly over a two minute
period. The mixture was stirred for an extra two minutes in the ice
bath before removal. DDS (9.83 mL, 15 wt. % in water) was then
added to the above mixture and stirred for two minutes. An organic
phase of the crosslinking monomer (32.94 mL, 18.66 mmol, 40 wt. %
in water) of formula X-R.sub.1-X (wherein X is halo such as chloro
or bromo and R.sub.1 is C.sub.12 core, C.sub.3 bisimidazolium),
heptanes (82.74 mL), and Span 80 solution (77.82 ml, 15 wt. % in
heptanes) was added to the mixture. The final mixture was stirred
at 220 rpm with an overhead stirrer and heated in oil bath at
75.degree. C. The internal temperature of the reaction was at
70.degree. C. After 3 hours, a Dean-Stark treatment was performed
to remove the water using the azeotrope of heptanes and water at
80.degree. C. This was achieved by increasing the temperature of
the oil bath. The endpoint of the process was when the temperature
of the mixture reached 100.degree. C. or when all the water in the
reaction mixture was collected.
[0236] The reaction mixture was cooled to ambient temperature,
stirring was stopped, and the organic layer was decanted. The beads
were washed with 150 mL isopropyl alcohol, followed by one wash
with HCl (150 mL, 1.0 M), one wash with water, one wash with
saturated aqueous NaCl solution, and three washes with water. The
beads were lyophilized for 48 hours. The final product was isolated
in 80% yield (4.9 g).
TABLE-US-00025 Aqueous Layer Monomer Crosslinker Organic layer BTA
Solvent Acid Surfactant C.sub.12 core/C.sub.3 solvent Surfactant
BTA wt water HCl DDS bisimidazolium heptanes span 80 Polymer Sample
# Core (mg) (mg) (mg) (mg) (mg) (mg) (mg) Product 82-D3 C.sub.4 100
853 11.53 50.3 356 2560 204.8 Bead 74-A1 C.sub.4 2000 17069 231
1006 7139 51207 4097 Beads 75-A1 C.sub.4 3000 25603 346 1509 10709
76810 6145 Beads 76-A1 C.sub.4 6000 51207 692 3019 21418 153620
12290 Beads 77-A1 C.sub.12 3794 26189 323 1118 10000 78566 6285
Beads 77-A2 C.sub.12 3794 26189 323 1118 10000 78566 6285 Beads
78-A1 C.sub.12 5000 34510 426 1474 13177 103529 8282 Beads
Bile acid binding capacity, affinity, and retention for each
resulting polymer were determined via the A assay, B assay and
hamster model and results are reported in the table below.
TABLE-US-00026 A In vivo % Primary BTA B Assay Assay binding Bile
Acid Swelling Ligand Sample # Core (mmol/g) (mmol/g) (mmoles/g) in
feces (g/g) Tackiness Grafted 77-A1 C.sub.12 2.74 0.62 0.49 9.6 32
0 77-A2 C.sub.12 2.83 0.62 0.44 12.4 25 1 75-A1 C.sub.4 3.06 0.54
0.34 3.7 25 1
Example 40: Hydrophobic Post Polymerization of Beads Prepared with
C.sub.4 BTA and C.sub.12 Core, C.sub.3 Bisimidazolium Crosslinker
for In Vivo Study
[0237] Sample 82-D3, described in example 39 was repeated on a
larger scale (3 g of BTA C.sub.4 core was used) on the bench. The
resultant beads were washed and described as above. To the
resulting beads the following procedure was performed.
N-methylpyrrolidone (NMP) was added to swell the C.sub.4 BTA
crosslinked C.sub.12 core, C.sub.3 bisimidazolium beads in 11 mL
glass tubes. The hydrophobizing agent (either 1,12-dibromododecane
or 1-bromodecane) was added and the glass tubes were fitted with
overhead stirrers, sealed, and purged with nitrogen. The post
polymerization reaction was allowed to proceed at 75.degree. C. for
18 hours. After cooling, the beads were diluted with ethanol and
purified by washing with ethanol (2.times.), 1M HCl (2.times.), and
water (3.times.). The beads were dried by lyophilization
overnight.
TABLE-US-00027 1,12- 1- N- Sample dibromododecane bromodecane
methylpyrrolidone # Beads (g) (g) (mL) 83-A1 1.00 1.00 4.50 83-A3
1.00 1.50 5.70 84-A1 1.00 1.00 4.50 84-A3 1.00 1.50 5.70
Bile acid binding capacity, affinity, and retention for each
resulting polymer were determined via the A assay, B assay and
hamster model and results are reported in the table below.
TABLE-US-00028 % Hamster Primary in vivo Bile B Assay A Assay
binding Acid in Swelling Sample # (mmol/g) (mmol/g) (mmol/g) feces
(g/g) 83-A1 2.94 0.60 10.1 83-A3 2.95 0.61 0.37 5.0 10.8 84-A1 2.99
0.61 47.4 84-A3 2.90 0.61 48.7
Example 41: Synthesis of C.sub.4 BTA Beads with TMBMP-DBD
(4,4'-(propane-1,3-diyl)bis(1-(10-bromodecyl)-1-methylpiperidinium))
[0238] A 1 L reactor equipped with overhead stirrer, condenser and
thermocouple was charged with C.sub.4 BTA (7.24 g 22.9 mmol), water
(56.0 mL), acetonitrile (27.2 mL), and DDS solution (23.9 mL, 15
wt. % in water). The mixture was stirred for 5 minutes. After a
homogeneous solution was obtained, TMBMP-DBD (30.7 g, 36.6 mmol)
was added. The resulting mixture was stirred for an extra 5 minutes
before the addition of heptanes (182.9 mL) and Span 80 solution
(172.0 mL, 15 wt. % in heptanes). The final mixture was stirred at
150 rpm with an overhead stirrer. The external oil was ramped to
75.degree. C. in 1 hour. The internal temperature of the reaction
was at 72-75.degree. C. After 16 hours, a Dean-Stark treatment was
performed to remove the acetonitrile and water at 80.degree. C.
This was achieved by increasing the temperature of the oil bath to
95.degree. C. The end point of the process end point was when the
temperature of the mixture reached 95.degree. C. or when all the
water in the reaction mixture was collected.
[0239] The reaction mixture was cooled to ambient temperature,
stirring was stopped, and the organic layer was removed by vacuum.
The beads were washed with 500 mL ethanol twice and collected by
filtration. The beads were vacuum dried for 24 hours before the
post polymerization. The final product was isolated in a 67% yield
(25 g).
[0240] Post polymerization, a further reaction with halogenated
hydrophobic ligand, was conducted using parallel synthesis. NMP and
dry beads obtained from previous procedure were placed into a 12 mL
test tube. Halogenated hydrophobic ligand solution (20 wt. % in
NMP) was then added. The amount of each component was summarized in
the table below. The mixture was stirred at 400 rpms with an
overhead stirrer for 5 minutes before applying heat to 75.degree.
C. for 16 hour. The resulting beads were washed with NMP twice,
ethanol twice, 0.5M HCl solution for three times, saturated NaCl
solution, and water for three times followed by drying under
vacuum.
TABLE-US-00029 Monomer:Crosslinking Hydrophobic Monomer:hydrophobic
beads ligand NMP Sample # Hydrophobic ligand ligand Ratio (mg) (mg)
(mg) 85-A1 1,12- 1:1.6:0.5 1000 99 4396 dibromododecane 85-B1 1,12-
1:1.6:1.5 1000 297 5187 dibromododecane 86-A1 1-bromododecane
1:1.6:0.5 1000 75 4300 86-B1 1-bromododecane 1:1.6:1.5 1000 225
4902 87-B1 1,12- 1:1.6:1.5 1000 216 4865 dichlorododecane 88-A1
1-Chlorooctane 1:1.6:1 1000 90 4359 88-B1 1-Chlorooctane 1:1.6:3
1000 269 5076
Bile acid binding capacity, affinity, and retention for each
resulting polymer were determined via the A assay, B assay and
hamster model and results are reported in the table below.
TABLE-US-00030 BA BA BA binding binding binding %
Monomer:Crosslinking affinity capacity retention Primary Sample
Hydrophobic Monomer:hydrophobic A assay B assay Hamster Bile Acid
Swelling # ligand ligand Ratio (mmol/g) (mmol/g) (mmol/g) in feces
(g/g) 85-A1 1,12- 1:1.6:0.5 0.58 2.7 8 dibromododecane 85-B1 1,12-
1:1.6:1.5 0.6 2.6 0.46 10.7 6 dibromododecane 86-A1 1-bromododecane
1:1.6:0.5 0.59 2.72 43 86-B1 1-bromododecane 1:1.6:1.5 0.63 2.56
0.48 8.3 39 87-B1 1,12- 1:1.6:1.5 0.59 2.61 0.38 5.9 7
dichlorododecane 88-A1 1-Chlorooctane 1:1.6:1 0.55 2.45 31 88-B1
1-Chlorooctane 1:1.6:3 0.57 2.61 0.38 4.8 25
Example 42: Synthesis of C.sub.4 BTA Beads with TMBMP-DBUD
(4,4'-(propane-1,3-diyl)bis(1-(11-bromoundecyl)-1-methylpiperidinium))
[0241] Synthesis of C.sub.4 BTA with TMBMP-DBUD was conducted using
parallel synthesis. TMBMP-DBUD (438 mg) was dispensed into a 12 mL
glass tube followed by addition of water (1,514 mg) and C.sub.4 BTA
(100 mg). After mixing C.sub.4 BTA with TMBMP-DBUD, DDS (179 mg, 15
wt. % in water) was added. After that, the organic phase of heptane
(2,733 mg) and Span 80 solution (2,667 mg, 15 wt. % in heptane) was
added. The reaction mixture was stirred with an overhead stirrer at
400 rpm. The vial was capped and heated for 17 hours at 75.degree.
C.
Example 43: Synthesis of Crosslinked Beads of C.sub.12 BTA Beads
with TMBMP-DBD
(4,4'-(propane-1,3-diyl)bis(1-(10-bromodecyl)-1-methylpiperidin-
ium)
[0242] A 250 mL 3-neck round flask equipped with overhead stirrer,
condenser and thermometer was charged with C.sub.12 BTA (1.63 g,
3.8 mmol) and water (14.4 mL). The resulting mixture was stirred in
an ice bath for 5 minutes and hydrochloric acid (374 uL, 3.8 mmol,
37 wt. % in water) was added slowly. After the ice bath was
removed, dodecylbenzenesulfonic acid sodium salt (2.77 mL, 15 wt. %
in water) was then added to the above mixture and stirred for 2
minutes, followed by the addition of
4,4'-(propane-1,3-diyl)bis(1-(10-bromodecyl)-1-methylpiperidinium)
(5.09 g, 6.01 mmol) was added. Heptanes (40.8 mL) and Span 80
solution (38.3 mL, 15 wt. % in heptanes) were then added
respectively. The final mixture was stirred at 170 rpm with an
overhead stirrer and heated in oil bath at 75.degree. C. The
internal temperature of the reaction was 75.degree. C. After 16
hours, a Dean-Stark treatment was performed to remove the water
using the azeotrope of heptanes and water (at 80.degree. C.);
achieved by increasing the temperature of the oil bath to
95.degree. C. The end point of the process was when the temperature
of the mixture reached 100.degree. C. or when all the water in the
reaction mixture was collected.
[0243] The reaction mixture was cooled to ambient temperature,
stirring was stopped, and the organic layer was decanted. The beads
were washed with two washes with ethanol, two washes with 0.5 M HCl
solution, one wash with saturated aqueous NaCl solution, and two
washes with water. The beads were vacuum-dried for 48 hours.
TABLE-US-00031 BA BA binding binding BA binding %
Monomer:Crosslinking affinity capacity retention Primary Monomer A
assay B assay Hamster Bile Acid Swelling Sample # Ratio (mmol/g)
(mmol/g) (mmol/g) in feces (g/g) 89-A1 1:1.6 0.58 2.72 0.28 3.7
33
Example 44: Synthesis of Crosslinked Beads of C.sub.4 BTA Beads
with Dibromodecane Via the Prepolymer Route
[0244] An Argonaut Advantage Series 3400 Process Chemistry
workstation equipped with over head stirrer, reflux condenser,
nitrogen inlet port, and Julabo FP88 refrigeration unit was used to
prepare prepolymer solution. To the 250 mL reaction flask, 50 g
(166.63 mmol) of 1, 10-dibromodecane and 50 g ethanol were added.
The mixture was heated to 50.degree. C. at 300 rpm to make sure
that 1,10-dibromodecane was completely dissolved in ethanol. In a
separate 100 mL beaker, 32.965 g (104.14 mmol) of C.sub.4 BTA and
32.96 g of ethanol were added to make a 50 wt. % solution of
C.sub.4 BTA in ethanol. This solution was then added to the 250 mL
reaction flask containing 50 wt. % 1,10-dibromodecane solution in
ethanol. The reaction was allowed to heat at 50.degree. C. for 90
minutes. The reaction viscosity increased over the time but no
gelation occurred. The reaction was cooled for 5 minutes using
refrigeration unit. Then hydrochloric acid solution (30.37 mL of 37
wt. % aqueous hydrochloric acid in 65.9 mL deionized water) was
added to the reaction mixture to quench the reaction. The reaction
mixture was allowed to cool down to room temperature and then
ethanol was removed by a rotary evaporator operated at room
temperature. The resulting prepolymer solution was then filtered to
remove any unreacted 1,10-dibromodecane. The solution was then
stored in a 250 mL pyrex glass bottle with cap before next
utilization. The percent solid content of the solution was
determined by thermogravimetric analysis and was found to be 58 wt.
% of prepolymer in water.
[0245] Bead synthesis was performed in a 250 mL Argonaut Advantage
Series 3400 Process Chemistry workstation equipped with an over
head stirrer, a reflux condenser, a nitrogen inlet port, and a
Julabo FP88 refrigeration unit. Mineral oil was used as a
continuous phase with 10 wt. % Span 80 as a surfactant. To the
reactor, 30 g (21.5 mmol) of prepolymer solution (58 wt. % in
water) was added. The reaction flask was stirred at 300 rpm and was
heated to 50.degree. C. Then 6.98 mL (27.925 mmol) of 4M sodium
hydroxide, prepared previously, was added to the reaction flask and
allowed to mix for 1 minute. The stirring was stopped and 101.17 mL
of mineral oil solution containing 10 wt. % Span 80 was added to
the reaction mixture. The stirring was resumed at 300 rpm, the
reaction temperature was increased to 60.degree. C. and the
reaction was allowed to continue for 17 hours under inert nitrogen
atmosphere. The reaction was cooled to room temperature with the
help of refrigeration unit. The reaction content was then
transferred to a filter frit to remove the excess continuous and
discrete phases. Beads thus formed were then washed with 100 mL
hexane (2 times), 100 mL ethanol (2 times), 100 mL aqueous
hydrochloric acid solution (0.5M), 100 mL 10 vol. % aqueous
ammonium hydroxide solution (2 times) and finally 100 mL deionized
water (3 times). The beads were then vacuum dried for 48 hours to
remove water. The final product weight was 5.2 gm.
[0246] Bile acid binding capacity, affinity, and retention for each
resulting polymer were determined via the A assay, B assay and
hamster model and results are reported in the table below.
TABLE-US-00032 BA BA BA Binding Binding Binding affinity capacity
retention % Primary A assay B assay Hamster Bile Acid Swelling
Sample # (mmol/g) (mmol/g) (mmol/g) in feces (g/g) 90-A2 0.647 3.23
0.45 15.8 0.38
Example 45: Solution Polymerization of
N,N,N',N'-(3-aminopropyl)-diaminododecane-2-methyl-1,
3-bis(oxiran-2-ylmethyl)-1H-imidazol-3-ium gel
[0247] A 40 mL vial equipped with magnetic stirrer was charged with
N,N,N',N'-(3-aminopropyl)-diaminododecane (4.0 g, 9.3 mmole) and
water (4.7 mL). The mixture was stirred for 5 minutes;
2-methyl-1,3-bis(oxiran-2-ylmethyl)-1H-imidazol-3-ium (3.0 g, 13.1
mmole) was then added. The vial was heated in an oil bath at
70.degree. C. with stirring for 17 hours. A slightly turbid hard
gel was obtained. The gel was ground with an ultrasonic mixer for
30 minutes in methanol and then washed with methanol twice, 0.5 M
hydrochloric acid once, and water three times.
TABLE-US-00033 Monomer/ Crosslinker Sample # Monomer Crosslinker
ratio 91-A1 Mon 4 Xlin 2 1:4 91-A2 Mon 4 Xlin 2 1:7
Abbreviation:
[0248] Mon4: N,N,N',N'-(3-aminopropyl)-diaminododecane Xlin2:
2-methyl-1,3-bis(oxiran-2-ylmethyl)-1H-imidazol-3-ium having the
structure:
##STR00067##
Bile acid binding capacity, affinity, and retention for each
resulting polymer were determined via the A assay, B assay and
hamster model and results are reported in the table below.
TABLE-US-00034 Bile acid binding Bile acid binding Bile acid
capacity affinity retention B assay A assay Hamster Swelling Sample
# (mmol/g) (mmol/g) (mmol/g) (g/g) 91-A1 3.07 0.58 0.40 10.68 91-A2
2.98 0.61 0.43 6.1
Example 46: Synthesis of Beads from Tris(3-aminopropyl)amine and
TMBMP-DBD Crosslinker (Monomer/Crosslinker=1/1.2)
[0249] A 500 mL three-neck flask equipped with overhead stirrer,
condenser was charged with tris(3-aminopropylamine) (3.37 g, 17.9
mmole), water (29.5 mL), acetonitrile (20.3 mL), and
dodecylbenzenesulfonic acid sodium salt solution (12.2 mL, 15 wt. %
in water). The mixture was stirred for 5 minutes. After homogeneous
solution was obtained, TMBMP-DBD (18.00 g, 21.4 mmol) was added.
The resulting mixture was stirred for an extra 5 minutes before the
addition of heptanes (95.7 mL) and sorbitan oleate (Span 80)
solution (90.0 mL, 15 wt. % in heptanes). The final mixture was
stirred at .about.160 rpm with an overhead stirrer. The external
oil was ramped to 75.degree. C. in 1 hour. After 16 hours, a
Dean-Stark treatment was performed to remove the acetonitrile and
water at 80.degree. C. This was achieved by increasing the
temperature of the oil bath to 105.degree. C. The process end point
was identified by the temperature of the mixture reaching
95.degree. C. or until all the water in the reaction mixture was
collected.
[0250] The reaction mixture was allowed to cool to ambient
temperature, stirring was stopped and the organic layer was removed
by vacuum. The beads were washed with 500 mL 2-propanl twice before
collecting by filtration. The beads were vacuum-dried for 24 hours
before the post polymerization. Final product isolated was 15.5 g
(70% yield).
Example 47: Synthesis of Beads from Tris(3-aminopropyl)amine and
TMBMP-DBD Crosslinker (Monomer/Crosslinker=1/1.5) (Sample
#97-A1)
[0251] A 250 mL three-neck flask equipped with overhead stirrer,
condenser was charged with tris(3-aminopropylamine) (1.35 g, 7.17
mmole), water (14.5 mL), acetonitrile (9.93 mL), and
dodecylbenzenesulfonic acid sodium salt solution (5.93 mL, 15 wt. %
in water). The mixture was stirred for 5 minutes. After homogeneous
solution was obtained, TMBMP-DBD (9.00 g, 10.7 mmol) was added. The
resulting mixture was stirred for an extra 5 minutes before the
addition of heptanes (46.8 mL) and sorbitan oleate (Span 80)
solution (44.0 mL, 15 wt. % in heptanes). The final mixture was
stirred at 150-200 rpm with an overhead stirrer. The external oil
was ramped to 75.degree. C. in 1 hour. After 16 hours, a Dean-Stark
treatment was performed to remove the acetonitrile and water at
80.degree. C. This was achieved by increasing the temperature of
the oil bath to 105.degree. C. The process end point was identified
by the temperature of the mixture reaching 95.degree. C. or until
all the water in the reaction mixture was collected.
[0252] The reaction mixture was allowed to cool to ambient
temperature, stirring was stopped and the organic layer was removed
by vacuum. The beads were washed with 500 mL 2-propanol twice,
saturated sodium carbonate solution twice, saturated sodium
chloride twice, and water twice before collecting by filtration.
The beads were vacuum-dried for 24 hours before the post
polymerization. Final product isolated was 10 g.
Example 48: Synthesis of Beads from Tris(3-aminopropyl)amine and
TMBMP-DBD Crosslinker (Monomer/Crosslinker=1/2.0) (Sample
#98-A1)
[0253] A 150 mL three-neck flask equipped with overhead stirrer,
condenser was charged with tris(3-aminopropylamine) (0.63 g 3.35
mmole), water (8.86 mL), acetonitrile (6.05 mL), and
dodecylbenzenesulfonic acid sodium salt solution (3.56 mL, 15 wt. %
in water). The mixture was stirred for 5 minutes. After homogeneous
solution was obtained, TMBMP-DBD (5.60 g, 6.68 mmol) was added. The
resulting mixture was stirred for an extra 5 minutes before the
addition of heptanes (28.5 mL) and sorbitan oleate (Span 80)
solution (26.8 mL, 15 wt. % in heptanes). The final mixture was
stirred at .about.180 rpm with an overhead stirrer. The external
oil was ramped to 75.degree. C. in 1 hour. After 16 hours, a
Dean-Stark treatment was performed to remove the acetonitrile and
water at 80.degree. C. This was achieved by increasing the
temperature of the oil bath to 105.degree. C. The process end point
was identified by the temperature of the mixture reaching
95.degree. C. or until all the water in the reaction mixture was
collected.
[0254] The reaction mixture was allowed to cool to ambient
temperature, stirring was stopped and the organic layer was removed
by vacuum. The beads were washed with hexane twice, ethanol twice,
0.5M HCl solution three times, saturated NaCl solution once, and
water three times. The beads were then vacuum-dried for 24
hours.
Example 49: Post Polymerization of Beads Made from
Tris(3-aminopropyl)amine and TMBMP-DBD with Halogenated Hydrophobic
Ligand
[0255] Post polymerization, a further reaction with halogenated
hydrophobic ligand, was conducted using parallel synthesis. NMP or
2-propanol and dry beads obtained from Examples 46-48 above were
placed into a 12 mL test tube. Halogenated hydrophobic ligand
solution (20 wt. % in NMP) was then added. The amount of each
component was summarized in the table below. The mixture was
stirred at 400 rpm with an overhead stirrer for 5 minutes before
applying heat to 75.degree. C. for 16 hours. The resulting beads
were washed with NMP twice, ethanol twice, 0.5M HCl solution three
times, saturated NaCl solution once, and water three times followed
by drying under vacuum.
TABLE-US-00035 Halogenated Monomer:Crosslinking Hydrophobic
Hydrophobic Monomer:hydrophobic beads ligand NMP 2-propanol Sample
# ligand ligand Ratio (mg) (mg) (mg) (mg) 92-A1 1,12-dibromo-
1:1.2:0.5 900 124 4094 NA dodecane 92-B1 1,12-dibromo- 1:1.2:1.5
900 371 5083 NA dodecane 93-A1 1,12-dibromo- 1:1.5:0.5 1000 113
4454 NA dodecane 94-A1 1,12-dibromo- 1:1.2:1.0 1000 275 5099 NA
dodecane 95-A1 1,12-dibromo- 1:1.2:0.5 1000 137 549 4000 dodecane
95-B1 1,12-dibromo- 1:1.2:1.0 1000 275 1099 4000 dodecane 95-C1
1,12-dibromo- 1:1.2:1.5 1000 412 1648 4000 dodecane 96-A1
1,12-dibromo- 1:1.5:0.5 1000 139 4556 NA dodecane 96-B1
1,12-dibromo- 1:1.5:1.0 1000 278 5113 NA dodecane Bile acid Bile
acid Bile acid Monomer:Crosslinking binding binding binding
Halogenated Monomer:hydrophobic affinity capacity retention Sample
Hydrophobic ligand A assay B assay Hamster Swelling # ligand Ratio
(mmol/g) (mmol/g) (mmol/g) (g/g) 97-A1 NA 1:1.5:0 0.48 2.31 0.23 79
98-A1 NA 1:2.0:0 0.5 2.67 85 92-A1 1,12-dibromo- 1:1.2:0.5 0.53
2.46 18 dodecane 92-B1 1,12-dibromo- 1:1.2:1.5 0.56 2.57 0.34 14
dodecane 93-A1 1,12-dibromo- 1:1.5:0.5 0.57 2.56 0.38 16 dodecane
94-A1 1,12-dibromo- 1:1.2:1.0 0.59 2.58 0.34 15 dodecane 95-A1
1,12-dibromo- 1:1.2:0.5 0.55 2.69 46 dodecane 95-B1 1,12-dibromo-
1:1.2:1.0 0.57 2.70 49 dodecane 95-C1 1,12-dibromo- 1:1.2:1.5 0.57
2.64 50 dodecane 96-A1 1,12-dibromo- 1:1.5:0.5 0.59 2.55 0.36 11
dodecane 96-B1 1,12-dibromo- 1:1.5:1.0 0.62 2.51 0.38 6
dodecane
Example 50: Preparation and Bile Acid Binding Study of
N,N,N',N'-tetrakis(3-aminopropyl)-1,12-diaminododecane Crosslinked
with 1.4 mol 1,3-dichloropropanol (Sample 99; S 99)
[0256] A 500 mL 3-neck flask equipped with overhead stirrer,
condenser, thermometer and an oil bath was charged with N, N, N, N
tetrakis (3-aminopropyl) 1, 12 diaminododecane (20.0 g, 46.65
mmole) and water (47.84 mL). The resulting mixture was stirred in
an ice-bath for 5 minutes. Hydrochloric acid, 5.06 mL (51.31 mmole,
37 wt % in water), was added slowly over a 10 minute period. The
mixture was stirred for an extra 10 minutes in the ice bath before
removal. The organic layer was then charged to the reactor as
heptane (83.69 mL) followed by sorbitan oleate (Span 80) solution
(78.71 ml, 15 wt. % in the heptane). The final mixture was stirred
at 200 rpm with an overhead stirrer. The internal temperature of
the reaction was raised to 70.degree. C. before starting the
addition of 1,3 dichloro-2-propanol (8.42 g, 65.31 mmole) slowly
over two hours. Heating then continued for 17 hours. Dean-Stark
treatment was subsequently performed to remove the water using the
azeotrope of heptane and water (at 80.degree. C.). This was
achieved by increasing the temperature of the circulating oil bath
to 100.degree. C. for 3 hours and then to 110.degree. C. The
process end point was identified by the temperature of the mixture
reaching 98.degree. C. or until all the water initially added into
the reaction mixture was collected. The reaction mixture was
allowed to cool to ambient temperature, stirring was stopped and
the organic layer was decanted off
[0257] Sample 99 was subsequently washed to remove excess solvents
and impurities as outlined in the table below. The beads were
further exposed to HCl to reach a final content of 10.04 wt. %
chloride by elemental analysis.
TABLE-US-00036 Solvent:beads Time Solvent ratio (gm:gm) (mins)
Toluene 6:1 20 Methanol 6:1 20 Methanol 6:1 20 Methanol 6:1 20 0.5M
Hydrochloric Acid 6:1 20 0.5M Hydrochloric Acid 6:1 20 Water Excess
- Flush until pH 4-5 2M Sodium Hydroxide 6:1 20 2M Sodium Hydroxide
6:1 20 Water Excess - Flush until pH 6-7 Methanol 6:1 20 Toluene
6:1 20 Methanol 6:1 20 Water 4L - flush on the filter
[0258] Bile acid binding capacity, affinity, and retention for
Sample 99 were determined via the A assay, B assay and hamster
model and results are reported in the table below, along with
swelling ratio and bead size.
TABLE-US-00037 Test Method Result Malvern Bead Size d(0.5) = 102.8
um Swelling 1.2-1.6 g/g B Assay 3.18 mmol/g A Assay 0.65 mmol/g
Hamster 0.43 mmol/g
[0259] Additional Polymers Tested.
[0260] Five additional polymers known to bind bile acids were
tested as comparator substances. Polymer lots and methods of
purification are noted in the table below.
TABLE-US-00038 Polymer Source Lot # Purification Cholestyramine
Sigma C4650 045K0658 None (CT) Colesevelam Pharmacy KB004434
Purification of API (CV) from tablets Colestipol (CP) Pharmacy
84RAC None Sevelamer (SV) Pharmacy 8-16-08 Purification of API from
tablets Colestimide Pharmacy KB04438 Purification of API (CM) from
tablets
[0261] Preparation of the BES Buffer.
[0262] A simple buffer was made consisting of 100 mM BES
(N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid) and 150 mM
NaCl at a final pH of 7.0 in 4 L batches. Briefly, 42.65 g of BES
(acid), 47.04 g of BES (Na-salt) and 35.06 g of NaCl were dissolved
in MilliQ pure water. The volume was adjusted to 4 L and the pH was
noted.
[0263] Preparation of the Binding Matrices.
[0264] On the day preceding the binding assay, a single bile acid
was added to 300 ml of BES buffer to a concentration of 20 mM. The
solution was allowed to mix 3-6 hours and then subsequently diluted
in a series of two fold dilutions. The final dilution set,
therefore, contained matrices at 0, 0.31, 0.62, 1.25, 2.5, 5, 10,
and 20 mM bile acid. The bile acid and the amount weighed into the
BES buffer are listed in the table below.
TABLE-US-00039 Bile Acid Abbreviation Amount added (g) Cholate CA
2.58 Glycocholate GC 2.925 Taurocholate TC 3.226 Glycodeoxycholate
GDC 2.829 Taurodeoxycholate TDC 3.13
[0265] Assay Methods.
[0266] Polymer samples were dispensed in duplicate into
16.times.100 mm glass tubes, with each tube containing accurately
weighed 8 to 12 mg of dried sample. Binding matrices as described
above were dispensed into the sample tubes to give a final
concentration of 1 mg test sample per mL of buffer. Control tubes
with buffer only were also prepared. The samples were incubated at
37.degree. C. for three hours to reach bile acid binding
equilibrium while rotating on a rotisserie platform. Following
incubation, the samples were centrifuged at 500.times.g for 30
minutes to pellet the bile acid binding polymer. The supernatant
was collected and transferred to a 0.45 micron Whatman 96-well
uniplate to remove small particles prior to analysis. The filtrate
was used to determine bile acid concentration as described below.
Samples were diluted with BES buffer as needed for a final
anticipated concentration of less than 2 mM.
[0267] Analytical Methods.
[0268] To determine the concentration of bile acid in the isotherm
sample, 50 .mu.L of the sample solution was injected onto a HPLC
system equipped with Phenomenex Luna C5 column (100 .ANG., 5 .mu.m,
50.times.2.00 mm) and a UV detector. The sample was analyzed using
a gradient of 15 mM aqueous phosphate buffer (pH=3) and
acetonitrile at a flow rate of 0.4 mL/min. The signal of the bile
acid was detected at a wavelength of 205 nm from the UV detector.
Calibration solutions comprised of the bile acid standards of
different concentrations were also injected onto the same HPLC
system. The calibration curve of the bile acid was then constructed
by plotting the peak area vs. concentration. Based on the peak area
of the bile acid peak found in the sample chromatogram and its
calibration curve, the concentration of the bile acid in the sample
was calculated.
[0269] Data Analysis.
[0270] Binding capacity was calculated as (Cstart-Ceq)/1, where
Cstart (mM) is the starting concentration of bile acid in the
binding matrix, Ceq (mM) is the concentration of bile acid
remaining in the sample at equilibrium after exposure to polymer,
and 1 corresponds to the concentration of the bile acid binder
(mg/ml). The units for the bound bile acid (e.g., TDC Bnd) and the
unbound bile acid (e.g., TDC Unbd) are mmol bile acid/g binder. All
assays were run in duplicate with values reported as an average,
+/-SD.
TABLE-US-00040 TDC GDC TC GC CA Start TDC TDC Start GDC GDC Start
TC TC Start GC GC Start CA CA Binder (mM) Bnd Unbd (mM) Bnd Unbd
(mM) Bnd Unbd (mM) Bnd Unbd (mM) Bnd Unbd CT 18.94 3.26 15.68 18.57
3.05 15.53 20.42 3.29 17.14 18.17 1.80 16.37 19.63 2.85 16.78 CT
9.50 3.11 6.38 9.08 2.85 6.23 10.34 2.98 7.35 9.27 1.47 7.81 10.18
2.10 8.08 CT 4.94 3.16 1.78 4.65 2.78 1.87 5.22 2.09 3.13 4.73 0.97
3.76 5.61 1.79 3.82 CT 2.56 2.20 0.36 2.36 1.75 0.60 2.64 1.07 1.57
2.42 0.60 1.82 2.68 0.91 1.78 CT 1.20 1.07 0.13 1.14 0.90 0.24 1.27
0.59 0.68 1.16 0.37 0.79 1.22 0.43 0.79 CT 0.61 0.55 0.06 0.57 0.46
0.11 0.64 0.32 0.32 0.59 0.20 0.39 0.63 0.24 0.39 CT 0.31 0.28 0.03
0.29 0.23 0.06 0.32 0.17 0.16 0.30 0.10 0.20 0.31 0.11 0.20 CT 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
0.00 CV 18.94 4.45 14.50 18.57 4.16 14.41 20.42 4.44 15.98 18.17
3.62 14.55 19.63 4.84 14.80 CV 9.50 4.15 5.34 9.08 4.08 5.00 10.34
4.06 6.28 9.27 2.95 6.32 10.18 4.01 6.17 CV 4.94 4.17 0.78 4.65
3.77 0.88 5.22 2.80 2.41 4.73 1.96 2.77 5.61 3.10 2.50 CV 2.56 2.40
0.16 2.36 2.12 0.24 2.64 1.42 1.22 2.42 1.13 1.29 2.68 1.61 1.07 CV
1.20 1.12 0.083 1.14 1.05 0.097 1.27 0.80 0.472 1.16 0.67 0.494
1.22 0.84 0.380 CV 0.61 0.58 0.029 0.57 0.53 0.038 0.64 0.50 0.133
0.59 0.44 0.156 0.63 0.53 0.101 CV 0.31 0.308 0.000 0.29 0.288
0.000 0.32 0.324 0.000 0.30 0.261 0.037 0.31 0.313 0.000 CV 0.00
0.00 0.000 0.00 0.00 0.000 0.00 0.00 0.000 0.00 0.00 0.000 0.00
0.00 0.000 CP 18.94 5.367 13.577 18.57 5.702 12.869 20.42 4.632
15.791 18.17 4.159 14.011 19.63 5.040 14.593 CP 9.50 5.098 4.397
9.08 5.025 4.056 10.34 3.874 6.462 9.27 3.183 6.092 10.18 3.976
6.203 CP 4.94 4.340 0.604 4.65 3.989 0.658 5.22 1.992 3.226 4.73
1.587 3.146 5.61 2.370 3.237 CP 2.56 2.246 0.313 2.36 2.002 0.355
2.64 0.378 2.260 2.42 0.238 2.182 2.68 0.492 2.191 CP 1.20 0.893
0.309 1.14 0.819 0.324 1.27 0.029 1.243 1.16 0.026 1.138 1.22 0.012
1.205 CP 0.61 0.327 0.282 0.57 0.261 0.309 0.64 0.007 0.630 0.59
0.012 0.578 0.63 0.013 0.619 CP 0.31 0.049 0.258 0.29 0.022 0.266
0.32 0.007 0.317 0.30 0.005 0.293 0.31 0.011 0.324 CP 0.00 0.000
0.000 0.00 0.000 0.000 0.00 0.000 0.000 0.00 0.000 0.000 0.00 0.000
0.000 SV 18.94 7.748 11.196 18.57 7.523 11.049 20.42 8.831 11.593
18.17 7.781 10.390 19.63 8.169 11.464 SV 9.50 7.648 1.848 9.08
7.297 1.784 10.34 6.714 3.622 9.27 5.722 3.553 10.18 6.505 3.675 SV
4.94 4.769 0.175 4.65 4.489 0.157 5.22 3.480 1.738 4.73 3.033 1.700
5.61 2.970 2.637 SV 2.56 2.411 0.147 2.36 2.215 0.142 2.64 1.030
1.608 2.42 0.939 1.481 2.68 1.018 1.665 SV 1.20 1.059 0.144 1.14
1.004 0.139 1.27 0.110 1.163 1.16 0.100 1.065 1.22 0.062 1.156 SV
0.61 0.466 0.143 0.57 0.435 0.135 0.64 0.029 0.608 0.59 0.029 0.562
0.63 0.032 0.600 SV 0.31 0.173 0.135 0.29 0.160 0.129 0.32 0.016
0.307 0.30 0.012 0.287 0.31 0.001 0.312 SV 0.00 0.000 0.000 0.00
0.000 0.000 0.00 0.000 0.000 0.00 0.000 0.000 0.00 0.000 0.000 S 99
18.94 7.181 11.763 18.57 7.022 11.549 20.42 6.626 13.797 18.17
5.559 12.611 19.63 7.338 12.295 S 99 9.50 6.867 2.628 9.08 6.880
2.201 10.34 5.537 4.799 9.27 4.674 4.601 10.18 5.843 4.337 S 99
4.94 4.729 0.216 4.65 4.445 0.202 5.22 3.563 1.655 4.73 3.168 1.565
5.61 4.432 1.175 S 99 2.56 2.478 0.081 2.36 2.283 0.074 2.64 1.890
0.748 2.42 1.679 0.741 2.68 2.106 0.577 S 99 1.20 1.144 0.058 1.14
1.090 0.052 1.27 0.831 0.441 1.16 0.734 0.430 1.22 0.888 0.329 S 99
0.61 0.564 0.045 0.57 0.531 0.039 0.64 0.374 0.263 0.59 0.334 0.256
0.63 0.425 0.207 S 99 0.31 0.274 0.034 0.29 0.260 0.028 0.32 0.171
0.153 0.30 0.148 0.151 0.31 0.186 0.127 S 99 0.00 0.000 0.000 0.00
0.000 0.000 0.00 0.000 0.000 0.00 0.000 0.000 0.00 0.000 0.000 CM
18.94 5.391 13.552 18.57 5.225 13.346 20.42 4.941 15.482 19.63
4.663 14.969 CM 9.50 5.068 4.427 9.08 4.798 4.283 10.34 4.194 6.141
10.18 3.281 6.898 CM 4.94 4.376 0.569 4.65 3.858 0.789 5.22 2.120
3.097 5.61 1.567 4.040 CM 2.56 2.250 0.309 2.36 1.819 0.538 2.64
0.306 2.332 2.68 0.375 2.309 CM 1.20 0.905 0.297 1.14 0.675 0.467
1.27 0.029 1.244 1.22 0.007 1.210 CM 0.61 0.324 0.285 0.57 0.127
0.443 0.64 0.008 0.630 0.63 0.014 0.618 CM 0.31 0.043 0.265 0.29
0.009 0.280 0.32 0.004 0.320 0.31 -0.009 0.322 CM 0.00 0.000 0.000
0.00 0.000 0.000 0.00 0.000 0.000 0.00 0.000 0.000
[0271] Data was graphically represented in an isotherm format in
which Bound Bile Acid (mmol bile acid/g polymer) was plotted vs
Unbound Bile Acid (mmol bile acid/g polymer). (FIGS. 1 and 2).
Unbound Bile Acid is calculated as Ceq (mM)/1 mg/ml polymer. Bound
Bile Acid is calculated as Cstart-Ceq/1 mg/ml polymer.
[0272] In view of the above, it will be seen that the several
objects of the invention are achieved and other advantageous
results attained. As various changes could be made in the above
polymers, pharmaceutical compositions, and methods of treatment
without departing from the scope of the invention, it is intended
that all matter contained in the above description and shown in the
accompanying drawing[s] shall be interpreted as illustrative and
not in a limiting sense.
* * * * *